Personensuche

Personensuche

Bitte geben Sie den Namen der gesuchten Person ein.

Es wurde 1 Person gefunden.

Prof. Dr. med. Martin Schuler

Telefon
+49 201 723 2000
Webseite
http://www.uk-essen.de/?id=2383

Funktionen

  • Direktor/in, Innere Klinik (Tumorforschung)

Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.

    Artikel in Zeitschriften

  • Arzideh, Kamyar; Hosch, René; Turki, Amin; Eryilmaz, Bahadir; Bahn, Mikel; Schäfer, Henning; Idrissi-Yaghir, Ahmad; Khattab, Sameh; Dada, Amin; Baba, Hideo Andreas; Schadendorf, Dirk; Schuler, Martin; Kleesiek, Jens; Hartmann, Sylvia; Nensa, Felix; Keyl, Julius
    Automated Tumor International Classification of Diseases Coding of Real-World Pathology Reports Using Self-Hosted Large Language Models
    In: JCO Clinical Cancer Informatics (JCO CCI), Jg. 10, 2026, e2500254
    DOI
  • Gromke, Tanja; Durand, Juliane; Mueller, Tamara T.; Neumaier, Felix; Liffers, Sven T.; Richly, Heike; Grubert, Matthias; Haubold, Johannes; Theysohn, Jens; Kalkavan, Halime; Bechrakis, Nikolaos E.; Schuler, Martin; Braren, Rickmer; Schaarschmidt, Benedikt; Siveke, Jens
    Clinical and radiomics parameter prognostication in metastatic uveal melanoma patients treated with hepatic arterial infusion chemotherapy
    In: The Oncologist, Jg. 31, 2026, Nr. 1, oyaf385
    DOI, Online Volltext (Open Access)
  • Keyl, Julius; Hosch, René; Hörst, Fabian; Keyl, Philipp; Dada, Amin; Haubold, Johannes; Straus, Jannis; Egger, Jan; Stahler, Arndt; Kurreck, Annika; Ballhausen, Alexej; Stintzing, Sebastian; Fruehauf, Stefan; Müller, Lothar; Alig, Annabel H S; Trarbach, Tanja; Hartmann, Sylvia; Nensa, Felix; Kleesiek, Jens; Kasper, Stefan; Schuler, Martin; Modest, Dominik P.
    Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer
    In: Clinical Cancer Research, Jg. 32, 2026, Nr. 5, S. 938 – 946
    DOI (Open Access)
  • Anker, Markus S.; Mahabadi, Amir Abbas; Totzeck, Matthias; Tewes, Mitra; Khan, Muhammad Shahzeb; Mincu, Raluca; Hendgen-Cotta, Ulrike B.; Michel, Lars; Mathew, Baicy; Drescher, Ophelia; Schuler, Martin; Keller, Ulrich; Rieger, Kathrin; Ahn, Johann; Bullinger, Lars; Modest, Dominik P.; Denecke, Corinna; Kretzler, Lucie; Ramer, Luisa V.; Krug, Danara; Landmesser, Ulf; Lehmann, Lorenz H.; Frey, Norbert; Bercker, Sven; Laufs, Ulrich; Böhm, Michael; Mahfoud, Felix; Merkely, Bela; Diek, Monika; Butler, Javed; Veiser, Anja; Heise, Tim; Hellmich, Martin; Placzek, Marius; Friede, Tim; Anker, Stefan D.; Rassaf, Tienush
    Heart failure therapy in patients with advanced cancer receiving specialized palliative care (EMPATICC trial)
    In: European Heart Journal, Jg. 47, 2026, Nr. 9, S. 1034 – 1046
    DOI (Open Access)
  • Achilleos, Nikolas; Schott, Inna; Doerr, Fabian; Grapatsas, Konstantinos; Baldes, Natalie; Taube, Christian; Theegarten, Dirk; Guberina, Maja; Guberina, Nika; Stuschke, Martin; Kalkavan, Halime; Metzenmacher, Martin; Schuler, Martin; Bölükbas, Servet
    Impact of Lymph Node Metastasis Patterns on Long-Term Survival in Upper Lobe Non-Small Cell Lung Cancer
    In: European Journal of Cardio-Thoracic Surgery, Jg. 68, 2026, Nr. 1
    DOI
  • Cuppens, Kristof; Wiesweg, Marcel; Baas, Paul; Maes, Brigitte; Du Pont, Bert; Ploenes, Till; Theegarten, Dirk; Vanbockrijck, Michel; Aigner, Clemens; Hartemink, Koen; Doerr, Fabian; Bölükbas, Servet; Pat, Karin; Schuler, Martin
    Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung)
    In: European Journal of Cancer (EJC), Jg. 233, 2026, 116165
    DOI (Open Access)
  • Judickiene, Julija; Metzenmacher, Martin; Zaun, Gregor; Wiesweg, Marcel; Meschke, Dorothea E.; Guberina, Nika; Özkan, Filiz; Hense, Jörg; Schuler, Martin; Theegarten, Dirk; Bolükbas, Servet; Stuschke, Martin; Eberhardt, Wilfried
    Pretherapeutic prognostic factors for survival under chemoimmunotherapy/immunotherapy of advanced NSCLC patients
    In: European Journal of Cancer (EJC), Jg. 238, 2026, 116600
    DOI (Open Access)
  • Kessler, Lukas; Schwaning, Felix; Metzenmacher, Martin; Pabst, Kim M.; Opitz, Marcel; Wiesweg, Marcel; Aigner, Clemens; Ploenes, Till; Bölükbas, Servet; Doerr, Fabian; Stuschke, Martin; Umutlu, Lale; Nader, Michael; Theegarten, Dirk; Eberhardt, Wilfried E.; Schuler, Martin; Herrmann, Ken; Fendler, Wolfgang P.; Kersting, David; Hautzel, Hubertus
    Prognostic Value of Fibroblast Activation Protein-Directed PET Imaging in Pleural Mesothelioma
    In: Journal of Nuclear Medicine (JNM), Jg. 67, 2026, Nr. 3, S. 383 – 390
    DOI
  • Herz, Andreas; Khouya, Aymane; Guberina, Maja; Metzenmacher, Martin; Opitz, Marcel; Pöttgen, Christoph; Fischedick, Gerrit; Hautzel, Hubertus; Gauler, Thomas; Herrmann, Ken; Büscher, Erik; Bölükbas, Servet; Doerr, Fabian; Baldes, Natalie; Klüner, Laura Valentina; Schaarschmidt, Benedikt; Karpf-Wissel, Rüdiger; Winantea, Jane; Bos, Denise; Jendrossek, Verena; Mladenov, Emil; Gockeln, Lena; Hetzel, Mario Andre; Wirsdörfer, Florian; Schuler, Martin; Stuschke, Martin; Guberina, Nika
    Radiation Dose-Dependent and -Independent Pulmonary Infiltrates in Patients with High-Grade Pneumonitis After Radiochemotherapy and Durvalumab Consolidation for Stage III NSCLC
    In: Diagnostics, Jg. 16, 2026, Nr. 6, 827
    DOI (Open Access)
  • Eberhardt, Wilfried; Schulte, Christina; Pöttgen, Christoph; Gauler, Thomas; Friedel, Godehard; Kopp, Hans-Georg; Fischer, Berthold; Schmidtberger, Heinz; Kimmich, Martin; Budach, Wilfried; Cordes, Sebastian; Metzenmacher, Martin; Zaun, Gregor; de Los Rios, Rodrigo Hepp; Spengler, Werner; Belka, Claus; Welter, Stephan; Luetke-Brintrup, Diana; Guberina, Nika; Guberina, Maja; Oezkan, Filiz; Darwiche, Kaid; Schuler, Martin; Stamatis, Georgios; Bölükbas, Servet; Hautzel, Hubertus; Stuschke, Martin
    Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial – Long-term survival and competing risk analysis
    In: European Journal of Cancer (EJC), Jg. 236, 2026, 116256
    DOI
  • Lanzafame, Helena; Heilig, Christoph E.; Wardelmann, Eva; Desaulniers, Mélanie; Pabst, Kim Magaly; Mavroeidi, Ilektra Antonia; Pretzell, Ina; Fragoso Costa, Pedro; Nader, Michael; Leyser, Stephan; Schuler, Martin; Bauer, Sebastian; Siveke, Jens Thomas; Kamkar, Leila; Kreutzfeldt, Simon; Fröhling, Stefan; Mühl, Sebastian; Herrmann, Ken; Fendler, Wolfgang Peter; Hamacher, Rainer
    90Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors
    In: Journal of Nuclear Medicine (JNM), Jg. 66, 2025, Nr. 9, S. 1378 – 1384
    DOI (Open Access)
  • Certa, Franziska; Horn, Peter; Keyl, Julius; Mende, Bastian; Lueong, Smiths; Hilser, Thomas; Theurer, Sarah; Virchow, Isabel; Zaun, Yasmin; Pogorzelski, Michael; Metzenmacher, Martin; Kalkavan, Halime; Kasper, Stefan; Schuler, Martin; Wiesweg, Marcel; Zaun, Gregor
    ABO‐Blood Group Associates With Survival Outcomes in Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy
    In: Thoracic Cancer, Jg. 16, 2025, Nr. 6, e70037
    DOI, Online Volltext (Open Access)
  • Lopez, Juanita; Powles, Thomas; Braiteh, Fadi; Siu, Lillian L.; LoRusso, Patricia; Friedman, Claire F.; Balmanoukian, Ani S.; Gordon, Michael; Yachnin, Jeffrey; Rottey, Sylvie; Karydis, Ioannis; Fisher, George A.; Schmidt, Marcus; Schuler, Martin; Sullivan, Ryan J.; Burris, Howard A.; Galvao, Vladimir; Henick, Brian S.; Dirix, Luc; Jaeger, Dirk; Ott, Patrick A.; Wong, Kit Man; Jerusalem, Guy; Schiza, Aglaia; Fong, Lawrence; Steeghs, Neeltje; Leidner, Rom S.; Rittmeyer, Achim; Laurie, Scott A.; Gort, Eelke; Aljumaily, Raid; Melero, Ignacio; Sabado, Rachel L.; Rhee, Ina; Mancuso, Michael R.; Muller, Lars; Fine, Gregg D.; Yadav, Mahesh; Kim, Leesun; Leveque, Vincent J. P.; Robert, Alberto; Darwish, Martine; Qi, Ting; Zhu, Jiawen; Zhang, Jingbin; Twomey, Patrick; Rao, Gautham K.; Low, Donald W.; Petry, Chris; Lo, Amy A.; Schartner, Jill M.; Delamarre, Lélia; Mellman, Ira; Löwer, Martin; Müller, Felicitas; Derhovanessian, Evelyna; Cortini, Andrea; Manning, Luisa; Maurus, Daniel; Brachtendorf, Sebastian; Lörks, Verena; Omokoko, Tana; Godehardt, Eva; Becker, Dirk; Hawner, Christine; Wallrapp, Christine; Albrecht, Christian; Kröner, Christoph; Tadmor, Arbel D.; Diekmann, Jan; Vormehr, Mathias; Jork, Anette; Paruzynski, Anna; Lang, Maren; Blake, Jonathon; Hennig, Oliver; Kuhn, Andreas N.; Sahin, Ugur; Türeci, Özlem; Camidge, D. Ross
    Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
    In: Nature Medicine, Jg. 31, 2025, Nr. 1, S. 152 – 164
    DOI (Open Access)
  • Vogelsang, Johannes; Pucher, Gernot; Hörst, Fabian; Hosch, René; Haubold, Johannes; Keyl, Philipp; Sauer, Christopher M.; Albers, David; Markus, Peter; Neuhaus, Jan Peter; Rink, Andreas D.; Treckmann, Jürgen Walter; Neumann, Ulf P.; Naßenstein, Kai; Forsting, Michael; Baba, Hideo Andreas; Egger, Jan; Kasper, Stefan; Schuler, Martin; Nensa, Felix; Kleesiek, Jens; Keyl, Julius
    Automated CT-based sarcopenia assessment for risk stratification of patients undergoing colorectal cancer resection
    In: Clinical Surgical Oncology (CSO), Jg. 4, 2025, Nr. 4, 100105
    DOI (Open Access)
  • Ramesh, Palaniappan; Al Kadi, Amal R.; Borse, Gaurav M.; Webendörfer, Maximilian; Zaun, Gregor; Metzenmacher, Martin; Doerr, Fabian; Bölükbas, Servet; Hegedüs, Balazs; Lueong, Smiths S.; Magne, Joelle; Liu, Beiyun; Nunez, Greisly; Schuler, Martin; Green, Douglas R.; Kalkavan, Halime
    BCL-B Promotes Lung Cancer Invasiveness by Direct Inhibition of BOK
    In: Cells, Jg. 14, 2025, Nr. 4, 246
    DOI, Online Volltext (Open Access)
  • Melero, Ignacio; de Miguel Luken, Maria; de Velasco, Guillermo; Garralda, Elena; Martín-Liberal, Juan; Joerger, Markus; Alonso, Guzman; Goebeler, Maria-Elisabeth; Schuler, Martin; König, David; Dummer, Reinhard; Reig, Maria; Rodriguez Ruiz, Maria-Esperanza; Calvo, Emiliano; Esteban-Villarrubia, Jorge; Oberoi, Arjun; Sabat, Paula; Soto-Castillo, Juan José; Koster, Kira-Lee; Saavedra, Omar; Sayehli, Cyrus; Gromke, Tanja; Läubli, Heinz; Ramelyte, Egle; Fortuny, Marta; Landa-Magdalena, Ana; Moreno, Irene; Torres-Jiménez, Javier; Hernando-Calvo, Alberto; Hess, Dagmar; Racca, Fabricio; Richly, Heike; Schmitt, Andreas M.; Eggenschwiler, Corinne; Sanduzzi-Zamparelli, Marco; Vilalta-Lacarra, Anna; Trojan, Jörg; Koch, Christine; Galle, Peter R.; Foerster, Friedrich; Trajanoski, Zlatko; Hackl, Hubert; Gogolla, Falk; Koll, Florestan J.; Wild, Peter; Chun, Felix Kyoung Hwan; Reis, Henning; Lloyd, Peter; Machacek, Matthias; Gajewski, Thomas F.; Fridman, Wolf H.; Eggermont, Alexander M. M.; Bargou, Ralf; Schöniger, Sandra; Rüschoff, Josef; Tereshchenko, Anastasiia; Zink, Carina; da Silva, Antonio; Lichtenegger, Felix S.; Akdemir, Julia; Rüdiger, Manfred; L’Huillier, Phil; Dutta, Aradhana; Haake, Markus; Auckenthaler, Alexandra; Gjorgjioska, Ana; Rössler, Bernhard; Hermann, Frank; Liebig, Mara; Reichhardt, Daniela; Schuberth-Wagner, Christine; Wischhusen, Jörg; Fettes, Petra; Auer, Marlene; Klar, Kathrin; Leo, Eugen
    Correction to: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
    In: Nature, Jg. 639, 2025, Nr. 8054, S. E18
    DOI (Open Access)
  • Keyl, Julius; Keyl, Philipp; Montavon, Grégoire; Hosch, René; Brehmer, Alexander; Mochmann, Liliana; Jurmeister, Philipp; Dernbach, Gabriel; Kim, Moon; Koitka, Sven; Bauer, Sebastian; Bechrakis, Nikolaos; Forsting, Michael; Führer-Sakel, Dagmar; Glas, Martin; Grünwald, Viktor; Hadaschik, Boris; Haubold, Johannes; Herrmann, Ken; Kasper, Stefan; Kimmig, Rainer; Lang, Stephan; Rassaf, Tienush; Roesch, Alexander; Schadendorf, Dirk; Siveke, Jens T.; Stuschke, Martin; Sure, Ulrich; Totzeck, Matthias; Welt, Anja; Wiesweg, Marcel; Baba, Hideo A.; Nensa, Felix; Egger, Jan; Müller, Klaus-Robert; Schuler, Martin; Klauschen, Frederick; Kleesiek, Jens
    Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence
    In: Nature Cancer, Jg. 6, 2025, Nr. 2, S. 307 – 322
    DOI (Open Access)
  • Hegedüs, Luca; Qaisieh, Silvia; Stülpnagel, Christian; Ganjeh Khor Dezfouli, Yavar; Tambo, Winny; Doerr, Fabian; Baldes, Natalie; Theegarten, Dirk; Schuler, Martin; Bölükbas, Servet; Hegedüs, Balazs
    Dual HDAC and PI3K Inhibitor CUDC-907 Inhibits Growth of Pleural Mesothelioma : The Impact of Cisplatin Sensitivity and Myc Expression
    In: Cells, Jg. 14, 2025, Nr. 20, 1599
    DOI (Open Access)
  • Webendoerfer, Maximilian; Wiesweg, Marcel; Winantea, Jane; Keyl, Julius; Hautzel, Hubertus; Metzenmacher, Martin; Theegarten, Dirk; Darwiche, Kaid; Bölükbas, Servet; Doerr, Fabian; Graw, Aleksandra; Taube, Christian; Stuschke, Martin; Opitz, Marcel; Kalkavan, Halime; Schuler, Martin; Eberhardt, Wilfried; Oezkan, Filiz
    Early years, advanced disease : The unmet need in young adults with non-small cell lung cancer
    In: European Journal of Cancer (EJC), Jg. 230, 2025, 116011
    DOI (Open Access)
  • Pucher, Gernot; Dada, Amin; Nensa, Felix; Schuler, Martin; Reinhardt, Christian; Kleesiek, Jens; Sauer, Christopher M.
    Evaluating Zero-Shot Foundation Models for Time Series Forecasting in Clinical Settings : A Simulation Study with Electronic Health Records
    In: Studies in Health Technology and Informatics, Jg. 329, 2025, S. 820 – 824
    DOI (Open Access)
  • Künnemann, Marc-David; Römer, Christian; Helfen, Anne; Bleckmann, Annalen; Kemper, Marcel; Heindel, Walter; Brix, Tobias J.; Forsting, Michael; Haubold, Johannes; Opitz, Marcel; Schuler, Martin; Nensa, Felix; Borys, Katarzyna; Hosch, René
    Exploration of Fully-Automated Body Composition Analysis Using Routine CT-Staging of Lung Cancer Patients for Survival Prognosis
    In: Journal of Cachexia, Sarcopenia and Muscle, Jg. 16, 2025, Nr. 4, e70021
    DOI (Open Access)
  • Schuler, Martin
    Facts and Hopes in Neoadjuvant Immunotherapy Combinations in Resectable Non-Small Cell Lung Cancer
    In: Clinical Cancer Research, Jg. 31, 2025, Nr. 5, S. 801 – 807
    DOI
  • Arzideh, Kamyar; Schäfer, Henning; Allende-Cid, Héctor; Baldini, Giulia; Hilser, Thomas; Idrissi-Yaghir, Ahmad; Laue, Katharina; Chakraborty, Nilesh; Doll, Niclas; Antweiler, Dario; Klug, Katrin; Beck, Niklas; Giesselbach, Sven; Friedrich, Christoph M.; Nensa, Felix; Schuler, Martin; Hosch, René
    From BERT to generative AI : Comparing encoder-only vs. large language models in a cohort of lung cancer patients for named entity recognition in unstructured medical reports
    In: Computers in Biology and Medicine, Jg. 195, 2025, 110665
    DOI (Open Access)
  • Borys, Katarzyna; Haubold, Johannes; Keyl, Julius; Bali, Maria A.; De Angelis, Riccardo; Boni, Kévin Brou; Coquelet, Nicolas; Kohnke, Judith; Baldini, Giulia; Kroll, Lennard; Schramm, Sara; Stang, Andreas; Malamutmann, Eugen; Kleesiek, Jens; Kim, Moon; Kasper, Stefan; Siveke, Jens T.; Wiesweg, Marcel; Merkel-Jens, Anja; Schaarschmidt, Benedikt M.; Gruenwald, Viktor; Bauer, Sebastian; Oezcelik, Arzu; Bölükbas, Servet; Herrmann, Ken; Kimmig, Rainer; Lang, Stephan; Treckmann, Jürgen; Stuschke, Martin; Hadaschik, Boris; Umutlu, Lale; Forsting, Michael; Schadendorf, Dirk; Friedrich, Christoph M.; Schuler, Martin; Hosch, René; Nensa, Felix
    Leveraging Sarcopenia index by automated CT body composition analysis for pan cancer prognostic stratification
    In: npj Digital Medicine, Jg. 8, 2025, Nr. 1, 611
    DOI (Open Access)
  • Skoulidis, Ferdinandos; Li, Bob T.; de Langen, Adrianus Johannes; Hong, David S.; Lena, Herve; Wolf, Juergen; Dy, Grace K.; Curioni Fontecedro, Alessandra; Tomasini, Pascale; Velcheti, Vamsidhar; van der Wekken, Anthonie J.; Dooms, Christophe; Paz-Ares Rodriguez, Luis; Mountzios, Giannis; Sacher, Adrian; Nadal, Ernest; Couraud, Sebastien; Kim, Sang-We; O’Byrne, Kenneth; Rocco, Danilo; Toyozawa, Ryo; Chmielewska, Izabela; Lindsay, Colin R.; Hindoyan, Antreas; Mukundan, Lata; Wilmanski, Tomasz; Anderson, Abraham; Ardito-Abraham, Christine; Pati, Amrita; Reddy, Anita; Mehta, Bhakti; Schuler, Martin
    Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
    In: Nature Medicine, Jg. 31, 2025, Nr. 8, S. 2755 – 2767
    DOI (Open Access)
  • Roesch, Romina M; Schnorbach, Johannes; Klotz, Laura V; Griffo, Raffaella; Thomas, Michael; Stenzinger, Albrecht; Christopoulos, Petros; Allgaeuer, Michael; Schneider, Marc; Schuler, Martin; Wiesweg, Marcel; Schramm, Alexander; Bölükbas, Servet; Doerr, Fabian; Hegedüs, Balazs; Cvetkovic, Jelena; Kirchner, Marietta; Eichhorn, Martin E; Winter, Hauke; Bozorgmehr, Farastuk; Eichhorn, Florian
    NeoTRACK trial : Neo adjuvant TiRagolumab, A tezolizumab and Chemotherapy-dissection of IO-efficacy in NSCLC by longitudinal tracKing-protocol of a non-randomised, open-label, single-Arm, phase II study
    In: BMJ Open, Jg. 15, 2025, Nr. 3, e096617
    DOI (Open Access)
  • Krawutschke, Marvin; Teufel, Martin; Schmidt, Kira; Pasche, Saskia; Schweig, Theresa; Bialek, Anna; Kowalski, Axel; Tewes, Mitra; Schuler, Martin; Schadendorf, Dirk; Scherbaum, Norbert; Skoda, Eva-Maria; Fink, Madeleine; Müller, Bernhard W.
    Neurofeedback Reduces P300 Amplitudes to Intensely Emotive Pictures in Depressed Cancer Patients
    In: Clinical EEG and Neuroscience, Jg. 56, 2025, Nr. 3, S. 217 – 229
    DOI (Open Access)
  • Wiesweg, Marcel; Küter, Claudia; Schnorbach, Johannes; Keyl, Julius; Metzenmacher, Martin; Cvetkovic, Jelena; Saalfeld, Felix Carl; Glanemann, Franziska; Eberhardt, Wilfried; Özkan, Filiz; Theegarten, Dirk; Stenzinger, Albrecht; Darwiche, Kaid; Koschel, Dirk; Herth, Felix; Bölükbas, Servet; Winter, Hauke; Weykamp, Fabian; Wermke, Martin; Stuschke, Martin; Plönes, Till; Thomas, Michael; Schuler, Martin; Christopoulos, Petros
    Oligometastatic non-small cell lung cancer : Impact of local and contemporary systemic treatment approaches on clinical outcome
    In: International Journal of Cancer, Jg. 156, 2025, Nr. 4, S. 776 – 787
    DOI (Open Access)
  • Frost, N.; Joosten, M.; Franzen, J.; Wiesweg, Marcel; Rasokat, A.; Kulhavy, J.; Kollmeier, J.; Reinmuth, N.; Grohé, C.; Roeper, J.; Rittmeyer, A.; Heinzen, S.; Wermke, M.; Wesseler, C.; Christopoulos, P.; Kauffmann-Guerrero, D.; Althoff, A.; Bleckmann, A.; Collienne, M.; Berezucki, E.; Overbeck, T.; Kropf-Sanchen, C.; Griesinger, F.; Sebastian, M.; Schuler, Martin; Braun, S.; Wenzel, C.; Furth, C.; Wolf, J.; Bischoff, P.; Reck, M.
    PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)
    In: Annals of Oncology, 2025, in press
    DOI (Open Access)
  • Guberina, Maja; Metzenmacher, Martin; Pöttgen, Christoph; Wiesweg, Marcel; Guberina, Nika; Merkel-Jens, Anja; Lütke-Brintrup, Diana; Bölükbas, Servet; Eberhardt, Wilfried; Stamatis, Georgios; Doerr, Fabian; Plönes, Till; Hoffmann, Christian; Zaun, Gregor; Höing, Benedikt; Kürten, Cornelius; Mladenov, Emil; Iliakis, George; Kersting, David; Fendler, Wolfgang; Gauler, Thomas; Opitz, Marcel; Milosevic, Aleksandar; Forsting, Michael; Nensa, Felix; Umutlu, Lale; Funke, Faustina; Hautzel, Hubertus; Herrmann, Ken; Taube, Christian; Theegarten, Dirk; Aigner, Clemens; Schuler, Martin; Stuschke, Martin
    Pathologic Complete Response Predicts Long-Term Survival Following Neoadjuvant Induction Chemotherapy and Chemo-Radiotherapy in Stage-III Non-Small Cell Lung Cancer
    In: Thoracic Cancer, Jg. 16, 2025, Nr. 22, e70183
    DOI (Open Access)
  • Kasper, Stefan; Elez, E.; Neumann, U.; Lang, S.; Trampe, A.-K.; Salva, F.; Dopazo, C.; Virchow, I.; Hartmann, Sylvia; Herrmann, Ken; Tabernero, J.; Westendorf, Astrid; Schuler, Martin; Schramm, A.
    Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases : The PURPLE trial
    In: ESMO Gastrointestinal Oncology, Jg. 9, 2025, 100226
    DOI (Open Access)
  • Demirdjian, Levon; Triantos, Spyros; Standish, Kristopher; Thomas, Shibu; Xia, Qi; Zhang, Jiarui; Greshock, Joel; Paone, Julie; Sheridan, Paige; Pant, Shubham; Massard, Christophe; Reardon, David A.; Loriot, Yohann; Schuler, Martin; Sweiti, Hussein
    Prognostic Impact of Oncogenic Fibroblast Growth Factor Receptor Alterations in Patients With Advanced Solid Tumors in a Real-World Setting
    In: Cancer Medicine, Jg. 14, 2025, Nr. 4, e70546
    DOI (Open Access)
  • Kalkavan, Halime; Scheulen, Max Ernst; Kämpgen, Eckhart; Keilholz, Ulrich; Heinzerling, Lucie; Lueong, Smiths S.; Hlinka, Annalena; Gromke, Tanja; Ochsenreither, Sebastian; Hilger, Ralf A.; Grubert, Matthias; Wetter, Axel; Guberina, Nika; Zeschnigk, Michael; Ferency, Peter; Held, Swantje; Hinke, Axel; Schuler, Gerold; Al-Ghazzawi, Karim; Bornfeld, Norbert; Bechrakis, Nikolaos E.; Schuler, Martin; Bauer, Sebastian; Richly, Heike; Siveke, Jens
    Sorafenib as first-line therapy for metastatic uveal melanoma : A multicenter, placebo-controlled randomized discontinuation study (STREAM)
    In: iScience, Jg. 28, 2025, Nr. 12, 114045
    DOI (Open Access)
  • de Langen, Adrianus Johannes; Johnson, Melissa L.; Mazieres, Julien; Dingemans, Anne-Marie C.; Mountzios, Giannis; Pless, Miklos; Wolf, Jürgen; Schuler, Martin; Lena, Hervé; Skoulidis, Ferdinandos; Yoneshima, Yasuto; Kim, Sang-We; Linardou, Helena; Novello, Silvia; van der Wekken, Anthonie J.; Chen, Yuanbin; Peters, Solange; Felip, Enriqueta; Solomon, Benjamin J.; Ramalingam, Suresh S.; Dooms, Christophe; Lindsay, Colin R.; Ferreira, Carlos Gil; Blais, Normand; Obiozor, Cynthia C.; Wang, Yang; Mehta, Bhakti; Varrieur, Tracy; Ngarmchamnanrith, Gataree; Stollenwerk, Björn; Waterhouse, David; Paz-Ares, Luis
    Sotorasib versus docetaxel for previously treated KRAS G12C–mutated non–small–cell lung cancer : a plain language summary
    In: Future Oncology, Jg. 21, 2025, Nr. 9, S. 1033 – 1044
    DOI (Open Access)
  • Schulte, Christina; Gauler, Thomas; Pöttgen, Christoph; Friedel, Godehard; Kopp, Hans-Georg; Fischer, Berthold; Schmidberger, Heinz; Kimmich, Martin; Budach, Wilfried; Cordes, Sebastian; Wienker, Johannes; Metzenmacher, Martin; de Los Rios, Rodrigo Hepp; Spengler, Werner; De Ruysscher, Dirk; Belka, Claus; Welter, Stefan; Luetke-Brintrup, Diana; Guberina, Maja; Oezkan, Filiz; Darwiche, Kaid; Schuler, Martin; Jöckel, Karl-Heinz; Aigner, Clemens; Stamatis, Georgios; Stuschke, Martin; Eberhardt, Wilfried
    Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE)
    In: International Journal of Cancer, Jg. 156, 2025, Nr. 1, S. 154 – 163
    DOI (Open Access)
  • Mountzios, Giannis; Sun, Longhua; Cho, Byoung Chul; Demirci, Umut; Baka, Sofia; Gümüş, Mahmut; Lugini, Antonio; Zhu, Bo; Yu, Yan; Korantzis, Ippokratis; Han, Ji-Youn; Ciuleanu, Tudor-Eliade; Ahn, Myung-Ju; Rocha, Pedro; Mazières, Julien; Lau, Sally C.M.; Schuler, Martin; Blackhall, Fiona; Yoshida, Tatsuya; Owonikoko, Taofeek K.; Paz-Ares, Luis; Jiang, Tony; Hamidi, Ali; Gauto, Diana; Recondo, Gonzalo; Rudin, Charles M.
    Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
    In: The New England Journal of Medicine, Jg. 393, 2025, Nr. 4, S. 349 – 361
    DOI
  • Herz, Andreas; Guberina, Maja; Pöttgen, Christoph; Gauler, Thomas; Ton, That Truong Mike; Fischedick, Gerrit; Kiwitt, Lars Oliver; Lübcke, Wolfgang; Hoffmann, Christian; Schuler, Martin; Metzenmacher, Martin; Schaarschmidt, Benedikt; Bos, Denise; Opitz, Marcel; Hautzel, Hubertus; Darwiche, Kaid; Bölükbas, Servet; Grapatsas, Konstantinos; Jendrossek, Verena; Gockeln, Lena; Wirsdörfer, Florian; Hetzel, Mario; Mladenov, Emil; Stuschke, Martin; Guberina, Nika
    The effect of durvalumab consolidation after definitive radiochemotherapy for non-operable stage III non-small cell lung cancer on the dose effect relation for therapy related pulmonary infiltrates as a risk factor for pneumonitis
    In: Translational Lung Cancer Research, Jg. 14, 2025, Nr. 6, S. 2074 – 2088
    DOI (Open Access)
  • Wiesweg, Marcel; Alaffas, Ali; Rasokat, Anna; Saalfeld, Felix Carl; Rost, Maximilian; Assmann, Christin; Herster, Franziska; Hilbrandt, Moritz; Griesinger, Frank; Kron, Anna; Roeper, Julia; Glanemann, Franziska; Kropf-Sanchen, Cornelia; Reck, Martin; Kulhavy, Jonas; Stenzinger, Albrecht; Wolf, Jürgen; Sebastian, Martin; Schuler, Martin; Wermke, Martin; Frost, Nikolaj; Kopp, Hans-Georg; Christopoulos, Petros; Scheffler, Matthias
    Treatment Sequences in BRAF-V600–Mutated NSCLC : First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy
    In: Journal of Thoracic Oncology, Jg. 20, 2025, Nr. 9, S. 1328 – 1335
    DOI (Open Access)
  • Kasper, Stefan; Liszio, Stefan; Schorrmann, Katrin; Gerigk, Monja; Jovic, Slobodan; Basu, Oliver; Kostbade, Karina; Goraus, Beate; Elsakka, Abdelrahman; Puladi, Behrus; Kleesiek, Jens; Schuler, Martin; Luijten, Gijs; Egger, Jan
    Virtual reality support during systemic cancer therapy to improve anxiety/depressive symptoms and reduce toxicity in patients with gastrointestinal cancers—OncoVR
    In: ESMO Gastrointestinal Oncology, Jg. 7, 2025, 100135
    DOI, Online Volltext (Open Access)
  • Hoffmann, Christian; Hautzel, Hubertus; Wiesweg, Marcel; Kersting, David; Guberina, Nika; Pöttgen, Christoph; Metzenmacher, Martin; Schuler, Martin; Gauler, Thomas; Höing, Benedikt; Kürten, Cornelius; Doerr, Fabian; Bölükbas, Servet; Baldes, Natalie; Opitz, Marcel; Milosevic, Aleksandar; Nensa, Felix; Umutlu, Lale; Funke, Faustina; Fendler, Wolfgang; Herrmann, Ken; Stuschke, Martin; Guberina, Maja
    [18F]FDG-PET/CT-based evaluation of tumor response kinetics during induction chemotherapy and concurrent radiochemotherapy in stage II - III small-cell lung cancer
    In: European Journal of Nuclear Medicine and Molecular Imaging, 2025, in press
    DOI (Open Access)
  • Pabst, Kim M; Weber, Manuel; Laschinsky, Christina; Sandach, Patrick; Bartel, Timo; Küper, Alina T; Kessler, Lukas; Trajkovic-Arsic, Marija; Eckstein, Markus; Gilman, Elena; Nader, Michael; Barbato, Francesco; Podleska, Lars; Hadaschik, Boris; Hamacher, Rainer; Kersting, David; von Ostau, Nicola; von Tresckow, Bastian; Kaelberlah, Hans-Peter; Kesch, Claudia; Kuemmel, Sherko; Reinacher-Schick, Anke; Schuler, Martin; Siveke, Jens; Grünwald, Viktor; Herrmann, Ken; Fendler, Wolfgang P.
    [⁶⁸Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation : A single-centre, single-arm, interventional, phase 2 trial
    In: The Lancet Oncology, Jg. 26, 2025, Nr. 9, S. 1204 – 1214
    DOI (Open Access)
  • Lanzafame, Helena; Mavroeidi, Ilektra A.; Pabst, Kim M.; Desaulniers, Mélanie; Ingenwerth, Marc; Hirmas, Nader; Kessler, Lukas; Nader, Michael; Bartel, Timo; Leyser, Stephan; Barbato, Francesco; Schuler, Martin; Bauer, Sebastian; Siveke, Jens T.; Herrmann, Ken; Hamacher, Rainer; Fendler, Wolfgang P.
    68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
    In: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 6, S. 880 – 887
    DOI (Open Access)
  • Pogorzelski, Michael; Schuler, Martin
    Aktuelle Standards und vielversprechende Innovationen in der medikamentösen Zweitlinientherapie des metastasierten kleinzelligen Lungenkarzinoms (ED-SCLC)
    In: Die Onkologie, Jg. 30, 2024, Nr. 9, S. 809 – 816
    DOI
  • Felip, E.; Cho, B.C.; Gutiérrez, V.; Alip, A.; Besse, B.; Lu, S.; Spira, A.I.; Girard, N.; Califano, R.; Gadgeel, S.M.; Yang, J.C.-H.; Yamamoto, S.; Azuma, K.; Kim, Y.J.; Lee, K.-H.; Danchaivijitr, P.; Ferreira, C.G.; Cheng, Y.; Sendur, M.A.N.; Chang, G.-C.; Wang, C.-C.; Prabhash, K.; Shinno, Y.; Stroyakovskiy, D.; Paz-Ares, L.; Rodriguez-Cid, J.R.; Martin, C.; Campelo, M.R.G.; Hayashi, H.; Nguyen, D.; Tomasini, P.; Gottfried, M.; Dooms, C.; Passaro, A.; Schuler, Martin; Gelatti, A.C.Z.; Owen, S.; Perdrizet, K.; Ou, S.-H.I.; Curtin, J.C.; Zhang, J.; Gormley, M.; Sun, T.; Panchal, A.; Ennis, M.; Fennema, E.; Daksh, M.; Sethi, S.; Bauml, J.M.; Lee, S.-H.
    Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease : a secondary analysis from MARIPOSA
    In: Annals of Oncology, Jg. 35, 2024, Nr. 9, S. 805 – 816
    DOI (Open Access)
  • Pfeifer, Klara; Tewes, Mitra; Kasper, Stefan; Hense, Jörg; Franco, Jan; Schuler, Martin; Schöbel, Christoph; Ates, Gülay
    Applicability of a digital health application for cancer patients : A qualitative non-participation analysis
    In: BMC Health Services Research, Jg. 24, 2024, Nr. 1, 1187
    DOI, Online Volltext (Open Access)
  • Richlitzki, Cedric; Wiesweg, Marcel; Metzenmacher, Martin; Guberina, Nika; Pöttgen, Christoph; Hautzel, Hubertus; Eberhardt, Wilfried E. E.; Darwiche, Kaid; Theegarten, Dirk; Aigner, Clemens; Bölükbas, Servet; Schuler, Martin; Stuschke, Martin; Guberina, Maja
    C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy
    In: Scientific Reports, Jg. 14, 2024, Nr. 1, 13765
    DOI, Online Volltext (Open Access)
  • Baldes, Natalie; Grapatsas, Konstantinos; Dörr, Fabian; Menghesha, Hruy; Schuler, Martin; Welt, Anja; Stuschke, Martin; Kimmig, Rainer; Hoffmann, Oliver; Bölükbas, Servet
    Chest wall resections for advanced breast cancer : a narrative review
    In: Journal of Thoracic Disease, Jg. 16, 2024, Nr. 10, S. 7182 – 7191
    DOI (Open Access)
  • Doerr, Fabian; Stange, Sebastian; Salamon, Sophie; Grapatsas, Konstantinos; Baldes, Natalie; Michel, Maximilian; Menghesha, Hruy; Schlachtenberger, Georg; Heldwein, Matthias B.; Hagmeyer, Lars; Wolf, Jürgen; Roessner, Eric D.; Wahlers, Thorsten; Schuler, Martin; Hekmat, Khosro; Bölükbas, Servet
    Closing the RCT Gap : A Large Meta-Analysis on the Role of Surgery in Stage I–III Small Cell Lung Cancer Patients
    In: Cancers, Jg. 16, 2024, Nr. 11, 2078
    DOI (Open Access)
  • Zaun, Gregor; Borchert, Sabrina; Metzenmacher, Martin; Lueong, Smiths; Wiesweg, Marcel; Zaun, Yasmin; Pogorzelski, Michael; Behrens, Franziska; Schildhaus, Hans-Ulrich; Virchow, Isabel; Kasper, Stefan; Schuler, Martin; Theurer, Sarah; Liffers, Sven
    Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies
    In: European Journal of Cancer (EJC), Jg. 200, 2024, 113540
    DOI (Open Access)
  • Nurtsch, Angelina; Teufel, Martin; Jahre, Lisa Maria; Esber, André; Rausch, Raya; Tewes, Mitra; Schöbel, Christoph; Palm, Stefan; Schuler, Martin; Schadendorf, Dirk; Skoda, Eva-Maria; Bäuerle, Alexander
    Drivers and barriers of patients’ acceptance of video consultation in cancer care
    In: Digital Health, Jg. 10, 2024
    DOI, Online Volltext (Open Access)
  • Schuler, Martin; Hense, Jörg; Darwiche, Kaid; Michels, Sebastian; Hautzel, Hubertus; Kobe, Carsten; Lueong, Smiths; Metzenmacher, Martin; Herold, Thomas; Zaun, Gregor; Laue, Katharina; Drzezga, Alexander; Theegarten, Dirk; Nensa, Felix; Wolf, Jürgen; Herrmann, Ken; Wiesweg, Marcel
    Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance
    In: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 6, S. 851 – 855
    DOI (Open Access)
  • Fasching, Peter A.; Decker, Thomas; Hartkopf, Andreas; Nusch, Arnd; Heinrich, Bernhard J.; Kurbacher, Christian; Fuchs, Roswitha; Tesch, Hans; Krabisch, Petra; Huober, Jens; Kümmel, Sherko; Brucker, Sara; Janni, Wolfgang; Schneeweiss, Andreas; Schuler, Martin; Fehm, Tanja; Lüftner, Diana; Quiering, Claudia; Voges, Claudia; Kreuzeder, Julia; Reinisch, Mattea
    Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole : Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer
    In: European Journal of Cancer (EJC), Jg. 198, 2024, 113480
    DOI (Open Access)
  • Kästner, Anika; Kron, Anna; van den Berg, Neeltje; Moon, Kilson; Scheffler, Matthias; Schillinger, Gerhard; Pelusi, Natalie; Hartmann, Nils; Rieke, Damian Tobias; Stephan-Falkenau, Susann; Schuler, Martin; Wermke, Martin; Weichert, Wilko; Klauschen, Frederick; Haller, Florian; Hummel, Horst-Dieter; Sebastian, Martin; Gattenlöhner, Stefan; Bokemeyer, Carsten; Esposito, Irene; Jakobs, Florian; von Kalle, Christof; Büttner, Reinhard; Wolf, Jürgen; Hoffmann, Wolfgang
    Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany : A historical cohort analysis
    In: The Lancet Regional Health - Europe, Jg. 36, 2024, 100788
    DOI (Open Access)
  • George, Julie; Maas, Lukas; Abedpour, Nima; Cartolano, Maria; Kaiser, Laura; Fischer, Rieke N.; Scheel, Andreas H.; Weber, Jan-Philipp; Hellmich, Martin; Bosco, Graziella; Volz, Caroline; Mueller, Christian; Dahmen, Ilona; John, Felix; Alves, Cleidson Padua; Werr, Lisa; Panse, Jens Peter; Kirschner, Martin; Engel-Riedel, Walburga; Jürgens, Jessica; Stoelben, Erich; Brockmann, Michael; Grau, Stefan; Sebastian, Martin; Stratmann, Jan A.; Kern, Jens; Hummel, Horst-Dieter; Hegedüs, Balazs; Schuler, Martin; Plönes, Till; Aigner, Clemens; Elter, Thomas; Toepelt, Karin; Ko, Yon-Dschun; Kurz, Sylke; Grohé, Christian; Serke, Monika; Höpker, Katja; Hagmeyer, Lars; Doerr, Fabian; Hekmath, Khosro; Strapatsas, Judith; Kambartel, Karl-Otto; Chakupurakal, Geothy; Busch, Annette; Bauernfeind, Franz-Georg; Griesinger, Frank; Luers, Anne; Dirks, Wiebke; Wiewrodt, Rainer; Luecke, Andrea; Rodermann, Ernst; Diel, Andreas; Hagen, Volker; Severin, Kai; Ullrich, Roland T.; Reinhardt, Hans Christian; Quaas, Alexander; Bogus, Magdalena; Courts, Cornelius; Nürnberg, Peter; Becker, Kerstin; Achter, Viktor; Büttner, Reinhard; Wolf, Jürgen; Peifer, Martin; Thomas, Roman K.
    Evolutionary trajectories of small cell lung cancer under therapy
    In: Nature, Jg. 627, 2024, Nr. 8005, S. 880 – 889
    DOI (Open Access)
  • Reimann, Patrick; Mavroeidi, Ilektra-Antonia; Burghofer, Jonathan; Taghizadeh, Hossein; Webersinke, Gerald; Kasper, Stefan; Schreil, Georg; Morariu, Darius; Reichinger, Andreas; Baba, Hideo Andreas; Kirchweger, Patrick; Schuler, Martin; Djanani, Angela; Prager, Gerald W.; Rumpold, Holger; Benda, Magdalena; Schneider, Eva-Maria; Mink, Sylvia; Winder, Thomas; Doleschal, Bernhard
    Exploring the impact of durvalumab on biliary tract cancer : insights from real-world clinical data
    In: Cancer Immunology, Immunotherapy, Jg. 73, 2024, Nr. 12, S. 251
    DOI (Open Access)
  • Hamacher, Rainer; Pabst, Kim M.; Cheung, Phyllis F.; Heilig, Christoph E.; Hüllein, Jennifer; Liffers, Sven-Thorsten; Borchert, Sabrina; Fragoso Costa, Pedro; Schaarschmidt, Benedikt; Kessler, Lukas; Miera, Monika A.; Droste, Margret; Akbulut, Merve; Falkenhorst, Johanna; Zarrad, Fadi; Kostbade, Karina; Mavroeidi, Ilektra A.; Glimm, Hanno; Umutlu, Lale; Schuler, Martin; Hübschmann, Daniel; Bauer, Sebastian; Fröhling, Stefan; Herrmann, Ken; Siveke, Jens T.; Schildhaus, Hans-Ulrich; Fendler, Wolfgang P.
    Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor
    In: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 2, S. 252 – 257
    DOI (Open Access)
  • Kessler, Lukas; Schwaning, Felix; Metzenmacher, Martin; Pabst, Kim; Siveke, Jens; Trajkovic-Arsic, Marija; Schaarschmidt, Benedikt; Wiesweg, Marcel; Aigner, Clemens; Plönes, Till; Darwiche, Kaid; Bölükbas, Servet; Stuschke, Martin; Umutlu, Lale; Nader, Michael; Theegarten, Dirk; Hamacher, Rainer; Eberhardt, Wilfried; Schuler, Martin; Herrmann, Ken; Fendler, Wolfgang P.; Hautzel, Hubertus
    Fibroblast Activation Protein-Directed Imaging Outperforms ¹⁸F-FDG PET/CT in Malignant Mesothelioma : A Prospective, Single-Center, Observational Trial
    In: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 8, S. 1188 – 1193
    DOI (Open Access)
  • Klug, Katrin; Beckh, Katharina; Antweiler, Dario; Chakraborty, Nilesh; Baldini, Giulia; Laue, Katharina; Hosch, René; Nensa, Felix; Schuler, Martin; Giesselbach, Sven
    From admission to discharge : A systematic review of clinical natural language processing along the patient journey
    In: BMC Medical Informatics and Decision Making, Jg. 24, 2024, Nr. 1, 238
    DOI (Open Access)
  • Pfeifer, Klara; Ates, G.; Pogorzelski, M.; Zaun, G.; Rötger, A.; Schuler, Martin; Schöbel, Christoph; Tewes, Mitra
    Investigation of screening questions to identify insomnia in cancer patients
    In: Scientific Reports, Jg. 14, 2024, Nr. 1, 18343
    DOI, Online Volltext (Open Access)
  • Doerr, Fabian; Giese, Annika; Höpker, Katja; Menghesha, Hruy; Schlachtenberger, Georg; Grapatsas, Konstantinos; Baldes, Natalie; Baldus, Christian J.; Hagmeyer, Lars; Fallouh, Hazem; Pinto dos Santos, Daniel; Bender, Edward M.; Quaas, Alexander; Heldwein, Matthias; Wahlers, Thorsten; Hautzel, Hubertus; Darwiche, Kaid; Taube, Christian; Schuler, Martin; Hekmat, Khosro; Bölükbas, Servet
    LIONS PREY : A New Logistic Scoring System for the Prediction of Malignant Pulmonary Nodules
    In: Cancers, Jg. 16, 2024, Nr. 4, 729
    DOI (Open Access)
  • Guberina, Maja; Pöttgen, Christoph; Guberina, Nika; Hoffmann, Christian; Wiesweg, Marcel; Richlitzki, Cedric; Metzenmacher, Martin; Aigner, Clemens; Bölükbas, Servet; Gauler, Thomas; Eberhardt, Wilfried; Forsting, Michael; Herrmann, Ken; Theegarten, Dirk; Darwiche, Kaid; Jendrossek, Verena; Stuschke, Martin; Schuler, Martin
    Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment : Comparison with Stage III Disease
    In: Cancers, Jg. 16, 2024, Nr. 6, 1174
    DOI (Open Access)
  • Dy, Grace K.; Govindan, Ramaswamy; Velcheti, Vamsidhar; Falchook, Gerald S.; Italiano, Antoine; Wolf, Jürgen; Sacher, Adrian G.; Takahashi, Toshiaki; Ramalingam, Suresh S.; Dooms, Christophe; Kim, Dong-Wan; Addeo, Alfredo; Desai, Jayesh; Schuler, Martin; Tomasini, Pascale; Hong, David S.; Lito, Piro; Tran, Qui; Jones, Simon; Anderson, Abraham; Hindoyan, Antreas; Snyder, Wendy; Skoulidis, Ferdinandos; Li, Bob T.
    Long-term benefit of sotorasib in patients with KRAS G12C–mutated non–small-cell lung cancer : Plain language summary
    In: Future Oncology, Jg. 20, 2024, Nr. 3, S. 113 – 120
    DOI (Open Access)
  • Schuler, Martin; Cuppens, Kristof; Plönes, Till; Wiesweg, Marcel; Du Pont, Bert; Hegedus, Balazs; Köster, Johannes; Mairinger, Fabian; Darwiche, Kaid; Paschen, Annette; Maes, Brigitte; Vanbockrijck, Michel; Lähnemann, David; Zhao, Fang; Hautzel, Hubertus; Theegarten, Dirk; Hartemink, Koen; Reis, Henning; Baas, Paul; Schramm, Alexander; Aigner, Clemens
    Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer : A randomized phase 2 trial
    In: Nature Medicine, Jg. 30, 2024, Nr. 6, S. 1602 – 1611
    DOI (Open Access)
  • De Lazzari, Nico; Götte, Miriam; Kasper, Stefan; Meier, Eileen; Schuler, Martin; Pogorzelski, Michael; Siveke, Jens T.; Tewes, Mitra
    P-move : A randomized control trial of exercise in patients with advanced pancreatic or biliary tract cancer (aPBC) receiving beyond first-line chemotherapy
    In: Supportive Care in Cancer, Jg. 32, 2024, Nr. 7, 437
    DOI (Open Access)
  • Abu Sabbah, Tanja; Theurer, Sarah; Baba, Hideo Andreas; Lueong, Smiths; Rashidi Alavijeh, Jassin; Hilser, Thomas; Zaun, Yasmin; Metzenmacher, Martin; Pogorzelski, Michael; Virchow, Isabel; Pretzell, Ina; Kostbade, Karina; Treckmann, Jürgen; Wiesweg, Marcel; Schuler, Martin; Kasper, Stefan; Zaun, Gregor
    PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors
    In: European Journal of Cancer (EJC), Jg. 210, 2024, 114268
    DOI (Open Access)
  • Doerr, Fabian; Leschczyk, Tobias; Grapatsas, Konstantinos; Menghesha, Hruy; Baldes, Natalie; Schlachtenberger, Georg; Heldwein, Matthias B.; Michel, Maximilian; Quaas, Alexander; Hagmeyer, Lars; Höpker, Katja; Wahlers, Thorsten; Darwiche, Kaid; Taube, Christian; Schuler, Martin; Hekmat, Khosro; Bölükbas, Servet
    Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients
    In: Cancers, Jg. 16, 2024, Nr. 2, 465
    DOI (Open Access)
  • Subbiah, Vivek; Hu, Mimi I.; Mansfield, Aaron S.; Taylor, Matthew H.; Schuler, Martin; Zhu, Viola W.; Hadoux, Julien; Curigliano, Giuseppe; Wirth, Lori; Gainor, Justin F.; Alonso, Guzman; Adkins, Douglas; Godbert, Yann; Ahn, Myung-Ju; Cassier, Philippe A.; Cho, Byoung Chul; Lin, Chia-Chi; Zalutskaya, Alena; Barata, Teresa; Trask, Peter; Scalori, Astrid; Bordogna, Walter; Heinzmann, Sebastian; Brose, Marcia S.
    Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer : Updated Efficacy and Safety Data from the ARROW Study
    In: Thyroid, Jg. 34, 2024, Nr. 1, S. 26 – 40
    DOI (Open Access)
  • Lever, Mael; Bogner, Simon; Giousmas, Melina; Mairinger, Fabian D.; Baba, Hideo A.; Richly, Heike; Gromke, Tanja; Schuler, Martin; Bechrakis, Nikolaos E.; Kalkavan, Halime
    Prognostic value of clinical and radiomic parameters in patients with liver metastases from uveal melanoma
    In: Pigment Cell and Melanoma Research, Jg. 37, 2024, Nr. 6, S. 831 – 838
    DOI (Open Access)
  • Keyl, Julius; Bucher, A.; Jungmann, F.; Hosch, R.; Ziller, A.; Armbruster, R.; Malkomes, P.; Reissig, T.M.; Koitka, S.; Tzianopoulos, I.; Keyl, P.; Kostbade, K.; Albers, David; Markus, P.; Treckmann, Jürgen-Walter; Naßenstein, Kai; Haubold, Johannes; Makowski, M.; Forsting, Michael; Baba, Hideo Andreas; Kasper, Stefan; Siveke, Jens T.; Nensa, Felix; Schuler, Martin; Kaissis, G.; Kleesiek, Jens; Braren, R.
    Prognostic value of deep learning-derived body composition in advanced pancreatic cancer : A retrospective multicenter study
    In: ESMO Open, Jg. 9, 2024, Nr. 1, 102219
    DOI, Online Volltext (Open Access)
  • Fink, Madeleine; Müller, Sandy; Warnecke, Eva; Hense, Jörg; Schuler, Martin; Teufel, Martin; Comino, Maria Rosa Salvador; Tewes, Mitra
    Relevance of Patient-Reported Outcome Measures in Patients with Cancer : Detection of Underrated Psychological Distress of Palliative Care Patients in an Outpatient Setting
    In: Palliative Medicine Reports, Jg. 5, 2024, Nr. 1, S. 194 – 200
    DOI, Online Volltext (Open Access)
  • Mavroeidi, Ilektra Antonia; Romanowicz, Anna; Haake, Tristan; Wienker, Johannes; Metzenmacher, Martin; Darwiche, Kaid; Oezkan, Filiz; Bölükbas, Servet; Stuschke, Martin; Umutlu, Lale; Opitz, Marcel; Nader, Michael; Hamacher, Rainer; Siveke, Jens; Winantea, Jane; Fendler, Wolfgang P.; Wiesweg, Marcel; Eberhardt, Wilfried; Herrmann, Ken; Theegarten, Dirk; Schuler, Martin; Hautzel, Hubertus; Kersting, David
    Theranostics with somatostatin receptor antagonists in SCLC : Correlation of 68Ga-SSO120 PET with immunohistochemistry and survival
    In: Theranostics, Jg. 14, 2024, Nr. 14, S. 5400 – 5412
    DOI, Online Volltext (Open Access)
  • Mavroeidi, Ilektra Antonia; Burghofer, Jonathan; Kalbourtzis, Stavros; Taghizadeh, Hossein; Webersinke, Gerald; Piringer, Gudrun; Kasper, Stefan; Schreil, Georg; Liffers, Sven Thorsten; Reichinger, Andreas; Kirchweger, P.; Heibl, Sonja; Hamacher, Rainer; Schmitt, Clemens A.; Schuler, Martin; Prager, Gerald W.; Kersting, David; Treckmann, Jürgen-Walter; Schildhaus, Hans-Ulrich; Rumpold, Holger F.; Siveke, Jens T.; Doleschal, Bernhard
    Understanding homologous recombination repair deficiency in biliary tract cancers : clinical implications and correlation with platinum sensitivity
    In: ESMO Open, Jg. 9, 2024, Nr. 8, 103630
    DOI (Open Access)
  • Kersting, David; Sandach, Patrick; Sraieb, Miriam; Wiesweg, Marcel; Metzenmacher, Martin; Darwiche, Kaid; Oezkan, Filiz; Bölükbas, Servet; Stuschke, Martin; Umutlu, Lale; Nader, Michael; Hamacher, Rainer; Fendler, Wolfgang; Wienker, Johannes; Eberhardt, Wilfried; Schuler, Martin; Herrmann, Ken; Hautzel, Hubertus
    68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients : A Single-Center Retrospective Study
    In: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 10, S. 1540 – 1549
    DOI (Open Access)
  • Virchow, Isabel; Treckmann, Jürgen-Walter; Prasnikar, Nicole; Linden, Gabriele; Markus, Peter; Schumacher, Brigitte; Albers, David; Herold, Thomas; Ting, Saskia; Schmidt, Hartmut; Radunz, Sonja; Wiesweg, Marcel; Siveke, Jens; Schuler, Martin; Kasper, Stefan
    A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO)
    In: Oncology Research and Treatment, Jg. 46, 2023, Nr. 3, S. 89 – 99
    DOI
  • Maßmann, M.; Treckmann, Jürgen Walter; Markus, P.; Schumacher, B.; Albers, D.; Ting, Saskia; Mende, B.; Roehrle, J.; Virchow, I.; Rosery, V.; Laue, K.; Zaun, G.; Kostbade, K.; Pogorzelski, M.; Schmid, Kurt Werner; Baba, Hideo Andreas; Siveke, Jens T.; Paul, A.; Schildhaus, Hans-Ulrich; Schuler, Martin; Wiesweg, Marcel; Kasper, Stefan
    A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma
    In: Journal of Cancer Research and Clinical Oncology, Jg. 149, 2023, Nr. 8, S. 5085 – 5094
    DOI (Open Access)
  • Schmidt, Kira; Krawutschke, Marvin; Kowalski, Axel; Pasche, Saskia; Bialek, Anna; Schweig, Theresa; Weismüller, Benjamin; Tewes, Mitra; Schuler, Martin; Hamacher, Rainer; Müller, Bernhard W.; Schadendorf, Dirk; Skoda, Eva-Maria; Teufel, Martin; Fink, Madeleine
    Cancer Patients’ Age-Related Benefits from Mobile Neurofeedback-Therapy in Quality of Life and Self-efficacy : A Clinical Waitlist Control Study
    In: Applied Psychophysiology Biofeedback, Jg. 48, 2023, Nr. 2, S. 217 – 227
    DOI (Open Access)
  • Roehrle, Julius; Kasper, Stefan; Treckmann, Jürgen-Walter; Markus, Peter; Schumacher, Brigitte; Albers, David; Wendling, Johanna; Ting, Saskia; Mende, Bastian; Maßmann, Marlene; Markus, Maximilian; Virchow, Isabel; Rosery, Vivian; Laue, Katharina; Zaun, Gregor; Kostbade, Karina; Pogorzelski, Michael; Reissig, Timm M.; Liffers, Sven-Thorsten; Schmid, Kurt Werner; Schildhaus, Hans-Ulrich; Schuler, Martin; Siveke, Jens T.; Wiesweg, Marcel
    Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols
    In: Oncology Research and Treatment, Jg. 46, 2023, Nr. 4, S. 140 – 150
    DOI
  • Keyl, Julius; Hosch, René; Berger, Aaron; Ester, Oliver; Greiner, Tobias; Bogner, Simon; Treckmann, Jürgen; Ting, Saskia; Schumacher, Brigitte; Albers, David; Markus, Peter; Wiesweg, Marcel; Forsting, Michael; Nensa, Felix; Schuler, Martin; Kasper, Stefan; Kleesiek, Jens
    Deep learning-based assessment of body composition and liver tumour burden for survival modelling in advanced colorectal cancer
    In: Journal of Cachexia, Sarcopenia and Muscle, Jg. 14, 2023, Nr. 1, S. 545 – 552
    DOI, Online Volltext (Open Access)
  • Sikosek, Tobias; Horos, Rastislav; Trudzinski, Franziska; Jehn, Julia; Frank, Maurice; Rajakumar, Timothy; Klotz, Laura V.; Mercaldo, Nathaniel; Kahraman, Mustafa; Heuvelman, Marco; Taha, Yasser; Gerwing, Jennifer; Skottke, Jasmin; Daniel-Moreno, Alberto; Sanchez-Delgado, Marta; Bender, Sophie; Rudolf, Christina; Hinkfoth, Franziska; Tikk, Kaja; Schenz, Judith; Weigand, Markus A.; Feindt, Peter; Schumann, Christian; Christopoulos, Petros; Winter, Hauke; Kreuter, Michael; Schneider, Marc A.; Muley, Thomas; Walterspacher, Stephan; Schuler, Martin; Darwiche, Kaid; Taube, Christian; Hegedus, Balazs; Rabe, Klaus F.; Rieger-Christ, Kimberly; Jacobsen, Francine L.; Aigner, Clemens; Reck, Martin; Bankier, Alexander A.; Sharma, Amita; Steinkraus, Bruno R.
    Early Detection of Lung Cancer Using Small RNAs
    In: Journal of Thoracic Oncology, Jg. 18, 2023, Nr. 11, S. 1504 – 1523
    DOI (Open Access)
  • Warnecke, Eva; Salvador Comino, Maria Rosa; Kocol, Dilara; Hosters, Bernadette; Wiesweg, Marcel; Bauer, Sebastian; Welt, Anja; Heinzelmann, Anna; Müller, Sandy; Schuler, Martin; Teufel, Martin; Tewes, Mitra
    Electronic Patient-Reported Outcome Measures (ePROMs) Improve the Assessment of Underrated Physical and Psychological Symptom Burden among Oncological Inpatients
    In: Cancers, Jg. 15, 2023, Nr. 11, 3029
    DOI, Online Volltext (Open Access)
  • Pant, Shubham; Schuler, Martin; Iyer, Gopa; Witt, Olaf; Doi, Toshihiko; Qin, Shukui; Tabernero, Josep; Reardon, David A.; Massard, Christophe; Minchom, Anna; Lugowska, Iwona; Carranza, Omar; Arnold, Dirk; Gutierrez, Martin; Winter, Helen; Stuyckens, Kim; Crow, Lauren; Najmi, Saltanat; Hammond, Constance; Thomas, Shibu; Santiago-Walker, Ademi; Triantos, Spyros; Sweiti, Hussein; Loriot, Yohann; Greco, Martin Alberto; Coward, Jim; Joshua, Anthony; Karapetis, Christos; Hart, Christopher; Zhang, Alison; Prenen, Hans; Goeminne, Jean-Charles; Machiels, Jean-Pascal; Rottey, Sylvie; Corassa, Marcelo; Molin, Graziela Zibetti Dal; Tiscoski, Katsuki; Jardim, Denis Leonardo Fontes; Mak, Milena; Fu, Wei; Yao, Herui; Huang, Jing; Jiang, Haiping; Chen, Baoshi; Yan, Dong; Yang, Yu; Le Tourneau, Christophe; Penel, Nicolas; Salas, Sébastien; Blay, Jean-Yves; Brachet, Pierre-Emmanuel; Durando, Xavier; Emambux, Sheik; Ravaud, Alain; Folprecht, Gunnar; Ahrens, Marit; Golf, Alexander; Haag, Georg Martin; Lordick, Florian; Desuki, Alexander; Cazzaniga, Marina; Ciardiello, Fortunato; Milella, Michele; Koyama, Takafumi; Hirooka, Yoshiki; Okamoto, Wataru; Aogi, Kenjiro; Kuboki, Yasutoshi; Lee, Jungyun; Kim, Sung-Bae; Ahn, Myung-Ju; Chang, Jong Hee; Kim, Yong-Man; Nam, Do-Hyun; Park, Jae-Sung; Paz-Ares, Luis; Moreno, Victor; Cervantes, Andres; Calvo, Mariona; Falcon, Alejandro; Gonzalez, Antonio; Martinez Bueno, Alejandro; García-Corbacho, Javier; Longo, Federico; Yen, Chia-Jui; Chen, Jen-Shi; Hou, Ming-Feng; Chao, Yee; Rau, Kun-Ming; Chiu, Tai-Jan; Feng, Yin-Hsun; Hsu, Chih-Hung; Huang, Wen-Tsung; Lai, Kuan-Ming; Yeh, Su-peng; Palmer, Daniel; Welsh, Liam; Plummer, Ruth; Iyer, Gopakumar; Bilen, Mehmet; Arrowsmith, Edward; Spigel, David Robert; Zandberg, Dan Paul; Doroshow, Deborah; Lu-Emerson, Christine; Moezi, Mehdi; Paulson, Scott; Ward, Patrick; Chaves, Jorge; Grigg, Claud; Hussein, Atif; Manda, Sudhir; Monticelli, Michael; Qamar, Rubina; Richey, Stephen L; Tamura, David; Wilks, Sharon
    Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR) : An international, single-arm, phase 2 study
    In: The Lancet Oncology, Jg. 24, 2023, Nr. 8, S. 925 – 935
    DOI, Online Volltext (Open Access)
  • Kraskowski, Oliver; Stratmann, Jan A.; Wiesweg, Marcel; Eberhardt, Wilfried; Metzenmacher, Martin; Schmid, Kurt Werner; Herold, Thomas; Schildhaus, Hans-Ulrich; Darwiche, Kaid; Aigner, Clemens; Stuschke, Martin; Laue, Katharina; Zaun, Gregor; Kasper, Stefan; Hense, Jörg; Sebastian, Martin; Schuler, Martin; Pogorzelski, Michael
    Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting
    In: Journal of Cancer Research and Clinical Oncology, Jg. 149, 2023, Nr. 11, S. 9243 – 9252
    DOI (Open Access)
  • Kansy, Benjamin A.; Wehrs, Tim P.; Bruderek, Kirsten; Si, Yu; Ludwig, Sonja; Droege, Freya; Hasskamp, Pia; Henkel, Uta; Dominas, Nina; Hoffmann, Thomas K.; Horn, Peter A.; Schuler, Martin; Gauler, Thomas C.; Lindemann, Monika; Lang, Stephan; Bankfalvi, Agnes; Brandau, Sven
    HPV-associated head and neck cancer is characterized by distinct profiles of CD8⁺ T cells and myeloid-derived suppressor cells
    In: Cancer Immunology, Immunotherapy, Jg. 72, 2023, S. 4367 – 4383
    DOI (Open Access)
  • Rosery, Vivian; Mika, Stephan; Schmid, Kurt Werner; Reis, Henning; Stuschke, Martin; Treckmann, Jürgen; Markus, Peter; Schumacher, Brigitte; Albers, David; Mende, Bastian; Lahner, Harald; Wiesweg, Marcel; Schuler, Martin; Siveke, Jens T.; Kasper, Stefan
    Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy
    In: Journal of Cancer Research and Clinical Oncology, Jg. 149, 2023, Nr. 8, S. 4315 – 4325
    DOI (Open Access)
  • Zurloh, M.; Goetz, M.; Herold, T.; Treckmann, Jürgen-Walter; Markus, P.; Schumacher, B.; Albers, D.; Rink, A.; Rosery, V.; Zaun, G.; Kostbade, K.; Pogorzelski, M.; Ting, S.; Schmidt, H.; Stiens, R.; Wiesweg, Marcel; Schuler, Martin; Kasper, Stefan; Virchow, I.
    Impact of encorafenib on survival of patients with BRAFV⁶⁰⁰E-mutant metastatic colorectal cancer in a real-world setting
    In: Journal of Cancer Research and Clinical Oncology, Jg. 149, 2023, Nr. 14, S. 12903 – 12912
    DOI (Open Access)
  • Stockhammer, Paul; Baumeister, Hannah; Ploenes, Till; Bonella, Francesco; Theegarten, Dirk; Dome, Balazs; Pirker, Christine; Berger, Walter; Hegedüs, Luca; Baranyi, Marcell; Schuler, Martin; Deshayes, Sophie; Bölükbas, Servet; Aigner, Clemens; Blanquart, Christophe; Hegedüs, Balazs
    Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma
    In: Lung Cancer, Jg. 185, 2023, 107360
    DOI (Open Access)
  • Dy, Grace K.; Govindan, Ramaswamy; Velcheti, Vamsidhar; Falchook, Gerald S.; Italiano, Antoine; Wolf, Jürgen; Sacher, Adrian G.; Takahashi, Toshiaki; Ramalingam, Suresh S.; Dooms, Christophe; Kim, Dong-Wan; Addeo, Alfredo; Desai, Jayesh; Schuler, Martin; Tomasini, Pascale; Hong, David S.; Lito, Piro; Tran, Qui; Jones, Simon; Anderson, Abraham; Hindoyan, Antreas; Snyder, Wendy; Skoulidis, Ferdinandos; Li, Bob T.
    Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer : 2-Year Analysis of CodeBreaK 100
    In: Journal of Clinical Oncology (JCO), Jg. 41, 2023, Nr. 18, S. 3311 – 3317
    DOI (Open Access)
  • Kersting, David; Mavroeidi, Ilektra-Antonia; Settelmeier, Stephan; Seifert, Robert; Schuler, Martin; Herrmann, Ken; Rassaf, Tienush; Rischpler, Christoph
    Molecular Imaging Biomarkers in Cardiooncology : A View on Established Technologies and Future Perspectives
    In: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. Suppl. 2, S. 29S – 38S
    DOI (Open Access)
  • Fink, Madeleine; Pasche, Saskia; Schmidt, Kira; Tewes, Mitra; Schuler, Martin; Mülley, Bernhard W.; Schadendorf, Dirk; Scherbaum, Norbert; Kowalski, Axel; Skoda, Eva-Maria; Teufel, Martin
    Neurofeedback Treatment Affects Affective Symptoms, But Not Perceived Cognitive Impairment in Cancer Patients : Results of an Explorative Randomized Controlled Trial
    In: Integrative Cancer Therapies, Jg. 22, 2023
    DOI, Online Volltext (Open Access)
  • Grapatsas, Konstantinos; Dörr, Fabian; Menghesha, Hruy; Schuler, Martin; Grünwald, Viktor; Bauer, Sebastian; Schmidt, Hartmut H. -J.; Lang, Stephan; Kimmig, Rainer; Kasper, Stefan; Baldes, Natalie; Bölükbas, Servet
    New Prognostic Score (Essen Score) to Predict Postoperative Morbidity after Resection of Lung Metastases
    In: Cancers, Jg. 15, 2023, Nr. 17, 4355
    DOI, Online Volltext (Open Access)
  • Schuler, Martin; Bölükbas, Servet; Darwiche, Kaid; Theegarten, Dirk; Herrmann, Ken; Stuschke, Martin
    Personalized Treatment for Patients With Lung Cancer
    In: Deutsches Ärzteblatt International, Jg. 120, 2023, Nr. 17, S. 300 – 310
    DOI (Open Access)
  • Sequist, Lecia V; Yang, James Chih-Hsin; Yamamoto, Nobuyuki; O'Byrne, Kenneth; Hirsh, Vera; Mok, Tony; Geater, Sarayut Lucien; Orlov, Sergey; Tsai, Chun-Ming; Boyer, Michael; Su, Wu-Chou; Bennouna, Jaafar; Kato, Terufumi; Gorbunova, Vera; Lee, Ki Hyeong; Shah, Riyaz; Massey, Dan; Zazulina, Victoria; Shahidi, Mehdi; Schuler, Martin
    Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
    In: Journal of Clinical Oncology (JCO), Jg. 41, 2023, Nr. 16, S. 2869 – 2876
    DOI
  • Grapatsas, Konstantinos; Menghesha, Hruy; Dörr, Fabian; Baldes, Natalie; Schuler, Martin; Stuschke, Martin; Darwiche, Kaid; Taube, Christian; Bölükbas, Servet
    Pneumonectomy for Primary Lung Tumors and Pulmonary Metastases : A Comprehensive Study of Postoperative Morbidity, Early Mortality, and Preoperative Clinical Prognostic Factors
    In: Current Oncology, Jg. 30, 2023, Nr. 11, S. 9458 – 9474
    DOI, Online Volltext (Open Access)
  • Okumus, Özlem; Mardanzai, Khaled; Plönes, Till; Theegarten, Dirk; Darwiche, Kaid; Schuler, Martin; Nensa, Felix; Hautzel, Hubertus; Herrmann, Ken; Stuschke, Martin; Hegedus, Balazs; Aigner, Clemens
    Preoperative PET-SUVmax and volume based PET parameters of the primary tumor fail to predict nodal upstaging in early-stage lung cancer
    In: Lung Cancer, Jg. 176, 2023, S. 82 – 88
    DOI
  • Maier, Daniel; Vehreschild, Jörg Janne; Uhl, Barbara; Meyer, Sandra; Berger-Thürmel, Karin; Boerries, Melanie; Braren, Rickmer; Grünwald, Viktor; Hadaschik, Boris; Palm, Stefan; Singer, Susanne; Stuschke, Martin; Juárez, David; Delpy, Pierre; Lambarki, Mohamed; Hummel, Michael; Engels, Cäcilia; Andreas, Stefanie; Gökbuget, Nicola; Ihrig, Kristina; Burock, Susen; Keune, Dietmar; Eggert, Angelika; Keilholz, Ulrich; Schulz, Hagen; Büttner, Daniel; Löck, Steffen; Krause, Mechthild; Esins, Mirko; Ressing, Frank; Schuler, Martin; Brandts, Christian; Brucker, Daniel P.; Husmann, Gabriele; Oellerich, Thomas; Metzger, Patrick; Voigt, Frederik; Illert, Anna L.; Theobald, Matthias; Kindler, Thomas; Sudhof, Ursula; Reckmann, Achim; Schwinghammer, Felix; Nasseh, Daniel; Weichert, Wilko; von Bergwelt-Baildon, Michael; Bitzer, Michael; Malek, Nisar; Öner, Öznur; Schulze-Osthoff, Klaus; Bartels, Stefan; Haier, Jörg; Ammann, Raimund; Schmidt, Anja Franziska; Guenther, Bernd; Janning, Melanie; Kasper, Bernd; Loges, Sonja; Stilgenbauer, Stephan; Kuhn, Peter; Tausch, Eugen; Runow, Silvana; Kerscher, Alexander; Neumann, Michael; Breu, Martin; Lablans, Martin; Serve, Hubert
    Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication Platform
    In: European Journal of Epidemiology, Jg. 38, 2023, Nr. 5, S. 573 – 586
    DOI (Open Access)
  • Zaun, Gregor; Weber, Manuel; Metzenmacher, Martin; Wiesweg, Marcel; Hilser, Thomas; Zaun, Yasmin; Liffers, Sven; Pogorzelski, Michael; Virchow, Isabel; Eberhardt, Wilfried; Theurer, Sarah; Sabbah, Tanja Abu; Reissig, Timm M.; Stuschke, Martin; Kürten, Cornelius; Hussain, Timon; Lang, Stephan; Kasper, Stefan; Fendler, Wolfgang; Herrmann, Ken; Schuler, Martin
    SUVmₐₓ Above 20 in ¹⁸F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown Primary
    In: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 8, S. 1191 – 1194
    DOI (Open Access)
  • Reissig, T.M.; Tzianopoulos, I.; Liffers, S.-T.; Rosery, V.K.; Guyot, M.; Ting, S.; Wiesweg, Marcel; Kasper, S.; Meister, P.; Herold, T.; Schmidt, H.H.; Schumacher, B.; Albers, David; Markus, P.; Treckmann, J.; Schuler, Martin; Schildhaus, Hans-Ulrich; Siveke, Jens T.
    Smaller panel, similar results : Genomic profiling and molecularly informed therapy in pancreatic cancer
    In: ESMO Open, Jg. 8, 2023, Nr. 3, 101539
    DOI (Open Access)
  • Strickler, John H.; Satake, Hironaga; George, Thomas J.; Yaeger, Rona; Hollebecque, Antoine; Garrido-Laguna, Ignacio; Schuler, Martin; Burns, Timothy F.; Coveler, Andrew L.; Falchook, Gerald S.; Vincent, Mark; Sunakawa, Yu; Dahan, Laetitia; Bajor, David; Rha, Sun-Young; Lemech, Charlotte; Juric, Dejan; Rehn, Marko; Ngarmchamnanrith, Gataree; Jafarinasabian, Pegah; Tran, Qui; Hong, David S.
    Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer
    In: The New England Journal of Medicine, Jg. 388, 2023, Nr. 1, S. 33 – 43
    DOI (Open Access)
  • de Langen, Adrianus Johannes; Johnson, Melissa L; Mazieres, Julien; Dingemans, Anne-Marie C; Mountzios, Giannis; Pless, Miklos; Wolf, Jürgen; Schuler, Martin; Lena, Hervé; Skoulidis, Ferdinandos; Yoneshima, Yasuto; Kim, Sang-We; Linardou, Helena; Novello, Silvia; van der Wekken, Anthonie J; Chen, Yuanbin; Peters, Solange; Felip, Enriqueta; Solomon, Benjamin J; Ramalingam, Suresh S.; Dooms, Christophe; Lindsay, Colin R; Ferreira, Carlos Gil; Blais, Normand; Obiozor, Cynthia C; Wang, Yang; Mehta, Bhakti; Varrieur, Tracy; Ngarmchamnanrith, Gataree; Stollenwerk, Björn; Waterhouse, David; Paz-Ares, Luis
    Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG¹²C mutation : a randomised, open-label, phase 3 trial
    In: Lancet, Jg. 401, 2023, Nr. 10378, S. 733 – 746
    DOI, Online Volltext (Open Access)
  • Hegedüs, Luca; Okumus, Özlem; Mairinger, Fabian; Ploenes, Till; Reuter, Sebastian; Schuler, Martin; Welt, Anja; Vega-Rubin-de-Celis, Silvia; Theegarten, Dirk; Bankfalvi, Agnes; Aigner, Clemens; Hegedüs, Balazs
    TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy
    In: Lung Cancer, Jg. 178, 2023, S. 237 – 246
    DOI
  • Martens, Uwe M.; Schröder, Jan; Bengsch, Fee; Sellmann, Ludger; Busies, Sabine; Frank-Gleich, Stefanie; Zaiss, Matthias; Decker, Thomas; Schneeweiss, Andreas; Schuler, Martin; Grebhardt, Sina; Zacharias, Stefan; Marschner, Norbert; Kasenda, Benjamin; Potthoff, Karin; Vannier, Corinne
    The INFINITY study protocol : A retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice
    In: BMC Cancer, Jg. 23, 2023, Nr. 1, 543
    DOI (Open Access)
  • Biersching, T.; Schweda, A.; Oechsle, K.; Nauck, F.; Schuler, U.; Hense, Jörg; Weber, M.; Junghanss, C.; Kramer, T.; Ostgathe, C.; Thuss-Patience, P.; Van Oorschot, B.; Teufel, Martin; Schuler, Martin; Bausewein, C.; Tewes, Mitra; Gahr, S.; Berendt, J.; Benze, G.; Rosenbruch, J.; Neukirchen, M.; Schwarz, J.; Reinholz, U.; Roch, C.
    The OUTREACH study: Oncologists of German university hospitals in rotation on a palliative care unit : Evaluation of attitude and competence in palliative care and hospice
    In: Journal of Cancer Research and Clinical Oncology, Jg. 149, 2023, Nr. 7, S. 2929 – 2936
    DOI (Open Access)
  • Kessler, Lukas; Ferdinandus, Justin; Hirmas, Nader; Bauer, Sebastian; Dirksen, Uta; Zarrad, Fadi; Nader, Michael; Chodyla, Michal; Milosevic, Aleksandar; Umutlu, Lale; Schuler, Martin; Podleska, Lars; Schildhaus, Hans-Ulrich; Fendler, Wolfgang; Hamacher, Rainer; Chodyla, Michal-Kamil
    68Ga-FAPI as a Diagnostic Tool in Sarcoma : Data from the 68Ga-FAPI PET Prospective Observational Trial
    In: Journal of Nuclear Medicine (JNM), Jg. 63, 2022, Nr. 1, S. 89 – 95
    DOI (Open Access)
  • Chan, Stephen L.; Schuler, Martin; Kang, Yoon-Koo; Yen, Chia-Jui; Edeline, Julien; Choo, Su Pin; Lin, Chia-Chi; Okusaka, Takuji; Weiss, Karl-Heinz; Macarulla, Teresa; Cattan, Stéphane; Blanc, Jean-Frederic; Lee, Kyung-Hun; Maur, Michela; Pant, Shubham; Kudo, Masatoshi; Assenat, Eric; Zhu, Andrew X.; Yau, Thomas; Lim, Ho Yeong; Bruix, Jordi; Geier, Andreas; Guillén-Ponce, Carmen; Fasolo, Angelica; Finn, Richard S.; Fan, Jia; Vogel, Arndt; Qin, Shukui; Riester, Markus; Katsanou, Vasiliki; Chaudhari, Monica; Kakizume, Tomoyuki; Gu, Yi; Porta, Diana Graus; Myers, Andrea; Delord, Jean-Pierre
    A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
    In: Journal of Experimental & Clinical Cancer Research, Jg. 41, 2022, Nr. 1, 189
    DOI (Open Access)
  • Yang, James Chih-Hsin; Schuler, Martin; Popat, Sanjay; Miura, Satoru; Park, Keunchil; Passaro, Antonio; De Marinis, Filippo; Solca, Flavio; Märten, Angela; Kim, Edward S.
    Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations : An Updated Database of 1023 Cases Brief Report
    In: Frontiers in Oncology, Jg. 12, 2022, 834704
    DOI (Open Access)
  • Metzenmacher, Martin; Hegedüs, Balazs; Forster, Jan; Schramm, Alexander; Horn, Peter; Klein, Christoph A.; Bielefeld, Nicola; Ploenes, Till; Aigner, Clemens; Theegarten, Dirk; Schildhaus, Hans-Ulrich; Siveke, Jens T.; Schuler, Martin; Lueong, Smiths S.
    Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancer
    In: Translational Oncology, Jg. 15, 2022, Nr. 1, 101279
    DOI (Open Access)
  • Wessolly, Michael; Stephan-Falkenau, Susann; Streubel, Anna; Wiesweg, Marcel; Borchert, Sabrina; Mairinger, Elena; Kollmeier, Jens; Reis, Henning; Bauer, Torsten; Schmid, Kurt Werner; Mairinger, Thomas; Schuler, Martin; Mairinger, Fabian D.
    Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy
    In: BMC Cancer, Jg. 22, 2022, Nr. 1, 46
    DOI, Online Volltext (Open Access)
  • Guberina, Maja; Guberina, Nika; Pöttgen, Christoph; Gauler, Thomas; Richlitzki, Cedric; Metzenmacher, Martin; Wiesweg, Marcel; Plönes, Till; Forsting, Michael; Wetter, Axel; Herrmann, Ken; Hautzel, Hubertus; Darwiche, Kaid; Theegarten, Dirk; Aigner, Clemens; Schuler, Martin; Stuschke, Martin; Eberhardt, Wilfried
    Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer : focus on treatment selection and prognostic factors
    In: Immunotherapy, Jg. 14, 2022, Nr. 12, S. 927 – 944
    DOI (Open Access)
  • Ferdinandus, Justin; Costa, Pedro Fragoso; Kessler, Lukas; Weber, Manuel; Hirmas, Nader; Kostbade, Karina; Bauer, Sebastian; Schuler, Martin; Ahrens, Marit; Schildhaus, Hans-Ulrich; Rischpler, Christoph; Grafe, Hong; Siveke, Jens T.; Herrmann, Ken; Fendler, Wolfgang P.; Hamacher, Rainer
    Initial Clinical Experience with ⁹⁰Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors : A Case Series of 9 Patients
    In: Journal of Nuclear Medicine (JNM), Jg. 63, 2022, Nr. 5, S. 727 – 734
    DOI (Open Access)
  • Guberina, Nika; Pöttgen, Christoph; Schuler, Martin; Guberina, Maja; Stamatis, Georgios; Plönes, Till; Metzenmacher, Martin; Theegarten, Dirk; Gauler, Thomas; Darwiche, Kaid; Aigner, Clemens; Eberhardt, Wilfried; Stuschke, Martin
    Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment
    In: Radiation Oncology, Jg. 17, 2022, Nr. 1, 126
    DOI, Online Volltext (Open Access)
  • Keyl, Julius; Kasper, S.; Wiesweg, Marcel; Götze, J.; Schönrock, M.; Sinn, M.; Berger, A.; Nasca, E.; Kostbade, K.; Schumacher, B.; Markus, P.; Treckmann, Jürgen-Walter; Schmid, Kurt Werner; Schildhaus, Hans-Ulrich; Siveke, Jens T.; Schuler, Martin; Kleesiek, Jens
    Multimodal survival prediction in advanced pancreatic cancer using machine learning
    In: ESMO Open, Jg. 7, 2022, Nr. 5, 100555
    DOI, Online Volltext (Open Access)
  • Chwallek, Daniel; Schweda, Adam; Neukirchen, M.; Hense, Jörg; Schwartz, J.; Mallmann, Bernhard; Teufel, Martin; Schuler, Martin; Tewes, Mitra
    PARPACT – Paramedic Palliative Care Test : Validierung eines Tests für palliatives Wissen und Selbstwirksamkeitserwartung bei Mitarbeiter*innen im Rettungswesen
    In: Der Schmerz, Jg. 36, 2022, Nr. 5, S. 333 – 341
    DOI (Open Access)
  • Müller, Sandy; Fink, M.; Hense, Jörg; Comino, M. R. Salvador; Schuler, M.; Teufel, Martin; Tewes, Mitra
    Palliative care outpatients in a German comprehensive cancer center : identifying indicators for early and late referral
    In: BMC Palliative Care, Jg. 21, 2022, Nr. 1, 221
    DOI, Online Volltext (Open Access)
  • Subbiah, Vivek; Cassier, Philippe A.; Siena, Salvatore; Garralda, Elena; Paz-Ares, Luis; Garrido, Pilar; Nadal, Ernest; Vuky, Jacqueline; Lopes, Gilberto; Kalemkerian, Gregory P.; Bowles, Daniel W.; Seetharam, Mahesh; Chang, Jianhua; Zhang, Hui; Green, Jennifer; Zalutskaya, Alena; Schuler, Martin; Fan, Yun; Curigliano, Giuseppe
    Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
    In: Nature Medicine, Jg. 28, 2022, Nr. 8, S. 1640 – 1645
    DOI (Open Access)
  • Schuler, Martin; Zimmer, Lisa; Kim, Kevin B.; Sosman, Jeffrey A.; Ascierto, Paolo A.; Postow, Michael A.; De Vos, Filip Y.F.L.; van Herpen, Carla M.L.; Carlino, Matteo S.; Johnson, Douglas B.; Berking, Carola; Reddy, Micaela B.; Harney, Allison S.; Berlin, Jordan D.; Amaria, Rodabe N.
    Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
    In: Clinical Cancer Research, Jg. 28, 2022, Nr. 14, S. 3002 – 3010
    DOI (Open Access)
  • Krebs, Matthew G.; Malapelle, Umberto; André, Fabrice; Paz-Ares, Luis; Schuler, Martin; Thomas, David M.; Vainer, Gilad; Yoshino, Takayuki; Rolfo, Christian
    Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer
    In: JAMA Oncology, Jg. 8, 2022, Nr. 12, S. 1830 – 1839
    DOI
  • Guberina, Maja; Herrmann, Ken; Pöttgen, Christoph; Guberina, Nika; Hautzel, Hubertus; Gauler, Thomas; Ploenes, Till; Umutlu, Lale; Wetter, Axel; Theegarten, Dirk; Aigner, Clemens; Eberhardt, Wilfried; Metzenmacher, Martin; Wiesweg, Marcel; Schuler, Martin; Karpf-Wissel, Rüdiger; Santiago Garcia, Alina; Darwiche, Kaid; Stuschke, Martin
    Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CT
    In: Scientific Reports, Jg. 12, 2022, Nr. 1, 17511
    DOI, Online Volltext (Open Access)
  • Scheffler, Matthias; Wiesweg, Marcel; Michels, Sebastian; Nogová, Lucia; Kron, Anna; Herold, Thomas; Scheel, Andreas H.; Metzenmacher, Martin; Eberhardt, Wilfried; Reis, Henning; Fassunke, Jana; Darwiche, Kaid; Aigner, Clemens; Schaufler, Diana; Riedel, Richard; Fischer, Rieke; Koleczko, Sophia; Schildhaus, Hans-Ulrich; Merkelbach-Bruse, Sabine; Schmid, Kurt Werner; Büttner, Reinhard; Wolf, Jürgen; Schuler, Martin
    Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications
    In: Lung Cancer, Jg. 168, 2022, S. 10 – 20
    DOI
  • Fendler, Wolfgang P.; Pabst, Kim M.; Kessler, Lukas; Fragoso Costa, Pedro; Ferdinandus, Justin; Weber, Manuel; Lippert, Maria; Lückerath, Katharina; Umutlu, Lale; Kostbade, Karina; Mavroeidi, Ilektra A.; Schuler, Martin; Ahrens, Marit; Rischpler, Christoph; Bauer, Sebastian; Herrmann, Ken; Siveke, Jens T.; Hamacher, Rainer
    Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
    In: Clinical Cancer Research, Jg. 28, 2022, Nr. 19, S. 4346 – 4353
    DOI (Open Access)
  • Thumser-Henner, Clotilde; Oeck, Sebastian; Kalmbach, Sophie; Forster, Jan; Kindl, Franziska; Sak, Ali; Schramm, Alexander; Schuler, Martin
    Syntaxin 18 regulates the DNA damage response and epithelial-to-mesenchymal transition to promote radiation resistance of lung cancer
    In: Cell Death and Disease, Jg. 13, 2022, Nr. 6, 529
    DOI, Online Volltext (Open Access)
  • Metzenmacher, Martin; Hegedüs, Balazs; Forster, Jan; Schramm, Alexander; Horn, Peter; Klein, Christoph A.; Bielefeld, Nicola; Ploenes, Till; Aigner, Clemens; Siveke, Jens T.; Schuler, Martin; Lueong, Smiths S.
    The clinical utility of cfRNA for disease detection and surveillance : A proof of concept study in non-small cell lung cancer
    In: Thoracic Cancer, Jg. 13, 2022, Nr. 15, S. 2180 – 2191
    DOI, Online Volltext (Open Access)
  • Wiesweg, Marcel; Eberhardt, Wilfried; Schuler, Martin; Plönes, Till
    Therapie früher und lokal fortgeschrittener Stadien des nicht-kleinzelligen Lungenkarzinoms
    In: Die Innere Medizin, Jg. 63, 2022, Nr. 7, S. 717 – 723
    DOI
  • Peuker, Caroline A.; Yaghobramzi, Sarvenaz; Grunert, Corinna; Keilholz, Luisa; Gjerga, Enio; Hennig, Steffen; Schaper, Sigrid; Na, Il-Kang; Keller, Ulrich; Brucker, Sara; Decker, Thomas; Fasching, Peter; Fehm, Tanja; Janni, Wolfgang; Kümmel, Sherko; Schneeweiss, Andreas; Schuler, Martin; Lüftner, Diana; Busse, Antonia
    Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer : findings from the RIBECCA trial
    In: European Journal of Cancer (EJC), Jg. 162, 2022, S. 45 – 55
    DOI, Online Volltext (Open Access)
  • Warnecke, Eva; Hosters, B.; Gottlieb, T.; Welt, Anja; Bauer, Sebastian; Wiesweg, Marcel; Schuler, Martin; Tewes, Mitra
    Vergleich der Eigen- und Fremderfassung der Symptomlast onkologischer Patient:innen im Rahmen einer stationären Versorgung
    In: Zeitschrift für Palliativmedizin, Jg. 23, 2022, Nr. 05, S. e38 – e39
    DOI
  • Metzenmacher, Martin; Kopp, Hans-Georg; Griesinger, Frank; Reinmuth, Niels; Sebastian, Martin; Serke, Monika; Waller, Cornelius Florian; Thomas, Michael; Eggert, Jochen; Schmid-Bindert, Gerald; Hoiczyk, Mathias; Christoph, Daniel; Kimmich, Martin; Deuß, Burkhard; Seifert, Stephanie; Held, Swantje; Schuler, Martin; Herold, Thomas; Breitenbücher, Frank; Eberhardt, Wilfried
    A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer
    In: Therapeutic Advances in Medical Oncology, Jg. 13, 2021
    DOI, Online Volltext (Open Access)
  • Metzenmacher, Martin; Goetz, Moritz; Herold, Thomas; Stuschke, Martin; Aigner, Clemens; Darwiche, Kaid; Eberhardt, Wilfried; Schuler, Martin; Wiesweg, Marcel
    Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V⁶⁰⁰-mutated Squamous Cell Lung Cancer : Concurrent Evolvement of PTEN and MEK1 Mutations
    In: Clinical Lung Cancer, Jg. 22, 2021, Nr. 5, S. E668 – E672
    DOI
  • Rosery, Vivian; Reis, Henning; Savvatakis, Konstantinos; Kowall, Bernd; Stuschke, Martin; Paul, Andreas; Dechene, Alexander; Yang, JiaJin; Zhao, Ben; Borgers, Arianna; Kasper, Stefan; Schuler, Martin; Cheung, Phyllis F.; Siveke, Jens T.
    Antitumor immune response is associated with favorable survival in GEP-NEN G3
    In: Endocrine-Related Cancer, Jg. 28, 2021, Nr. 10, S. 683 – 693
    DOI
  • Mrotzek, Simone M.; Lena, Alessia; Hadzibegovic, Sara; Ludwig, Ria; Al-Rashid, Fadi; Mahabadi, Amir Abbas; Mincu, Raluca I.; Michel, Lars; Johannsen, Laura; Hinrichs, Lena; Schuler, Martin; Keller, Ulrich; Anker, Stefan D.; Landmesser, Ulf; Rassaf, Tienush; Anker, Markus S.; Totzeck, Matthias
    Assessment of coronary artery disease during hospitalization for cancer treatment
    In: Clinical Research in Cardiology, Jg. 110, 2021, Nr. 2, S. 200 – 210
    DOI (Open Access)
  • Wiesweg, Marcel; Preuß, Cedric; Roeper, Julia; Metzenmacher, Martin; Eberhardt, Wilfried; Stropiep, Ursula; Wedeken, Katrin; Reis, Henning; Herold, Thomas; Darwiche, Kaid; Aigner, Clemens; Stuschke, Martin; Schildhaus, Hans-Ulrich; Schmid, Kurt Werner; Falk, Markus; Heukamp, Lukas; Tiemann, Markus; Griesinger, Frank; Schuler, Martin
    BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy
    In: European Journal of Cancer (EJC), Jg. 149, 2021, S. 211 – 221
    DOI
  • Frikkel, Johanna; Beckmann, Mingo B.; de Lazzari, Nico; Götte, Miriam; Kasper, Stefan; Hense, Jörg; Schuler, Martin; Teufel, Martin; Tewes, Mitra
    Changes in fatigue, barriers, and predictors towards physical activity in advanced cancer patients over a period of 12 months : A comparative study
    In: Supportive Care in Cancer, Jg. 29, 2021, Nr. 9, S. 5127 – 5137
    DOI (Open Access)
  • Markus, M.; Abendroth, Annalena; Noureddine, R.; Paul, Andreas; Breitenbuecher, Sandra; Virchow, Isabel; Schmid, Kurt Werner; Markus, Peter; Schumacher, Brigitte M.; Wiesweg, Marcel; Wendling, Johanna; Mende, Bastian; Siveke, Jens T.; Schuler, Martin; Kasper, Stefan
    Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy
    In: Journal of Cancer Research and Clinical Oncology, Jg. 147, 2021, Nr. 2, S. 579 – 591
    DOI (Open Access)
  • Guberina, Maja; Sak, Ali; Pöttgen, Christoph; Tinhofer-Keilholz, Ingeborg; Budach, Volker; Balermpas, Panagiotis; Von der Grün, Jens; Rödel, Claus Michael; Gkika, Eleni; Grosu, Anca-Ligia; Abdollahi, Amir; Debus, Jürgen; Belka, Claus; Pigorsch, Steffi; Combs, Stephanie E.; Mönnich, David; Zips, Daniel; De-Colle, Chiara; Welz, Stefan; Linge, Annett; Lohaus, Fabian; Baretton, Gustavo; Gauler, Thomas; Baumann, Michael; Krause, Mechthild; Schuler, Martin; Bankfalvi, Agnes; Höing, Benedikt; Lang, Stephan; Stuschke, Martin
    Correction: ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy
    In: The Pharmacogenomics Journal, Jg. 21, 2021, Nr. 2, S. 273
    DOI (Open Access)
  • Schuler, Martin
    Corrigendum to “Inhibiting fibroblast growth factor receptors in cancer – The next generation”
    In: Annals of Oncology, Jg. 32, 2021, Nr. 1, S. 126
    DOI (Open Access)
  • Guberina, Maja; Sak, Ali; Pöttgen, Christoph; Tinhofer-Keilholz, Ingeborg; Budach, Volker; Balermpas, Panagiotis; Von der Grün, Jens; Rödel, Claus Michael; Gikka, Eleni; Grosu, Anca-Ligia; Abdollahi, Amir; Debus, Jürgen; Belka, Claus; Pigorsch, Steffi; Combs, Stephanie; Mönnich, David; Zips, Daniel; De-Colle, Chiara; Welz, Stefan; Linge, Annett; Lohaus, Fabian; Baretton, Gustavo; Gauler, Thomas; Baumann, Michael; Krause, Mechthild; Schuler, Martin; Bankfalvi, Agnes; Höing, Benedikt; Lang, Stephan; Stuschke, Martin
    ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy
    In: The Pharmacogenomics Journal, Jg. 21, 2021, Nr. 1, S. 37 – 46
    DOI (Open Access)
  • Şahin, Uǧur; Türeci, Özlem; Manikhas, Georgiy Moiseevich; Lordick, Florian; Rusyn, Andrii; Vynnychenko, Ihor A.; Dudov, Asen; Bazin, Igor S.; Bondarenko, Igor; Melichar, Bohuslav; Dhaene, Karl F.L.; Wiechen, Kai; Huber, Claudia; Maurus, Daniel; Arozullah, A.; Park, J.W.; Schuler, Martin; Al-Batran, Salah Eddin
    FAST : a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
    In: Annals of Oncology, Jg. 32, 2021, Nr. 5, S. 609 – 619
    DOI (Open Access)
  • Adamczyk, Alexandra; Pastille, Eva; Kehrmann, Jan; Vu, Vivian P.; Geffers, Robert; Wasmer, Marie-Hélène; Kasper, Stefan; Schuler, Martin; Lange, Christian; Muggli, Beat; Rau, Tilman T.; Klein, Diana; Hansen, Wiebke; Krebs, Philippe; Buer, Jan; Westendorf, Astrid
    GPR15 facilitates recruitment of regulatory T cells to promote colorectal cancer
    In: Cancer Research, Jg. 81, 2021, Nr. 11, S. 2970 – 2982
    DOI (Open Access)
  • Ho, Cassandra S. L.; Tüns, Alicia I.; Schildhaus, Hans-Ulrich; Wiesweg, Marcel; Grüner, Barbara M.; Hegedus, Balazs; Schuler, Martin; Schramm, Alexander; Oeck, Sebastian
    HER2 mediates clinical resistance to the KRASG¹²C inhibitor sotorasib, which is overcome by co-targeting SHP2
    In: European Journal of Cancer (EJC), Jg. 159, 2021, S. 16 – 23
    DOI
  • Pogorzelski, Michael; Hilser, Thomas; Ting, Saskia; Kansy, Benjamin; Gauler, Thomas; Stuschke, Martin; Schmid, Kurt Werner; Lang, Stephan; Grünwald, Viktor; Schuler, Martin; Kasper, Stefan
    Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab
    In: Frontiers in Oncology, Jg. 11, 2021, 635096
    DOI, Online Volltext (Open Access)
  • Guberina, Maja; Darwiche, Kaid; Hautzel, Hubertus; Ploenes, Till; Pöttgen, Christoph; Guberina, Nika; Herrmann, Ken; Umutlu, Lale; Wetter, Axel; Theegarten, Dirk; Aigner, Clemens; Eberhardt, Wilfried; Schuler, Martin; Karpf-Wissel, Rüdiger; Stuschke, Martin
    Impact of EBUS-TBNA in addition to [¹⁸F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC
    In: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 48, 2021, S. 2894 – 2903
    DOI (Open Access)
  • Stefani, Dirk; Plönes, Till; Viehof, Jan; Darwiche, Kaid; Stuschke, Martin; Schuler, Martin; Aigner, Clemens
    Lung Cancer Surgery after Neoadjuvant Immunotherapy
    In: Cancers, Jg. 13, 2021, Nr. 16, 4033
    DOI, Online Volltext (Open Access)
  • Chih-Hsin Yang, J.; Schuler, Martin; Popat, S.; Miura, S.; Heeke, S.; Passaro, A.; de Marinis, F.; Park, K.; Kim, E.S.
    MO01.36 Afatinib in Asian and Non-Asian Patients (pts) with EGFR Mutation-Positive (EGFRm+) NSCLC Harboring Major Uncommon Mutations
    In: Journal of Thoracic Oncology, Jg. 16, 2021, Nr. 1, S. 31
    DOI (Open Access)
  • Hautzel, Hubertus; Alnajdawi, Yazan; Fendler, Wolfgang; Rischpler, Christoph; Darwiche, Kaid; Eberhardt, Wilfried; Umutlu, Lale; Theegarten, Dirk; Stuschke, Martin; Schuler, Martin; Aigner, Clemens; Herrmann, Ken; Plönes, Till
    N-staging in large cell neuroendocrine carcinoma of the lung : diagnostic value of [¹⁸F]FDG PET/CT compared to the histopathology reference standard
    In: EJNMMI Research, Jg. 11, 2021, Nr. 1, 68
    DOI, Online Volltext (Open Access)
  • Guberina, Maja; Darwiche, Kaid; Hautzel, Hubertus; Pöttgen, Christoph; Guberina, Nika; Gauler, Thomas; Ploenes, Till; Umutlu, Lale; Theegarten, Dirk; Aigner, Clemens; Eberhardt, Wilfried; Metzenmacher, Martin; Wiesweg, Marcel; Karpf-Wissel, Rüdiger; Schuler, Martin; Herrmann, Ken; Stuschke, Martin
    Patterns of nodal spread in stage III NSCLC : Importance of EBUS-TBNA and ¹⁸F-FDG PET/CT for radiotherapy target volume definition
    In: Radiation Oncology, Jg. 16, 2021, Nr. 1, 176
    DOI, Online Volltext (Open Access)
  • Wick, Antje; Bahr, Oliver; Schuler, Martin; Rohrberg, Kristoffer; Chawla, Sant P.; Janku, Filip; Schiff, David; Heinemann, Volker; Narita, Yoshitaka; Lenz, Heinz-Josef; Ikeda, Masafumi; Ando, Yuichi; Wick, Wolfgang; Steinbach, Joachim P.; Burger, Michael C.; Wenger, Katharina; Lassen, Ulrik; Sankhala, Kamalesh K.; Roggia, Cristiana; Genvresse, Isabelle; Munhoz, Catya; Rentzsch, Christine; Reschke, Susanne; Langer, Simon; Wagner, Markus; Kaulfuss, Stefan; Cai, Charles; Lagkadinou, Eleni; Jeffers, Michael; Peña, Carol; Tabatabai, Ghazaleh
    Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors
    In: Clinical Cancer Research, Jg. 27, 2021, Nr. 10, S. 2723 – 2733
    DOI (Open Access)
  • Valdivia, Daniel; Cheufou, Danjouma; Fels, Benjamin; Puhlvers, Stephan; Mardanzai, Khaled; Zaatar, Mohamed; Weinreich, Gerhard; Taube, Christian; Theegarten, Dirk; Stuschke, Martin; Schuler, Martin; Stamatis, Georgios; Hegedus, Balazs; Aigner, Clemens
    Potential Prognostic Value of Preoperative Leukocyte Count, Lactate Dehydrogenase and C-Reactive Protein in Thymic Epithelial Tumors
    In: Pathology & Oncology Research, Jg. 27, 2021, S. 629993
    DOI, Online Volltext (Open Access)
  • Subbiah, Vivek; Hu, Mimi I.; Wirth, Lori J.; Schuler, Martin; Mansfield, Aaron S.; Curigliano, Giuseppe; Brose, Marcia S.; Zhu, Viola W.; Leboulleux, Sophie; Bowles, Daniel W.; Baik, Christina S.; Adkins, Douglas; Keam, Bhumsuk; Matos, Ignacio; Garralda, Elena; Gainor, Justin F.; Lopes, Gilberto; Lin, Chia-Chi; Godbert, Yann; Sarker, Debashis; Miller, Stephen G.; Clifford, Corinne; Zhang, Hui; Turner, Christopher D.; Taylor, Matthew H.
    Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW) : a multi-cohort, open-label, registrational, phase 1/2 study
    In: The Lancet Diabetes and Endocrinology, Jg. 9, 2021, Nr. 8, S. 491 – 501
    DOI
  • Guberina, Maja; Pöttgen, Christoph; Metzenmacher, Martin; Wiesweg, Marcel; Schuler, Martin; Aigner, Clemens; Ploenes, Till; Umutlu, Lale; Gauler, Thomas; Darwiche, Kaid; Stamatis, Georgios; Theegarten, Dirk; Hautzel, Hubertus; Jentzen, Walter; Guberina, Nika; Herrmann, Ken; Eberhardt, Wilfried E.E.; Stuschke, Martin
    Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Non-Small Cell Lung Cancer Patients Receiving Definitive Chemoradiotherapy
    In: Journal of Nuclear Medicine (JNM), Jg. 62, 2021, Nr. 12, S. 1684 – 1691
    DOI, Online Volltext (Open Access)
  • Skoulidis, Ferdinandos; Li, Bob T.; Dy, Grace K.; Price, Timothy J.; Falchook, Gerald S.; Wolf, Jürgen; Italiano, Antoine; Schuler, Martin; Borghaei, Hossein; Barlesi, Fabrice; Kato, Terufumi; Curioni-Fontecedro, Alessandra; Sacher, Adrian; Spira, Alexander; Ramalingam, Suresh S.; Takahashi, Toshiaki; Besse, Benjamin; Anderson, Abraham; Ang, Agnes; Tran, Qui; Mather, Omar; Henary, Haby; Ngarmchamnanrith, Gataree; Friberg, Gregory; Velcheti, Vamsidhar; Govindan, Ramaswamy
    Sotorasib for Lung Cancers with KRAS p.G12C Mutation
    In: The New England Journal of Medicine, Jg. 384, 2021, Nr. 25, S. 2371 – 2381
    DOI, Online Volltext (Open Access)
  • Zaun, Gregor; Schuler, Martin
    Systemische Tumortherapien des CUP-Syndroms
    In: Der Onkologe, Jg. 27, 2021, Nr. 7, S. 658 – 662
    DOI
  • Yang, James Chih-Hsin; Schuler, Martin; Popat, Sanjay; Miura, Satoru; Heeke, Simon; Park, Keunchil; Märten, Angela; Kim, Edward S.
    Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations : A Database of 693 Cases
    In: Journal of Thoracic Oncology, Jg. 15, 2020, Nr. 5, S. 803 – 815
    DOI (Open Access)
  • Bhat, Hilal; Zaun, Gregor; Hamdan, Thamer A.; Lang, Judith; Adomati, Tom; Schmitz, Rosa; Friedrich, Sarah-Kim; Bergerhausen, Michael; Cham, Lamin B.; Li, Fanghui; Ali, Murtaza; Zhou, Fan; Khairnar, Vishal; Duhan, Vikas; Brandenburg, Tim; Machlah, Yara Maria; Schiller, Maximilian; Berry, Arshia; Xu, Haifeng; Vollmer, Jörg; Häussinger, Dieter; Thier, Beatrice; Pandyra, Aleksandra A.; Schadendorf, Dirk; Paschen, Annette; Schuler, Martin; Lang, Philipp A.; Lang, Karl S.
    Arenavirus Induced CCL5 Expression Causes NK Cell-Mediated Melanoma Regression
    In: Frontiers in Immunology, Jg. 11, 2020, S. 1849
    DOI, Online Volltext (Open Access)
  • Kasper, Stefan; Meiler, Johannes; Knipp, Heike; Höhler, Thomas; Reimer, Peter; Steinmetz, Tilman; Berger, Winfried; Linden, Gabriele; Reis, Henning; Markus, Peter; Paul, Andreas; Dechene, Alexander; Schumacher, Brigitte; Kostbade, Karina; Virchow, Isabel; Ting, Saskia; Worm, Karl; Schmid, Kurt Werner; Herold, Thomas; Wiesweg, Marcel; Schuler, Martin; Trarbach, Tanja
    Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer : The CEBIFOX Trial
    In: Clinical Colorectal Cancer, Jg. 19, 2020, Nr. 4, S. 236 – 247.e6
    DOI
  • Welt, Anja; Wiesweg, Marcel; Theurer, Sarah; Abenhardt, Wolfgang; Groschek, Matthias; Müller, Lothar; Schröder, Jan; Tewes, Mitra; Chiabudini, Marco; Potthoff, Karin; Bankfalvi, Agnes; Marschner, Norbert; Schuler, Martin; Breitenbücher, Frank
    Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression
    In: Cancer Medicine, Jg. 9, 2020, Nr. 13, S. 4527 – 4539
    DOI, Online Volltext (Open Access)
  • Wiesweg, Marcel; Herold, Thomas; Metzenmacher, Martin; Eberhardt, Wilfried; Reis, Henning; Darwiche, Kaid; Aigner, Clemens; Stuschke, Martin; Herrmann, Ken; Nensa, Felix; Schildhaus, Hans-Ulrich; Schuler, Martin
    Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation
    In: Lung Cancer, Jg. 139, 2020, S. 165 – 168
    DOI
  • Bilecz, Agnes; Stockhammer, Paul; Theegarten, Dirk; Kern, Izidor; Jakopovic, Marko; Samarzija, Miroslav; Klikovits, Thomas; Hoda, Mir A.; Döme, Balázs; Oberndorfer, Felicitas; Muellauer, Leonhard; Fillinger, János; Kovács, Ildikó; Pirker, Christine; Schuler, Martin; Plönes, Till; Aigner, Clemens; Klepetko, Walter; Berger, Walter; Brcic, Luka; Laszlo, Viktória; Hegedus, Balazs
    Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma
    In: Histopathology, Jg. 77, 2020, Nr. 1, S. 55 – 66
    DOI (Open Access)
  • Guberina, Nika; Pöttgen, Christoph; Schuler, Martin; Guberina, Maja; Stamatis, Georgios; Plönes, Till; Krebs, Bettina; Metzenmacher, Martin; Theegarten, Dirk; Gauler, Thomas; Jöckel, Karl-Heinz; Darwiche, Kaid; Aigner, Clemens; Stuschke, Martin; Eberhardt, Wilfried
    Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment : Only few risks left to improve
    In: European Journal of Cancer (EJC), Jg. 138, 2020, S. 156 – 168
    DOI
  • Wiesweg, Marcel; Schuler, Martin; Schildhaus, Hans-Ulrich
    Crizotinib in ROS1 and MET deregulated NSCLC-letter
    In: Clinical Cancer Research, Jg. 26, 2020, Nr. 7, S. 1774
    DOI (Open Access)
  • Stockhammer, Paul; Ploenes, Till; Theegarten, Dirk; Schuler, Martin; Maier, Sandra; Aigner, Clemens; Hegedus, Balazs
    Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma
    In: Lung Cancer, Jg. 139, 2020, S. 124 – 132
    DOI
  • Reissig, Timm M.; Sara, Linda; Ting, Saskia; Reis, Henning; Metzenmacher, Martin; Eberhardt, Wilfried; Zaun, Gregor; Herold, Thomas; Aigner, Clemens; Darwiche, Kaid; Stuschke, Martin; Schildhaus, Hans-Ulrich; Schuler, Martin; Wiesweg, Marcel
    ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer
    In: Lung Cancer, Jg. 149, 2020, S. 10 – 16
    DOI
  • Frikkel, Johanna; Götte, Miriam; Beckmann, Mingo B.; Kasper, Stefan; Hense, Jörg; Teufel, Martin; Schuler, Martin; Tewes, Mitra
    Fatigue, barriers to physical activity and predictors for motivation to exercise in advanced Cancer patients
    In: BMC Palliative Care, Jg. 19, 2020, Nr. 1, S. 43
    DOI, Online Volltext (Open Access)
  • Nothdurft, Silke; Thumser-Henner, Clotilde; Breitenbücher, Frank; Okimoto, Ross A.; Dorsch, Madeleine; Opitz, Christiane A.; Sadik, Ahmed; Esser, Charlotte; Hölzel, Michael; Asthana, Saurabh; Forster, Jan; Beisser, Daniela; Kalmbach, Sophie; Grüner, Barbara M.; Bivona, Trever G.; Schramm, Alexander; Schuler, Martin
    Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis
    In: Oncogenesis, Jg. 9, 2020, Nr. 11, S. 102
    DOI, Online Volltext (Open Access)
  • Stockhammer, Paul; Ho, Cassandra Su Lyn; Hegedus, Luca; Lotz, Gabor; Molnár, Eszter; Bankfalvi, Agnes; Herold, Thomas; Kalbourtzis, Stavros; Ploenes, Till; Eberhardt, Wilfried; Schuler, Martin; Aigner, Clemens; Schramm, Alexander; Hegedus, Balazs
    HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model
    In: Lung Cancer, Jg. 144, 2020, S. 20 – 29
    DOI
  • Welt, Anja; Bogner, Simon; Arendt, Marina; Kossow, Josef; Huffziger, Antonia; Pohlkamp, Christian; Steiniger, Heike; Becker, Ute; Alashkar, Ferras; Kohl, Marzena; Wiesweg, Marcel; Richly, Heike; Hense, Jörg; Scheulen, Max Ernst; Schuler, Martin; Seeber, Siegfried; Tewes, Mitra
    Improved survival in metastatic breast cancer : results from a 20-year study involving 1033 women treated at a single comprehensive cancer center
    In: Journal of Cancer Research and Clinical Oncology, 2020
    DOI (Open Access)
  • Wiesweg, Marcel; Mairinger, Fabian; Reis, Henning; Goetz, Moritz; Kollmeier, Jens; Misch, Daniel; Stephan-Falkenau, Susann; Mairinger, Thomas; Walter, Robert F.H.; Hager, Thomas; Metzenmacher, Martin; Eberhardt, Wilfried; Zaun, Gregor; Köster, Johannes; Stuschke, Martin; Aigner, Clemens; Darwiche, Kaid; Schmid, Kurt Werner; Rahmann, Sven; Schuler, Martin
    Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context
    In: European Journal of Cancer (EJC), Jg. 140, 2020, S. 76 – 85
    DOI
  • Schuler, Martin; Berardi, Rossana; Lim, Darren Wan Teck; de Jonge, Maja J. A.; Bauer, Todd M.; Azaro, Analía; Gottfried, Maya; Han, Jiyoun; Lee, Dae-hee; Wollner, M.; Hong, David S.; Vogel, Arndt; Delmonte, Angelo; Akimov, Mikhail; Ghebremariam, Samson; Cui, X.; Nwana, N.; Giovannini, Monica; Kim, Tae-min
    Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer : Clinical and biomarker results from a phase I trial
    In: Annals of Oncology, Jg. 31, 2020, Nr. 6, S. 789 – 797
    DOI (Open Access)
  • Bang, Yung-Jue; Su, Wu-Chou; Schuler, Martin; Nam, Do-Hyun; Lim, Wan Teck; Bauer, Todd M.; Azaro, Analia; Poon, Ronnie Tung Ping; Hong, David; Lin, Chia-Chi; Akimov, Mikhail; Ghebremariam, Samson; Zhao, Sylvia; Giovannini, Monica; Ma, Brigette
    Phase 1 study of capmatinib in MET-positive solid tumor patients : Dose escalation and expansion of selected cohorts
    In: Cancer Science, Jg. 111, 2020, Nr. 2, S. 536 – 547
    DOI, Online Volltext (Open Access)
  • Bardia, Aditya; Gounder, Mrinal; Rodon, Jordi; Janku, Filip; Lolkema, Martijn P.; Stephenson, Joe J.; Bedard, Philippe L.; Schuler, Martin; Sessa, Cristiana; LoRusso, Patricia; Thomas, Michael; Maacke, Heiko; Evans, Helen; Sun, Yongjian; Tan, Daniel S.W.
    Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations
    In: The Oncologist, Jg. 24, 2020, Nr. 1, S. e160 – e169
    DOI (Open Access)
  • Metzenmacher, Martin; Váraljai, Renáta; Hegedüs, Balazs; Cima, Igor; Forster, Jan; Schramm, Alexander; Scheffler, Björn; Horn, Peter; Klein, Christoph A.; Szarvas, Tibor; Reis, Henning; Bielefeld, Nicola; Rösch, Alexander; Aigner, Clemens; Kunzmann, Volker; Wiesweg, Marcel; Siveke, Jens T.; Schuler, Martin; Lueong, Smiths S.
    Plasma next generation sequencing and droplet digital-qpcr-based quantification of circulating cell-free rna for noninvasive early detection of cancer
    In: Cancers, Jg. 12, 2020, Nr. 2, 353
    DOI, Online Volltext (Open Access)
  • Such, Lina; Zhao, Fang; Liu, Derek; Thier, Beatrice; Le-Trilling, Vu Thuy Khanh; Sucker, Antje; Coch, Christoph; Pieper, Natalia; Howe, Sebastian; Bhat, Hilal; Kalkavan, Halime; Ritter, Cathrin; Brinkhaus, Robin; Ugurel, Selma; Köster, Johannes; Seifert, Ulrike; Dittmer, Ulf; Schuler, Martin; Lang, Karl S.; Kufer, Thomas A.; Hartmann, Gunther; Becker, Jürgen; Horn, Susanne; Ferrone, Soldano; Liu, David; Van Allen, Eliezer M.; Schadendorf, Dirk; Griewank, Klaus; Trilling, Mirko; Paschen, Annette
    Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy
    In: The Journal of Clinical Investigation (JCI), Jg. 130, 2020, Nr. 8, S. 4266 – 4281
    DOI, Online Volltext (Open Access)
  • Schuler, Martin
    The quest for efficient trial designs in precision oncology
    In: The Lancet Oncology, Jg. 21, 2020, Nr. 12, S. 1539 – 1541
    DOI
  • Ghanim, Bahil; Rosenmayr, Anna; Stockhammer, Paul; Vogl, Melanie; Celik, Ali; Bas, Aynur; Kurul, Ismail Cuneyt; Akyurek, Nalan; Varga, Alexander; Plönes, Till; Bankfalvi, Agnes; Hager, Thomas; Schuler, Martin; Hackner, Klaus; Errhalt, Peter; Scheed, Axel; Seebacher, Gernot; Hegedus, Balazs; Stubenberger, Elisabeth; Aigner, Clemens
    Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion : the impact of C-reactive protein and immune-checkpoint inhibition
    In: Scientific Reports, Jg. 10, 2020, Nr. 1, S. 5784
    DOI (Open Access)
  • Türeci, Özlem; Sahin, Ugur; Schulze-Bergkamen, Henning; Zvirbule, Zanete; Lordick, Florian; Koeberle, Dieter; Thuss-Patience, Peter C.; Ettrich, Thomas J.; Arnold, Dirk; Bassermann, Florian; Al-Batran, Salah Eddin; Wiechen, K.; Dhaene, Karl F. L.; Maurus, D.; Gold, M.; Huber, Christopher H.; Krivoshik, Andrew P.; Arozullah, A.; Park, J. W.; Schuler, Martin
    A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus : the MONO study
    In: Annals of Oncology, Jg. 30, 2019, Nr. 9, S. 1487 – 1495
    DOI (Open Access)
  • Taylor, Matthew H.; Gainor, Justin F.; Hu, Mimi I-Nan; Zhu, Viola Weijia; Lopes, Gilberto; Leboulleux, Sophie; Brose, Marcia S.; Schuler, Martin; Bowles, Daniel W.; Kim, Dong-Wan; Baik, Christina S; Garralda, Elena; Lin, Chia-Chi; Adkins, Douglas; Sarker, Debashis; Curigliano, Giuseppe; Zhang, Hui; Clifford, Corinne; Turner, Christopher D.; Subbiah, Vivek
    Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers
    In: Journal of Clinical Oncology (JCO), Jg. 37, 2019, Nr. 15_Suppl, S. 6018
    DOI
  • Juric, Dejan; Janku, Filip; Rodón, Jordi; Burris, Howard A.; Mayer, Ingrid A.; Schuler, Martin; Seggewiss-Bernhardt, Ruth; Gil-Martin, Marta; Middleton, Mark R.; Baselga, José; Bootle, Douglas; Demanse, David; Blumenstein, Lars; Schumacher, Karl; Huang, Alan; Quadt, Cornelia; Rugo, Hope S.
    Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer : A Phase 1b Clinical Trial
    In: JAMA Oncology, Jg. 5, 2019, Nr. 2, S. e184475
    DOI (Open Access)
  • Totzeck, Matthias; Schuler, Martin; Stuschke, Martin; Heusch, Gerd; Rassaf, Tienush
    Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease
    In: International Journal of Cardiology, Jg. 280, 2019, S. 163 – 175
    DOI
  • Pöttgen, Christoph; Kleinhans, J.; Gauler, Thomas; Wrede, Karsten; Schuler, Martin; Aigner, Clemens; Stamatis, Georgios; Eberhardt, Wilfried; Stuschke, Martin
    Cerebral Recurrence after trimodal Therapy of Patients with locally advanced NSCLC - Prognostic Factors and prognostic Importance
    In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics, Jg. 195, 2019, Nr. Suppl. 1, S. S66 – S67
  • Subbiah, Vivek; Gervais, Radj; Riely, Gregory; Hollebecque, Antoine; Blay, Jean-Yves; Felip, Enriqueta; Schuler, Martin; Gonçalves, Anthony; Italiano, Antonio; Keedy, Vicki; Chau, Ian; Puzanov, Igor; Raje, Noopur S.; Meric-Bernstam, Funda; Makrutzki, Martina; Riehl, Todd; Pitcher, Bethany; Baselga, Jose; Hyman, David M.
    Efficacy of vemurafenib in patients with non–small-cell lung cancer with BRAF V600 mutation : An open-label, single-arm cohort of the histology-independent VE-Basket study
    In: JCO Precision Oncology, Jg. 3, 2019, S. 1 – 9
    DOI (Open Access)
  • Schuler, Martin; Paz-Ares, Luis; Sequist, Lecia V.; Hirsh, Vera; Lee, Ki Hyeong; Wu, Yi-Long; Lu, Shun; Zhou, Caicun; Feng, Jifeng; Ellis, Stuart H.; Samuelsen, Carl H.; Tang, Wenbo; Märten, Angela; Ehrnrooth, Eva; Park, Keunchil; Yang, James Chih-Hsin
    First-line afatinib for advanced EGFRm+ NSCLC : Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials
    In: Lung Cancer, Jg. 133, 2019, S. 10 – 19
    DOI (Open Access)
  • Schuler, Martin; Tan, Eng-Huat; O’Byrne, Kenneth; Zhang, Li; Boyer, Michael; Mok, Tony; Hirsh, Vera; Yang, James Chih-Hsin; Lee, Ki Hyeong; Lu, Shun; Shi, Yuankai; Kim, Sang-We; Laskin, Janessa; Kim, Dong-Wan; Arvis, Catherine Dubos; Kölbeck, Karl; Massey, Dan; Märten, Angela; Paz-Ares, Luis; Park, Keunchil
    First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7) : impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
    In: Journal of Cancer Research and Clinical Oncology, Jg. 145, 2019, Nr. 6, S. 1569 – 1579
    DOI (Open Access)
  • Joos, Stefan; Nettelbeck, Dirk M.; Reil-Held, Anette; Engelmann, Katja; Moosmann, Alexandra; Eggert, Angelika; Hiddemann, Wolfgang; Krause, Mechthild; Peters, Christoph; Schuler, Martin; Schulze-Osthoff, Klaus; Serve, Hubert; Wick, Wolfgang; Puchta, Josef; Baumann, Michael
    German Cancer Consortium (DKTK) : A national consortium for translational cancer research
    In: Molecular Oncology, Jg. 13, 2019, Nr. 3, S. 535 – 542
    DOI (Open Access)
  • Wiesweg, Marcel; Kasper, Stefan; Worm, Karl; Herold, Thomas; Reis, Henning; Sara, Linda; Metzenmacher, Martin; Abendroth, Annalena; Darwiche, Kaid; Aigner, Clemens; Wedemeyer, Heiner; Helfritz, Fabian A.; Stuschke, Martin; Schumacher, Brigitte; Markus, Peter; Paul, Andreas; Rahmann, Sven; Schmid, Kurt Werner; Schuler, Martin
    Impact of RAS mutation subtype on clinical outcome : A cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer
    In: Oncogene, Jg. 38, 2019, Nr. 16, S. 2953 – 2966
    DOI
  • Abendroth, A.; Noureddine, R.; Abramczyk, M.; Paul, Andreas; Gerken, Guido; Schmid, Kurt Werner; Markus, P.; Schumacher, B.; Wiesweg, Marcel; Köhler, Jens; Markus, M.; Mende, B.; Dechene, Alexander; Schuler, Martin; Kasper, Stefan
    Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols
    In: Journal of Cancer Research and Clinical Oncology, Jg. 145, 2019, Nr. 2, S. 445 – 455
    DOI
  • Cheufou, Danjouma Housmanou; Valdivia, Daniel; Puhlvers, Stephan; Fels, Benjamin; Weinreich, Gerhard; Taube, Christian; Theegarten, Dirk; Stuschke, Martin; Schuler, Martin; Hegedus, Balazs; Stamatis, Georgios; Aigner, Clemens
    Lymph Node Involvement and the Surgical Treatment of Thymic Epithelial and Neuroendocrine Carcinoma
    In: The Annals of Thoracic Surgery, Jg. 107, 2019, Nr. 6, S. 1632 – 1638
    DOI (Open Access)
  • Wiesweg, Marcel; Mairinger, Fabian; Reis, Henning; Goetz, Moritz; Walter, Robert; Hager, Thomas; Metzenmacher, Martin; Eberhardt, Wilfried; McCutcheon, A.; Köster, J.; Stuschke, Martin; Aigner, Clemens; Darwiche, Kaid; Schmid, Kurt Werner; Rahmann, Sven; Schuler, Martin
    Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer
    In: Annals of Oncology, Jg. 30, 2019, Nr. 4, S. 655 – 657
    DOI (Open Access)
  • Al-Batran, Salah-Eddin; Homann, Nils; Pauligk, Claudia; Goetze, Thorsten O.; Meiler, Johannes; Kasper, Stefan; Kopp, Hans-Georg; Mayer, Frank; Haag, Georg Martin; Luley, Kim; Lindig, Udo; Schmiegel, Wolff; Pohl, Michael; Stoehlmacher, Jan; Folprecht, Gunnar; Probst, Stephan; Prasnikar, Nicole; Fischbach, Wolfgang; Mahlberg, Rolf; Trojan, Jörg; Koenigsmann, Michael; Martens, Uwe M.; Thuss-Patience, Peter; Egger, Matthias; Block, Andreas; Heinemann, Volker; Illerhaus, Gerald; Moehler, Markus; Schenk, Michael; Kullmann, Frank; Behringer, Dirk M.; Heike, Michael; Pink, Daniel; Teschendorf, Christian; Löhr, Carmen; Bernhard, Helga; Schuch, Gunter; Rethwisch, Volker; Weikersthal, Ludwig Fischer von; Hartmann, Jörg T.; Kneba, Michael; Daum, Severin; Schulmann, Karsten; Weniger, Jörg; Belle, Sebastian; Gaiser, Timo; Oduncu, Fuat S.; Güntner, Martina; Hozaeel, Wael; Reichart, Alexander; Jäger, Elke; Kraus, Thomas; Mönig, Stefan; Bechstein, Wolf O.; Schuler, Martin; Schmalenberg, Harald; Hofheinz, Ralf D.
    Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4) : A randomised, phase 2/3 trial
    In: Lancet, Jg. 393, 2019, Nr. 10184, S. 1948 – 1957
    DOI
  • Guberina, Maja; Eberhardt, Wilfried; Stuschke, Martin; Gauler, Thomas; Aigner, Clemens; Schuler, Martin; Stamatis, Georgios; Theegarten, Dirk; Jentzen, Walter; Herrmann, Ken; Pöttgen, Christoph
    Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules : analysis of the ESPATUE randomized phase 3 trial
    In: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 46, 2019, Nr. 7, S. 1439 – 1447
    DOI
  • Schuler, Martin; Cho, Byoung Chul; Sayehli, Cyrus Michael; Navarro, Alejandro; Soo, Ross A.; Richly, Heike; Cassier, Philippe Alexandre; Tai, David; Penel, Nicolas; Nogova, Lucia; Park, Se Hoon; Schostak, Martin; Gajate, Pablo; Cathomas, Richard; Rajagopalan, Prabhu; Grevel, Joachim; Bender, Sebastian; Boix, Oliver; Nogai, Hendrik; Ocker, Matthias; Ellinghaus, Peter; Joerger, Markus
    Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression : a phase 1 dose-escalation and dose-expansion study
    In: The Lancet Oncology, Jg. 20, 2019, Nr. 10, S. 1454 – 1466
    DOI
  • Park, Keunchil; Bennouna, Jaafar; Boyer, Michael; Hida, Toyoaki; Hirsh, Vera; Kato, Terufumi; Lu, Shun; Mok, Tony; Nakagawa, Kazuhiko; O'Byrne, Kenneth; Paz-Ares, Luis; Schuler, Martin; Sibilot, Denis Moro; Tan, Eng-Huat; Tanaka, Hiroshi; Wu, Yi-Long; Yang, James C.-H.; Zhang, Li; Zhou, Caicun; Märten, Angela; Tang, Wenbo; Yamamoto, Nobuyuki
    Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
    In: Lung Cancer, Jg. 132, 2019, S. 126 – 131
    DOI (Open Access)
  • Pastille, Eva; Wasmer, Marie-Hélène; Adamczyk, Alexandra; Vu, Vivian P.; Mager, Lukas F.; Phuong, Nhi Ngo Thi; Palmieri, Vittoria; Simillion, Cedric; Hansen, Wiebke; Kasper, Stefan; Schuler, Martin; Muggli, Beat; McCoy, Kathy D.; Buer, Jan; Zlobec, Inti; Westendorf, Astrid; Krebs, Philippe
    The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer
    In: Mucosal Immunology, Jg. 12, 2019, Nr. 4, S. 990 – 1003
    DOI (Open Access)
  • Sahin, Ugur; Tureci, Özlem; Manikhas, Georgy M.; Lordick, Florian; Rusyn, Andriy; Vynnychenko, Ihor; Dudov, Assen; Bazin, Igor; Bondarenko, Igor; Melichar, Bohuslav; Dhaene, Karl; Wiechen, Kai; Maurus, Daniel; Schuler, Martin; Al-Batran, Salah-Eddin
    Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma : Updated results from the FAST trial.
    In: Journal of Clinical Oncology (JCO), Jg. 37, 2019, Nr. 4_Suppl, S. 16
    DOI
  • Tamiya, A.; Märten, A.; Popat, S.; Yamamoto, N.; Yang, J.C-H.; Hirsh, V.; Wu, Y-L.; Schuler, Martin; O'Byrne, K.
    143PD Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7
    In: Journal of Thoracic Oncology, Jg. 13, 2018, Nr. 4, S. S84 – S85
    DOI (Open Access)
  • Sahin, Ugur; Schuler, Martin; Richly, Heike; Bauer, Stefan; Krilova, Anna; Dechow, Tobias; Jerling, Markus; Utsch, Magdalena; Rohde, Christoph; Dhaene, Karl; Huber, Christoph; Türeci, Özlem
    A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer
    In: European Journal of Cancer (EJC), Jg. 100, 2018, S. 17 – 26
    DOI (Open Access)
  • Wu, Yi-Long; Sequist, Lecia V.; Tan, Eng-Huat; Geater, Sarayut L.; Orlov, Sergey; Zhang, Li; Lee, Ki Hyeong; Tsai, Chun-Ming; Kato, Terufumi; Barrios, Carlos H.; Schuler, Martin; Hirsh, Vera; Yamamoto, Nobuyuki; O'Byrne, Kenneth; Boyer, Michael; Mok, Tony; Peil, Barbara; Märten, Angela; Chih-Hsin Yang, James; Paz-Ares, Luis; Park, Keunchil
    Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non–Small-Cell Lung Cancer : Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
    In: Clinical Lung Cancer, Jg. 19, 2018, Nr. 4, S. e465 – e479
    DOI (Open Access)
  • Zaun, Gregor; Schuler, Martin; Herrmann, Ken; Tannapfel, Andrea
    CUP syndrome : Metastatic malignancy with unknown primary tumor
    In: Deutsches Ärzteblatt International, Jg. 115, 2018, Nr. 10, S. 157 – 162
    DOI (Open Access)
  • Yang, J. C.; Wu, Y.; Hirsh, V.; O'Byrne, K.; Yamamoto, N.; Popat, S.; Tamiya, A.; Kaen, D.; Marten, A.; Schuler, Martin
    Competing CNS or Systemic Progression Analysis for EGFR Mutation-Positive NSCLC Patients on Afatinib in LUX-Lung 3, 6, and 7
    In: Journal of Thoracic Oncology, Jg. 13, 2018, Nr. Suppl. 9, S. 163
  • Yang, J.C.-.; Wu, Y.; Hirsh, V.; O’Byrne, K.; Yamamoto, N.; Popat, S.; Tamiya, A.; Kaen, D.; Märten, A.; Schuler, Martin
    Competing CNS or Systemic Progression Analysis for EGFR Mutation-Positive NSCLC Patients on Afatinib in LUX-Lung 3, 6, and 7
    In: Journal of Thoracic Oncology, Jg. 13, 2018, Nr. 9, Suppl., S. 163
    DOI (Open Access)
  • Wu, Yi-Long; Hirsh, Vera; Sequist, Lecia V.; Hu, Cheng-Ping; Feng, Jifeng; Lu, Shun; Huang, Yunchao; Schuler, Martin; Mok, Tony; Yamamoto, Nobuyuki; O’Byrne, Kenneth; Geater, Sarayut L.; Zhou, Caicun; Massey, Dan; Märten, Angela; Lungershausen, Juliane; Yang, James Chih-Hsin
    Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)
    In: The Patient, Jg. 11, 2018, Nr. 1, S. 131 – 141
    DOI (Open Access)
  • Hamacher, Rainer; Kämpfe, Dietrich; Reuter-Jessen, Kirsten; Pöttgen, Christoph; Podleska, Lars; Farzaliyev, Farhad; Steinau, Hans-Ulrich; Schuler, Martin; Schildhaus, Hans-Ulrich; Bauer, Sebastian
    Dramatic response of a PD-L1- positive advanced angiosarcoma of the scalp to pembrolizumab
    In: JCO Precision Oncology, Jg. 2, 2018
    DOI
  • Cappuzzo, Federico; Soo, Ross; Hochmair, Maximilian; Schuler, Martin; Lam, Kwok Chi; Stehle, Gerd; Cseh, Agnieszka; Lorence, Robert M; Linden, Stephan; Forman, Nicole D; Hilbe, Wolfgang; Jazieh, Abdul Rahman; Tsai, Chun-Ming
    Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies
    In: Future Oncology, Jg. 14, 2018, Nr. 15, S. 1477 – 1486
    DOI (Open Access)
  • Gautschi, O.; Drilon, A.; Milia, J.; Lusque, A.; Mhanna, L.; Li, B.; Sabari, J.; Cortot, A.; Besse, B.; Mezquita, L.; Solomon, B.; Thai, A.; Couraud, S.; Veilion, R.; Mascaux, C.; Barlesi, F.; Van den Heuvel, M.; Schouten, R.; Wakelee, H.; Mah, A.; Camidge, D. R.; Ng, T.; Peled, N.; Lilach, Y.; Popat, S.; Ou, S.; Zhu, V.; Velcheti, V.; Fontecedro, A. C.; Akhoundova, D.; Fruh, M.; Zalcman, G.; Gounant, V.; Novello, S.; Bironzo, P.; Felip, E.; Martinez-Marti, A.; Moro-Sibilot, D.; Rosell, R.; Karachaliou, N.; Schuler, Martin; Wiesweg, Marcel; Diebold, J.; Mazieres, J.
    Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations : New Results from the Global IMMUNOTARGET Registry
    In: Journal of Thoracic Oncology, Jg. 13, 2018, Nr. Suppl. 10, S. 367
    DOI (Open Access)
  • Nadjm, S.; Pöttgen, Christoph; Gauler, Thomas; Exner, J. P.; Krebs, B.; Cheufou, D.; Umutlu, Lale; Deuschl, C.; Darwiche, Kaid; Schuler, Martin; Eberhardt, Wilfried; Stuschke, Martin
    Investigations of Long-term Survivors with locally advanced NSCLC on Morbidity of curative Therapy - Analysis of neurocognitive Effects
    In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics, Jg. 194, 2018, Nr. Suppl. 1, S. 110
    DOI (Open Access)
  • Reis, Henning; Metzenmacher, Martin; Goetz, Moritz; Savvidou, Nikoleta; Darwiche, Kaid; Aigner, Clemens; Herold, Thomas; Eberhardt, Wilfried; Skiba, Charlotte; Hense, Jörg; Virchow, Isabel; Westerwick, Daniela; Bogner, Simon; Ting, Saskia; Kasper, Stefan; Stuschke, Martin; Nensa, Felix; Herrmann, Ken; Hager, Thomas; Schmid, Kurt Werner; Schuler, Martin; Wiesweg, Marcel
    MET Expression in Advanced Non–Small-Cell Lung Cancer : Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy
    In: Clinical Lung Cancer, Jg. 19, 2018, Nr. 4, S. e441 – e463
    DOI
  • Reis, Henning; van der Vos, Kristan E.; Niedworok, Christian; Herold, Thomas; Módos, Orsolya; Szendroi, Attila; Hager, Thomas; Ingenwerth, Marc; Vis, Daniël J.; Behrendt, Mark A.; de Jong, Jeroen; van der Heijden, Michiel S.; Peyronnet, Benoit; Mathieu, Romain; Wiesweg, Marcel; Ablat, Jason; Okon, Krzysztof; Tolkach, Yuri; Keresztes, David; Nagy, Nikolett; Bremmer, Felix; Gaisa, Nadine T.; Chlosta, Piotr; Kriegsmann, Joerg; Kovalszky, Ilona; Timar, József; Kristiansen, Glen; Radzun, Heinz-Joachim; Knüchel, Ruth; Schuler, Martin; Black, Peter C.; Rübben, Herbert; Hadaschik, Boris; Schmid, Kurt Werner; van Rhijn, Bas W.G.; Nyirády, Péter; Szarvas, Tibor
    Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas
    In: International Journal of Cancer, Jg. 143, 2018, Nr. 7, S. 1764 – 1773
    DOI, Online Volltext (Open Access)
  • Tewes, Mitra; Rettler, Teresa Maria; Beckmann, Mingo; Scheer, Karin; Ritterbusch, Ulrike; Schuler, Martin; Hense, Jörg
    Patient-Reported-Outcome-Messung (PROM) psychosozialer Belastung und Symptome für ambulante Patienten unter kurativer oder palliativer Tumortherapie : eine retrospektive Analyse eines Comprehensive Cancer Center
    In: Der Onkologe, Jg. 24, 2018, Nr. 1, S. 69 – 75
    DOI
  • Rodon, Jordi; Pérez-Fidalgo, Alejandro; Krop, Ian E.; Burris, Howard; Guerrero-Zotano, Angel; Britten, Carolyn D.; Becerra, Carlos; Schellens, Jan; Richards, Donald A.; Schuler, Martin; Abu-Khalaf, Maysa; Johnson, Faye M.; Ranson, Malcolm; Edenfield, Jeff; Silva, Antonio P.; Hackl, Wolfgang; Quadt, Cornelia; Demanse, David; Duval, Vincent; Baselga, Jose
    Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
    In: Cancer Chemotherapy and Pharmacology, Jg. 82, 2018, Nr. 2, S. 285 – 298
    DOI, Online Volltext (Open Access)
  • Juric, Dejan; Rodon, Jordi; Tabernero, Josep; Janku, Filip; Burris, Howard A.; Schellens, Jan H.M.; Middleton, Mark R.; Berlin, Jordan; Schuler, Martin; Marta, Gil-Martin; Rugo, Hope S.; Ruth, Seggewiss-Bernhardt; Huang, Alan; Bootle, Douglas; Demanse, David; Blumenstein, Lars; Coughlin, Christina; Quadt, Cornelia; Baselga, José
    Phosphatidylinositol 3-kinase a–selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors : Results from the first-in-human study
    In: Journal of Clinical Oncology (JCO), Jg. 36, 2018, Nr. 13, S. 1291 – 1299
    DOI, Online Volltext (Open Access)
  • Wiesweg, Marcel; Reis, Henning; Köster, Tobias; Goetz, Moritz; Worm, Karl; Herold, Thomas; Paul, Andreas; Dechene, Alexander; Schumacher, Brigitte; Markus, Peter; Virchow, Isabel; Kostbade, Karina; Wolf, Nathalie; Zaun, Gregor; Metzenmacher, Martin; Schmid, Kurt Werner; Schuler, Martin; Kasper, Stefan
    Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer
    In: Clinical Colorectal Cancer, Jg. 17, 2018, Nr. 2, S. e331 – e352
    DOI
  • Guberina, M.; Eberhardt, Wilfried; Stuschke, Martin; Gauler, Thomas; Aigner, Clemens; Schuler, Martin; Stamatis, Georgios; Pöttgen, Christoph
    Pre-therapeutic metabolic Tumor Volume (MTV) in (18) F-FDG-PET/CT as a prognostic Factor in Patients with Stage IIIA-IIIB NSCLC before Trimodal Therapy or definitive Chemoradiotherapy - Results of Phase 3 Study
    In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics, Jg. 194, 2018, Nr. Suppl.1, S. S41 – S42
    DOI (Open Access)
  • Tewes, Mitra; Rettler, Teresa; Wolf, Nathalie; Hense, Jörg; Schuler, Martin; Teufel, Martin; Beckmann, Mingo
    Predictors of outpatients’ request for palliative care service at a medical oncology clinic of a German comprehensive cancer center
    In: Supportive Care in Cancer, Jg. 26, 2018, Nr. 10, S. 3641 – 3647
    DOI
  • Guberina, M.; Eberhardt, Wilfried; Stuschke, Martin; Gauler, Thomas; Cheufou, D.; Schuler, Martin; Stamatis, Georgios; Pöttgen, Christoph
    Pretreatment metabolic volume in PET : Prognostic in lung cancer? German ESPATUE randomised phase3trial
    In: Radiotherapy and Oncology (The Green Journal), Jg. 127, 2018, Nr. Suppl.1, S. S253 – S254
    DOI (Open Access)
  • Oezkan, Filiz; Herold, Thomas; Darwiche, Kaid; Eberhardt, Wilfried; Worm, Karl; Christoph, Daniel; Wiesweg, Marcel; Freitag, Lutz; Schmid, Kurt Werner; Theegarten, Dirk; Hager, Thomas; Koenig, Michael J.; He, Kai; Taube, Christian; Schuler, Martin; Breitenbücher, Frank
    Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung Adenocarcinoma
    In: Clinical Lung Cancer, Jg. 19, 2018, Nr. 6, S. e879 – e884
    DOI
  • Pöttgen, Christoph; Abu Jawad, Jehad; Gauler, Thomas; Guberina, M.; Darwiche, Kaid; Aigner, Clemens; Theegarten, Dirk; Schuler, Martin; Eberhardt, Wilfried; Stuschke, Martin
    Sequential Dose Escalation Study NEOAHA for locally advanced NSCLC - Phase I-Results of Stage 1 (Integrated Boost-Radiation in neoadjuvant Therapy)
    In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics, Jg. 194, 2018, Nr. Suppl. 1, S. S23 – S24
    DOI (Open Access)
  • Joerger, M.; Soo, R. A.; Cho, B. C.; Navarro, A.; Sayehli, C. M.; Richly, Heike; Tai, D.; Kim, D. W.; Wolf, J.; Cassier, P.; Bender, S.; Ellinghaus, P.; Ince, S.; Rajagopalan, P.; Ocker, M.; Schuler, Martin
    A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors : Results from rogaratinib Phase-1 study
    In: Annals of Oncology, Jg. 28, 2017, Nr. Suppl. 5
  • Van Geel, Robin M. J. M.; Tabernero, Josep; Elez, Elena; Bendell, Johanna C.; Spreafico, Anna; Schuler, Martin; Yoshino, Takayuki; Delord, Jean-Pierre; Yamada, Yasuhide; Lolkema, Martijn P.; Faris, Jason E.; Eskens, Ferry A. L. M.; Sharma, Sunil; Yaeger, Rona; Lenz, Heinz-Josef; Wainberg, Zev A.; Avsar, Emin; Chatterjee, Arkendu; Jaeger, Savina; Tan, Eugene; Maharry, Kati; Demuth, Tim; Schellens, Jan H. M.
    A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer
    In: Cancer Discovery, Jg. 7, 2017, Nr. 6, S. 610 – 619
    DOI, Online Volltext (Open Access)
  • Schadendorf, Dirk; Schuler, Martin
    Checkpointinhibitoren
    In: Der Onkologe, Jg. 23, 2017, Nr. 8, S. 619 – 625
    DOI
  • Breitenbücher, Frank; Von Pawel, Joachim; Sebastian, Martin; Kortsik, Cornelius; Ting, Saskia; Kasper, Stefan; Wohlschläger, Jeremias; Worm, Karl; Morresi-Hauf, Alicia; Schad, Arno; Westerwick, Daniela; Wehler, Beatrice; Werner, Martin; Munzert, Gerd; Gaschler-Markefski, Birgit; Schmid, Kurt Werner; Schuler, Martin
    Comprehensive biomarker analyses in patients with advanced or metastatic non-small cell lung cancer prospectively treated with the polo-like Kinase 1 Inhibitor BI2536
    In: Oncology Research and Treatment, Jg. 40, 2017, Nr. 7-8, S. 435 – 439
    DOI
  • Wieczorek, Sarah A.; Breitenbücher, Frank; Soni, Aashish; Paul-Konietzko, Katja; Ziegler, Sophie; Sak, Ali; Iliakis, George; Schuler, Martin
    Deregulated BCL-2 family proteins impact on repair of DNA double-strand breaks and are targets to overcome radioresistance in lung cancer
    In: Journal of Cancer Research and Clinical Oncology, Jg. 143, 2017, Nr. 9, S. 1733 – 1744
    DOI
  • Al-Batran, S. E.; Pauligk, C.; Homann, N.; Schmalenberg, H.; Kopp, H. G.; Haag, G. M.; Luley, K.; Folprecht, G.; Probst, S.; Thuss-Patience, P.; Trojan, J.; Koenigsmann, M.; Lindig, U.; Pohl, M.; Kasper, Stefan; Hler, M. M.; Goetze, T.; Schuler, Martin; Jaeger, E.; Hofheinz, R. D.
    Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer : Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)
    In: Annals of Oncology, Jg. 28, 2017, Nr. Suppl. 5
  • Wu, Yi-Long; Sequist, Lecia V; Hu, Cheng-Ping; Feng, Jifeng; Lu, Shun; Huang, Yunchao; Li, Wei; Hou, Mei; Schuler, Martin; Mok, Tony; Yamamoto, Nobuyuki; O'Byrne, Kenneth; Hirsh, Vera; Gibson, Neil; Massey, Dan; Kim, Miyoung; Yang, James Chih-Hsin
    EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients : analysis of LUX-Lung 3 and 6
    In: British Journal of Cancer (BJC), Jg. 116, 2017, Nr. 2, S. 175 – 185
    DOI (Open Access)
  • Nogova, Lucia; Sequist, Lecia V.; Garcia, Jose Manuel Perez; Andre, Fabrice; Delord, Jean-Pierre; Hidalgo, Manuel; Schellens, Jan H.M.; Cassier, Philippe A.; Camidge, D. Ross; Schuler, Martin; Vaishampayan, Ulka; Burris, Howard; Tian, G. Gary; Campone, Mario; Wainberg, Zev A.; Lim, Wan-Teck; LoRusso, Patricia; Shapiro, Geoffrey I.; Parker, Katie; Chen, Xueying; Choudhury, Somesh; Ringeisen, Francois; Graus-Porta, Diana; Porter, Dale; Isaacs, Randi; Buettner, Reinhard; Wolf, Jürgen
    Evaluation of BGJ398, a Fibroblast growth factor receptor 1-3 kinase inhibitor, in patientswith advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors : Results of a global phase I, dose-escalation and dose-expansion study
    In: Journal of Clinical Oncology (JCO), Jg. 35, 2017, Nr. 2, S. 157 – 165
    DOI, Online Volltext (Open Access)
  • Tureci, Özlem; Wiechen, Kai; Bazin, Igor; Maurus, Daniel; Schuler, Martin; Zvirbule, Zanete; Sahin, Ugur; Dhaene, Karl; Al-Batran, Salah-Eddin; Vynnychenko, Ihor; Melichar, Bohuslav; Rusyn, Andriy V.; Manikhas, Georgy; Dudov, Assen; Lordick, Florian
    Expression of Claudin 18.2 and HER2 in gastric, gastroesophageal junction, and esophageal cancers : Results from the FAST study
    In: Journal of Clinical Oncology (JCO), Jg. 35, 2017, S. 4038 – 4038
    DOI
  • Schuler, Martin; Paz-Ares, L.; Sequist, L. V.; Tan, E. H.; Mok, T.; Hirsh, V.; O'Byrne, K.; Zhang, Lihua; Yamamoto, N.; Boyer, M.; Shah, R.; Bennouna, J.; Dickgreber, N. J.; De Greve, J.; Love, J.; Marten, A.; Fan, J.; Ehrnrooth, E.; Park, K.; Yang, JCH
    First-line afatinib for advanced EGFR mutation-positive (EGFRm plus ) NSCLC : analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials
    In: European Journal of Cancer (EJC), Jg. 72 1, 2017, S. 176 – S177
    DOI
  • Schuler, Martin; Paz-Ares, L.; Sequist, L. V.; Wu, Y. L.; Geater, S. L.; Marten, A.; Fandrey, Joachim; Park, K.; Yang, JCH
    First-line afatinib for advanced EGFRm1 NSCLC : Analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trials
    In: Annals of Oncology, Jg. 28, 2017, Nr. Suppl. 2
  • Schuler, Martin; Paz-Ares, L.; Sequist, L. V.; Sebastian, M.; Wu, Y. L.; Geater, S. L.; Marten, A.; Fan, J.; Park, K.; Yang, JCH
    First-line afatinib in patients with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) : analysis of long-term responders (LTRs) in the LUX-Lung 3, 6 and 7 trials
    In: Oncology Research and Treatment, Jg. 40, 2017, Nr. Suppl. 3: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Stuttgart, 29. September-3. Oktober 2017: Abstracts, S. 172
    DOI
  • Hochmair, M.; Cappuzzo, F.; Tsai, C. M.; Schuler, Martin; Lam, K. C.; Stehle, G.; Cseh, A.; Lorence, R. M.; Linden, S.; Carriere, P.; Soo, R.
    Global named patient use (NPU) program of afatinib in heavily pretreated advanced NSCLC patients who progressed following prior therapies, including erlotinib or gefitinib
    In: European Journal of Cancer (EJC), Jg. 72 1, 2017, S. 183 – S184
    DOI
  • Guberina, M.; Eberhardt, Wilfried; Stuschke, Martin; Gauler, Thomas; Heinzelmann, F.; Cheufou, D.; Kimmich, M.; Friedel, G.; Schmidberger, H.; Darwiche, Kaid; Jendrossek, Verena; Schuler, Martin; Stamatis, Georgios; Pöttgen, Christoph
    Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer : secondary analysis of a randomized trial
    In: Annals of Oncology, Jg. 28, 2017, Nr. 5, S. 1084 – 1089
    DOI (Open Access)
  • Tewes, Mitra; Peis, Michael Wilhelm; Bogner, Simon; Theysohn, Jens; Reinboldt, Marcus Paul; Schuler, Martin; Welt, Anja
    Hepatic arterial infusion chemotherapy for extensive liver metastases of breast cancer : efficacy, safety and prognostic parameters
    In: Journal of Cancer Research and Clinical Oncology, Jg. 143, 2017, Nr. 10, S. 2131 – 2141
    DOI
  • Wiesweg, Marcel; Eberhardt, Wilfried; Reis, Henning; Ting, Saskia; Savvidou, Nikoleta; Skiba, Charlotte; Herold, Thomas; Christoph, Daniel; Meiler, Johannes; Worm, Karl; Kasper, Stefan; Theegarten, Dirk; Hense, Jörg; Hager, Thomas; Darwiche, Kaid; Oezkan, Filiz; Aigner, Clemens; Welter, Stefan; Kühl, Hilmar; Stuschke, Martin; Schmid, Kurt Werner; Schuler, Martin
    High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer
    In: Journal of Thoracic Oncology, Jg. 12, 2017, Nr. 1, S. 54 – 64
    DOI (Open Access)
  • Okimoto, Ross A; Breitenbücher, Frank; Olivas, Victor R; Wu, Wei; Gini, Beatrice; Hofree, Matan; Asthana, Saurabh; Hrustanovic, Gorjan; Flanagan, Jennifer; Tulpule, Asmin; Blakely, Collin M; Haringsma, Henry J; Simmons, Andrew D; Gowen, Kyle; Suh, James; Miller, Vincent A; Ali, Siraj; Schuler, Martin; Bivona, Trever G.
    Inactivation of Capicua drives cancer metastasis
    In: Nature Genetics, Jg. 49, 2017, Nr. 1, S. 87 – 96
    DOI, Online Volltext (Open Access)
  • Thress, Kenneth S.; Jacobs, Vivien; Angell, Helen K.; Yang, James Chih-Hsin; Sequist, Lecia V.; Blackhall, Fiona; Su, Wu-Chou; Schuler, Martin; Wolf, Jürgen; Gold, Kathryn A.; Cantarini, Mireille; Barrett, J. Carl; Jänne, Pasi A.
    Modulation of Biomarker Expression by Osimertinib : Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial
    In: Journal of Thoracic Oncology, Jg. 12, 2017, Nr. 10, S. 1588 – 1594
    DOI
  • Kasper, Stefan; Reis, Henning; Ziegler, Sophie; Nothdurft, Silke; Mueller, Andre; Goetz, Moritz; Wiesweg, Marcel; Phasue, Jeannette; Ting, Saskia; Wieczorek, Sarah; Even, Anna; Worm, Karl; Pogorzelski, Michael; Breitenbuecher, Sandra; Meiler, Johannes; Paul, Andreas; Trarbach, Tanja; Schmid, Kurt Werner; Breitenbücher, Frank; Schuler, Martin
    Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy
    In: OncoTarget, Jg. 8, 2017, Nr. 28, S. 45898 – 45917
    DOI (Open Access)
  • Al-Batran, S. E.; Pauligk, C.; Homann, N.; Schmalenberg, H.; Kopp, H. G.; Haag, G. M.; Luley, K. B.; Schmiegel, W.; Folprecht, G.; Probst, S.; Prasnikar, N.; Thuss-Patience, P.; Fischbach, W.; Trojan, J.; Koenigsmann, M.; Goetze, T. O.; Kraus, T. W.; Battmann, A.; Moenig, S. P.; Bechstein, W.; Gaiser, T.; Tannapfel, A.; Jäger, E.; Schuler, Martin; Lindig, U.; Pohl, M.; Kasper, Stefan; Möhler, M.; Hofheinz, R. D.
    Perioperative chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO) : a rando
    In: Oncology Research and Treatment, Jg. 40, 2017, Nr. Suppl. 3: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Stuttgart, 29. September-3. Oktober 2017: Abstracts, S. 200 – 201
    DOI
  • Al-Batran, Salah-Eddin; Homann, Nils; Schmalenberg, Harald; Kopp, Hans-Georg; Haag, Georg Martin; Luley, Kim Barbara; Schmiegel, Wolff H.; Folprecht, Gunnar; Probst, Stephan; Prasnikar, Nicole; Thuss-Patience, Peter C.; Fischbach, Wolfgang; Trojan, Jorg; Koenigsmann, Michael; Pauligk, Claudia; Goetze, Thorsten Oliver; Jaeger, Elke; Meiler, Johannes; Schuler, Martin; Hofheinz, Ralf
    Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO) : A multicenter, randomized phase 3 trial
    In: Journal of Clinical Oncology (JCO), Jg. 35, 2017, Nr. 15_suppl, 4004
    DOI
  • Schuler, Martin; Chan, S. L.; Yen, C.; Lin, C.; Choo, S. P.; Weiss, K.; Geier, A.; Okusaka, T.; Lim, H. Y.; Macarulla, T.; Zhu, A. X.; Kakizume, T.; Gu, Y.; Porta, D. G.; Myers, A. P.; Delord, J.
    Phase I/II study of FGF401 in adult patients (pts) with hepatocellular carcinoma (HCC) or solid tumors and positive FGFR4/KLB expression
    In: Oncology Research and Treatment, Jg. 40, 2017, Nr. Suppl. 3, S. 234 – 235
    DOI
  • Sebastian, M.; Schuler, Martin; Schulz, C.; Deschler-Baier, B.; Kimmich, M.; Hilgert-Daute, K.; Griesinger, F.
    Randomised Phase III study of osimertinib vs platinum-pemetrexed for EGFR T790M-positive advanced NSCLC (AURA3)
    In: Oncology Research and Treatment, Jg. 40, 2017, Nr. Suppl. 3: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Stuttgart, 29. September-3. Oktober 2017: Abstracts, S. 170
    DOI
  • Oezkan, Filiz; Herold, Thomas; Darwiche, Kaid; Eberhardt, Wilfried; Christoph, Daniel; Worm, Karl; Freitag, Lutz; Schmid, Kurt Werner; Hager, Thomas; Breitenbücher, Frank; Schuler, Martin
    Rapid and Highly Sensitive EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA Specimen of Lung Adenocarcinoma
    In: Journal of Thoracic Oncology, Jg. 12, 2017, Nr. Suppl. 1, S. S1201 – S1201
  • Scheulen, Max Ernst; Kaempgen, Eckhart; Keilholz, Ulrich; Heinzerling, Lucie; Ochsenreither, Sebastian; Abendroth, Annalena; Huger, Ralf A.; Grubert, Matthias; Wetter, Axel; Guberina, Nika; Bauer, Sebastian; Schuler, Gerold; Bornfeld, Norbert; Schuler, Martin; Richly, Heike
    STREAM : A randomized discontinuation, blinded, placebo-controlled phase II study of sorafenib (5) treatment of chemonaive patients (pts) with metastatic uveal melanoma (MUM)
    2017 ASCO Annual Meeting, June 2-6, 2017, Chicago, Ill., USA,
    In: Journal of Clinical Oncology (JCO), Jg. 35, 2017, Nr. 15, 9511
    DOI
  • Kalkavan, Halime; Sharma, Piyush; Kasper, Stefan; Helfrich, Iris; Pandyra, Aleksandra A.; Gassa, Asmae; Virchow, Isabel; Flatz, Lukas; Brandenburg, Tim; Namineni, Sukumar; Heikenwalder, Mathias; Höchst, Bastian; Knolle, Percy A.; Wollmann, Guido; Von Laer, Dorothee; Drexler, Ingo; Rathbun, Jessica; Cannon, Paula M.; Scheu, Stefanie; Bauer, Jens; Chauhan, Jagat; Häussinger, Dieter; Willimsky, Gerald; Löhning, Max; Schadendorf, Dirk; Brandau, Sven; Schuler, Martin; Lang, Philipp A.; Lang, Karl S.
    Spatiotemporally restricted arenavirus replication induces immune surveillance and type i interferon-dependent tumour regression
    In: Nature Communications, Jg. 8, 2017, S. 14447
    DOI (Open Access)
  • Sequist, L.; Wu, Y. L.; Schuler, Martin; Kato, T.; Yang, JCH; Tanaka, H.; Hida, T.; Lu, S.; Park, K.; Laurie, S.; Bennouna, J.; Sibilot, D. M.; Marten, A.; Peil, B.; Ehrnrooth, E.; Yamamoto, N.; Nakagawa, K.
    Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC in LUX-Lung (LL) 3, 6 and 7
    In: Annals of Oncology, Jg. 28, 2017, Nr. Suppl. 5
    DOI
  • Cappuzzo, Federico; Soo, Ross Andrew; Hochmair, Maximilian Johannes; Schuler, Martin; Mok, Tony Shu Kam; Stehle, Gerd; Cseh, Agnieszka; Lorence, Robert M..; Linden, Stephan; Forman, Nicole D.; Tsai, Chunming
    1236P - Global named patient use (NPU) program of afatinib, an oral ErbB family blocker, in heavily pretreated advanced non-small cell lung carcinoma (NSCLC) patients who progressed following prior therapies, including erlotinib or gefitinib (E/G)
    In: Annals of Oncology, Jg. 27, 2016, Nr. Supplement 6, S. vi427
    DOI
  • Kim, Dong-Wan; Mehra, Ranee; Tan, Daniel S W; Felip, Enriqueta; Chow, Laura Q M; Camidge, D Ross; Vansteenkiste, Johan; Sharma, Sunil; De Pas, Tommaso; Riely, Gregory J; Solomon, Benjamin J; Wolf, Jürgen; Thomas, Michael; Schuler, Martin; Liu, Geoffrey; Santoro, Armando; Sutradhar, Santosh; Li, Siyu; Szczudlo, Tomasz; Yovine, Alejandro; Shaw, Alice T
    Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1) : updated results from the multicentre, open-label, phase 1 trial
    In: The Lancet Oncology, Jg. 17, 2016, Nr. 4, S. 452 – 463
    DOI, Online Volltext (Open Access)
  • Fein, Luis; Wu, Yi-Long; Sequist, Lecia V; Geater, Sarayut L; Orlov, Sergey; Lee, Ki Hyeong; Tsai, Chun-Ming; Kato, Terufumi; Kiura, Katsuyuki; Barrios, Carlos H; Schuler, Martin; Hirsh, Vera; Yamamoto, Nobuyuki; O'Byrne, Kenneth; Mok, Tony; Massey, Dan; Märten, Angela; Chih-Hsin Yang, James
    Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged >=65 Years : Subgroup Analysis of LUX-Lung 3/6: P1.33: Track: Advanced NSCLC
    In: Journal of Thoracic Oncology, Jg. 11, 2016, Nr. 10 Supplement, S. 202 – S.203
    DOI (Open Access)
  • Yang, J C-H; Park, K; Kim, J-H; Bennouna, J; Chen, Y-M; Chouaid, C; De Marinis, F; Feng, J-F; Grossi, F; Kim, D-W; Liu, X; Lu, S; Strausz, J; Vinnyk, Y; Wiewrodt, R; Zhou, C; Wang, B; Chand, V K; Planchard, D; Ignatius Ou, Sai Hong; Planchard, David; Park, Keunchil; Schuler, Martin; Yang, James; Chand, Vikram; Rohr, Klaus; Bagnes, Claudia; Martin, Claudio Marcelo; Recondo, Gonzalo; Zarba, Juan Jose; Blajman, Cesar; Richardet, Martín; McLachlan, Sue-Anne; Parente, Phillip; Underhill, Craig; Crombie, Catherine; Mainwaring, Paul; Greil, Richard; Humblet, Yves; Bustin, Frédérique; Carestia, Luciano; Galdermans, Danny; Lambrechts, Marc; Delval, Laetitia; Vercauter, Piet; Zhou, Caicun; Wang, Jin; Huang, Cheng; Lin, Xiaoyan; Wu, Yilong; Liu, Xiaoqing; Cheng, Ying; Qin, Shukui; Feng, Jifeng; Huang, Jianjin; Zhang, Yiping; Lu, Shun; Zereu, Manuela; Garicochea, Bernardo; Zadra, Cyntia Albuquerque; Riska, Henrik; Alanko, Tuomo; Cadranel, Jacques; Chouaid, Christos; Zalcman, Gérard; Sibilot, Denis Moro; Perol, Maurice; Planchard, David; Bennouna, Jaafar; Fournel, Pierre; Gervais, Radj; Rotarski, Maciej; Coudert, Bruno; Schuler, Martin; Thomas, Michael; Wehler, Thomas; Faehling, Martin; Keilholz, Ulrich; Laack, Eckart; von Pawel, Joachim; Huber, Rudolf; Dickgreber, Nicolas; Wiewrodt, Rainer; Mark, Zsuzsanna; Tehenes, Sandor; Strausz, Janos; Sarosi, Veronika; Prabhash, Kumar; Jain, Minish; Venkatesan, Srinivasan; Sharma, Lalit; Dadhich, Hemant; Nagarkar, Rajnish Vasant; Onn, Amir; Gottfried, Maya; Stemmer, Solomon; Migliorino, Maria Rita; Grossi, Francesco; Bidoli, Paolo; Bearz, Alessandra; Gridelli, Cesare; Milandri, Carlo; Platania, Marco; Ceresoli, Giovanni Luca; Cruciani, Giorgio; Delgado, Francisco Gutierrez; Gonzalez Perez, José Luis; Luna, Gabriela Alvarado; Baca, Othon Padilla; Aerts, J G J V; Stigt, J A; Dingemans, A M C; Herder, G J M; Gans, S J M; Salas Sánchez, Jorge Fernando; Alvarez Barreda, Renzo Luzgardo; Pantigoso, Wilbert Rodriguez; Palomino, Osbert Luis Mejia; Jaskiewicz, Piotr; Kazarnowicz, Andrzej; Serwatowski, Piotr; Szczesna, Aleksandra; Jassem, Jacek; Lubennikov, Vladimir; Karaseva, Nina; Orlov, Sergey; Ragulin, Yuri; Garrido, Pilar; González Larriba, José Luis; Camps, Carlos; Campelo, Rosario García; Lianes, Pilar; Cobo, Manuel; Felip, Enriqueta; Kim, Dong-Wan; Kim, Sang-We; Park, Keunchil; Kim, Joo-Hang; Han, Ji-Youn; Kim, Young-Chul; Yang, Chih-Hsin; Hsia, Te-Chun; Chen, Yuh-Min; Tsai, Ying-Huang; Chang, Gee-Chen; Tsao, Thomas Chang-Yao; Su, Wu-Chou; Huang, Ming-Shyan; Ho, Ching-Liang; Hsieh, Ruey-Kuen; Vinnyk, Yuriy; Popovych, Oleksandr; Ponomarova, Olga; Bondarenko, Igor; Polishchuk, Iryna; Shah, Riyaz; Mitra, Sanka; Popat, Sanjaykumar; Spicer, James; Toy, Elizabeth; Popat, Sanjaykumar; Talbot, Toby; Brown, Emma; Upadhyay, Sunil; Summers, Yvonne; Gurtler, Jayne; Meza, Luis; Thropay, John
    Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib : phase III randomized LUX-Lung 5 trial
    In: Annals of Oncology, Jg. 27, 2016, Nr. 3, S. 417 – 423
    DOI (Open Access)
  • Reimer, P.; Höhler, T.; Schuler, Martin; Markus, P.; Knipp, Heike; Schumacher, B.; Dechene, Alexander; Ting, Saskia; Kasper, S.; Meiler, Johannes; Kostbade, K.; Berger, W.; Herold, T.; Trarbach, Tanja; Linden, G.; Steinmetz, H.T.; Schmid, Kurt Werner; Worm, K.; Paul, A.
    Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trial
    In: Annals of Oncology, Jg. 27, 2016, Nr. Suppl.6, S. 508P
    DOI
  • Nel, Ivonne; Gauler, Thomas; Bublitz, Kira; Lazaridis, Lazaros; Goergens, André; Giebel, Bernd; Schuler, Martin; Hoffmann, Andreas-Claudius
    Circulating Tumor Cell Composition in Renal Cell Carcinoma
    In: PLoS ONE, Jg. 11, 2016, Nr. 4, e0153018
    DOI (Open Access)
  • Köhler, Jens; Schuler, Martin; Gauler, Thomas; Nöpel-Dünnebacke, Stefanie; Ahrens, Maike; Hoffmann, Andreas-Claudius; Kasper, Stefan; Nensa, Felix; Gomez, Benedikt; Hahnemann, Maria; Breitenbücher, Frank; Cheufou, Danjouma; Özkan, Filiz; Darwiche, Kaid; Hoiczyk, Mathias; Reis, Henning; Welter, Stefan; Eberhardt, Wilfried; Eisenacher, Martin; Teschler, Helmut; Stamatis, Georgios; Schmiegel, Wolff; Hahn, Stephan Albrecht; Baraniskin, Alexander
    Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients
    In: Journal of Cancer Research and Clinical Oncology, Jg. 142, 2016, Nr. 4, S. 795 – 805
    DOI
  • Tabernero, J.; van Geel, R.; Guren, T.; Yaeger, R.; Spreafico, A.; Faris, J.; Yoshino, T.; Yamada, Y.; Tae, W. K.; Bendell, J.; Schuler, Martin; Lenz, H. J.; Eskens, F.; Desai, J.; Hochster, H.; Avsar, E.; Demuth, T.; Sandor, V.; Elez, E.; Schellens, J.
    Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC) : phase 2 results
    In: Annals of Oncology, Jg. 27, 2016, Nr. Suppl. 2, S. ii127 – ii128
    DOI
  • Stang, Andreas; Jöckel, Karl-Heinz; Kühl, Hilmar; Darwiche, Kaid; Schuler, Martin; Kowall, Bernd
    Concluding remarks : [Korrespondenz zu "Lung Cancer Screening Using Low Dose CT Scanning in Germany by Prof. Dr. med. Andreas Stang, MPH, Prof. Dr. med. Martin Schuler, Dr. rer. nat. Dr. rer. san. Bernd Kowall, Dr. med. Kaid Darwiche, PD Dr. med. Hilmar Kühl, and Prof. Dr. rer. nat. Karl-Heinz Jöckel in issue 38/2015"]
    In: Deutsches Ärzteblatt International, Jg. 113, 2016, Nr. 17, S. 297 – 298
    DOI (Open Access)
  • Stintzing, S.; Modest, D. P.; Jung, A.; Kirchner, T.; Schafer, R.; Sers, C.; Hildebrandt, B.; Daum, S.; Folprecht, G.; Schuler, Martin; Kasper, Stefan; Trojan, J.; Jaeger, D.; Schulze-Bergkamen, H.; von Weikersthal, L. F.; Schalhorn, A.; Heinemann, V.
    Differences in gene-expression in mCRC tissue samples with regard to tumor location and used chemotherapeutic substances : Data of the FIRE-1 study
    In: Journal of Clinical Oncology (JCO), Jg. 34, 2016, Nr. Suppl. 4, S. 562
    DOI
  • Yang, J C-H; Sequist, L V; Zhou, C; Schuler, Martin; Geater, S L; Mok, T; Hu, C-P; Yamamoto, N; Feng, J; O'Byrne, K; Lu, S; Hirsh, V; Huang, Y; Sebastian, M; Okamoto, I; Dickgreber, N; Shah, R; Märten, A; Massey, D; Wind, S; Wu, Y-L
    Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma : post hoc analyses of the randomized LUX-Lung 3 and 6 trials
    In: Annals of Oncology, Jg. 27, 2016, Nr. 11, S. 2103 – 2110
    DOI (Open Access)
  • Schuler, Martin; Sequist, Lecia; Popat, Sanjay; Mok, Tony; Yamamoto, Nobuyuki; O'Byrne, Kenneth; Hirsh, Vera; Wu, Yi-Long
    First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
    In: Journal of Thoracic Oncology, Jg. 11, 2016, Nr. 3, S. 380 – 390
    DOI (Open Access)
  • Stang, Andreas; Kowall, Bernd; Schuler, Martin; Jöckel, Karl-Heinz
    Früherkennung von Lungenkrebs : Low-dose-Computertomographie-Screening
    In: Der Onkologe, Jg. 22, 2016, Nr. 8, S. 568 – 577
    DOI
  • Al-Batran, Salah-Eddin; Hofheinz, Ralf D; Pauligk, Claudia; Kopp, Hans-Georg; Haag, Georg Martin; Luley, Kim Barbara; Meiler, Johannes; Homann, Nils; Lorenzen, Sylvie; Schmalenberg, Harald; Probst, Stephan; Koenigsmann, Michael; Egger, Matthias; Prasnikar, Nicole; Caca, Karel; Trojan, Jörg; Martens, Uwe M; Block, Andreas; Fischbach, Wolfgang; Mahlberg, Rolf; Clemens, Michael; Illerhaus, Gerald; Zirlik, Katja; Behringer, Dirk M; Schmiegel, Wolff; Pohl, Michael; Heike, Michael; Ronellenfitsch, Ulrich; Schuler, Martin; Bechstein, Wolf O; Königsrainer, Alfred; Gaiser, Timo; Schirmacher, Peter; Hozaeel, Wael; Reichart, Alexander; Goetze, Thorsten O; Sievert, Mark; Jäger, Elke; Mönig, Stefan; Tannapfel, Andrea
    Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO
    In: The Lancet Oncology, Jg. 17, 2016, Nr. 12, S. 1697 – 1708
    DOI
  • Al-Batran, S. E.; Schuler, Martin; Zvirbule, Z.; Manikhas, G.; Lordick, F.; Tureci, O.; Huber, C.; Sahin, U.
    IMAB362 : a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer
    In: Annals of Oncology, Jg. 27, 2016, Nr. Suppl. 2, S. ii141 – ii142
    DOI
  • Barrios, Carlos H; Wu, Yi-Long; Chih-Hsin Yang, James; Sequist, Lecia V; Geater, Sarayut L; Mok, Tony; Hu, Cheng-Ping; Yamamoto, Nobuyuki; O'Byrne, Kenneth; Lu, Shun; Hirsh, Vera; Sebastian, Martin; Okamoto, Isamu; Shah, Riyaz; Märten, Angela; Massey, Dan; Wind, Sven; Schuler, Martin
    Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6: Track: Advanced NSCLC
    In: Journal of Thoracic Oncology, Jg. 11, 2016, Nr. 10 Supplement, S. 210 - S. 211
    DOI (Open Access)
  • Schuler, Martin; Yang, J; Sequist, L V; Yamamoto, N; Zhou, C; O'Byrne, K; Hirsh, V; Mok, T; Shah, R; Wu, Y-L
    Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) : 138PD
    In: Journal of Thoracic Oncology, Jg. 11, 2016, Nr. Suppl. 4, S. 116 – 117
    DOI
  • Falkenhorst, Johanna; Grunewald, Susanne; Mühlenberg, Thomas; Marino-Enriquez, Adrian; Reis, Anna-Carina; Corless, Christopher; Heinrich, Michael; Treckmann, Jürgen-Walter; Podleska, Lars; Schuler, Martin; Fletcher, Jonathan Alfred; Bauer, Sebastian
    Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib
    In: OncoTarget, Jg. 7, 2016, Nr. 27, S. 41390 – 41403
    DOI (Open Access)
  • Schuler, Martin; Yang, J. C.-H.; Planchard, D.
    Reply to the letter to the editor ‘What is the clinical impact of the LUX-Lung 5 trial?’ by Addeo
    In: Annals of Oncology, Jg. 27, 2016, Nr. 6, S. 1172 – 1173
    DOI
  • Hoya, V.; Stuschke, Martin; Sauerwein, Wolfgang; Bornfeld, Norbert; Metz, Klaus; Schuler, Martin; Kasper, Stefan
    Small cell neuroendocrine carcinoma of the right eye : A case report
    In: Oncology Research and Treatment, Jg. 39, 2016, Nr. Suppl. 3, S. 189 – 189
  • Joerger, M.; Soo, R.; Cho, B.C.; Mendivil, A. Navarro; Sayehli, C.; Richly, Heike; Tai, D.; Kim, D.-W.; Wolf, J.; Cassier, P.; Ellinghaus, P.; Hildebrandt, S.; Behre, S.; Helmbrecht, C.; Kerpen, S.; Zielinski, D.; Ince, S.; Rajagopalan, P.; Ocker, M.; Schuler, Martin
    developmental therapeuticsPhase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levels
    In: Annals of Oncology, Jg. 27, 2016, Nr. Suppl. 6, 360O_PR
    DOI
  • Pöttgen, Christoph; Abu Jawad, Jehad; Gkika, Eleni; Freitag, Lutz; Lübcke, Wolfgang; Welter, Stefan; Gauler, Thomas; Schuler, Martin; Eberhardt, Wilfried; Stamatis, Georgios; Stuschke, Martin
    Accelerated radiotherapy and concurrent chemotherapy for patients with contralateral central or mediastinal lung cancer relapse after pneumonectomy
    In: Journal of Thoracic Disease, Jg. 7, 2015, Nr. 3, S. 264 – 272
    DOI
  • Wu, Y. L.; Sequist, L. V.; Geater, S. L.; Orlov, S.; Lee, K. H.; Tsai, C. M.; Kato, T.; Kiura, K.; Barrios, C. H.; Schuler, Martin; Hirsh, V.; Yamamoto, N.; OByrne, K.; Mok, T.; Massey, D.; Marten, A.; Yang, J. C. H.
    Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged ≥65 years : Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
    In: Annals of Oncology, Jg. 26, 2015, Nr. S 9: ESMO Asia Congress, 18-21 December 2015, Singapore : Submitted Abstracts, S. 136 – 137
  • Schuler, Martin; Yang, J. C. H.; Park, K.; Chand, V. K.; Wang, B.; Planchard, D.
    Afatinib (a) plus paclitaxel (p) following progression on a monotherapy in patients (pts) with metastatic non-small-cell lung cancer (nsclc) who previously benefited from erlotinib (e)/gefitinib (g) : a global randomised phase iii triallux-lung 5 (ll5)
    In: Annals of Oncology, Jg. 26, 2015, Nr. S 1, S. i33 – i34
    DOI
  • Yang, James Chih-Hsin; Wu, Yi-Long; Schuler, Martin; Sebastian, Martin; Popat, Sanjay; Yamamoto, Nobuyuki; Zhou, Caicun; Hu, Cheng-Ping; O'Byrne, Kenneth; Feng, Jifeng; Lu, Shun; Huang, Yunchao; Geater, Sarayut L; Lee, Kye Young; Tsai, Chun-Ming; Gorbunova, Vera; Hirsh, Vera; Bennouna, Jaafar; Orlov, Sergey; Mok, Tony; Boyer, Michael; Su, Wu-Chou; Lee, Ki Hyeong; Kato, Terufumi; Massey, Dan; Shahidi, Mehdi; Zazulina, Victoria; Sequist, Lecia V
    Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6) : analysis of overall survival data from two randomised, phase 3 trials
    In: The Lancet Oncology, Jg. 16, 2015, Nr. 2, S. 141 – 151
    DOI
  • Breitenbücher, Frank; Schuler, Martin; Markova, Boyka
    Alternative tumor suppressor mechanisms in lung carcinomas - modulation of senescence by growth factor-induced signaling
    In: Cancer Research, Jg. 75, 2015, Nr. 15 Suppl., S. 1033
    DOI
  • Richly, Heike; Kim, Tae Min; Schuler, Martin; Kim, Dong-Wan; Harrison, Simon J.; Shaw, Alice T.; Boral, Anthony L.; Yovine, Alejandro; Solomon, Benjamin
    Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma
    In: Blood, Jg. 126, 2015, Nr. 10, S. 1257 – 1258
    DOI
  • Kasper, Stefan; Meiler, Johannes; Knipp, Heike; Hoehler, Thomas; Reimer, Peter; Steinmetz, Tilman; Berger, Winfried; Linden, Gabriele; Ting, Saskia; Markus, Peter; Paul, Andreas; Dechene, Alexander; Schumacher, Brigitte; Kosbade, Karina; Worm, Karl; Schmid, Kurt Werner; Herold, Thomas; Schuler, Martin; Trarbach, Tanja
    Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) : Primary endpoint and subgroup analysis of the CEBIFOX trial
    In: Journal of Clinical Oncology (JCO), Jg. 33, 2015, Nr. 15 Suppl., S. 3568
    DOI
  • Yang, James C.-H.; Sequist, Lecia V.; Geater, Sarayut Lucien; Tsai, Chun-Ming; Mok, Tony Shu Kam; Schuler, Martin; Yamamoto, Nobuyuki; Yu, Chong-Jen; Ou, Sai-Hong I.; Zhou, Caicun; Massey, Daniel; Zazulina, Victoria; Wu, Yi-Long
    Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations : A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
    In: The Lancet Oncology, Jg. 16, 2015, Nr. 7, S. 830 – 838
    DOI
  • George, Julie; Lim, Jing Shan; Jang, Se Jin; Cun, Yupeng; Ozretia, Luka; Kong, Gu; Leenders, Frauke; Lu, Xin; Fernández-Cuesta, Lynnette; Bosco, Graziella; Müller, Christian; Dahmen, Ilona; Jahchan, Nadine S.; Park, Kwon-Sik; Yang, Dian; Karnezis, Anthony N.; Vaka, Dedeepya; Torres, Angela; Wang, Maia Segura; Korbel, Jan O.; Menon, Roopika; Chun, Sung-Min; Kim, Deokhoon; Wilkerson, Matt; Hayes, Neil; Engelmann, David; Pützer, Brigitte; Bos, Marc; Michels, Sebastian; Vlasic, Ignacija; Seidel, Danila; Pinther, Berit; Schaub, Philipp; Becker, Christian; Altmüller, Janine; Yokota, Jun; Kohno, Takashi; Iwakawa, Reika; Tsuta, Koji; Noguchi, Masayuki; Muley, Thomas; Hoffmann, Hans; Schnabel, Philipp A.; Petersen, Iver; Chen, Yuan; Soltermann, Alex; Tischler, Verena; Choi, Chang-Min; Kim, Yong-Hee; Massion, Pierre P.; Zou, Yong; Jovanovic, Dragana; Kontic, Milica; Wright, Gavin M.; Russell, Prudence A.; Solomon, Benjamin; Koch, Ina; Lindner, Michael; Muscarella, Lucia A.; La Torre, Annamaria; Field, John K.; Jakopovic, Marko; Knezevic, Jelena; Castaños-Vélez, Esmeralda; Roz, Luca; Pastorino, Ugo; Brustugun, Odd-Terje; Lund-Iversen, Marius; Thunnissen, Erik; Köhler, Jens; Schuler, Martin; Botling, Johan; Sandelin, Martin; Sanchez-Cespedes, Montserrat; Salvesen, Helga B.; Achter, Viktor; Lang, Ulrich; Bogus, Magdalena; Schneider, Peter M.; Zander, Thomas; Ansén, Sascha; Hallek, Michael; Wolf, Jürgen; Vingron, Martin; Yatabe, Yasushi; Travis, William D.; Nürnberg, Peter; Reinhardt, Christian; Perner, Sven; Heukamp, Lukas; Büttner, Reinhard; Haas, Stefan A.; Brambilla, Elisabeth; Peifer, Martin; Sage, Julien; Thomas, Roman K.
    Comprehensive genomic profiles of small cell lung cancer
    In: Nature, Jg. 524, 2015, Nr. 7563, S. 47 – 53
    DOI (Open Access)
  • Tewes, Mitra; Kasimir-Bauer, Sabine; Welt, Anja; Schuler, Martin; Kimmig, Rainer; Aktas, Bahriye
    Detection of disseminated tumor cells in bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer
    In: Journal of Cancer Research and Clinical Oncology, Jg. 141, 2015, Nr. 1, S. 87 – 92
    DOI
  • Jaeger, Savina; Spreafico, Anna; van Geel, Robin; Bendell, Johanna C.; Lolkema, Martijn P.; Tabernero, Josep; Lenz, Heinz-Josef; Schellens, Jan H. M.; Avsar, Emin; Wainberg, Zev A.; Yoshino, Takayuki; Eskens, Ferry A. L. M.; Sharma, Sunil; Delord, Jean-Pierre; Schuler, Martin; Chatterjee, Arkendu; Faris, Jason E.; Yaeger, Rona; Demuth, Tim; Yamada, Yasuhide
    Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer
    In: Cancer Research, Jg. 75, 2015, Nr. 15 Suppl., S. CT136
    DOI
  • Reis, Henning; Herold, Thomas; Ting, S.; Worm, Karl Heinz; Huber, U.; Christoph, Daniel; Eberhardt, Wilfried; Kostbade, K.; Kasper, Stefan; Stamatis, Georgios; Welter, Stefan; Darwiche, Kaid; Karpf-Wissel, Rüdiger; Theegarten, Dirk; Schmidt, K. W.; Schuler, Martin; Wiesweg, Marcel
    HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas
    In: Lung Cancer, Jg. 88, 2015, Nr. 1, S. 34 – 41
    DOI
  • Yang, James Chih-Hsin; Ahn, Myung-Ju; Dickgreber, Nicolas J.; Halmos, Balazs; Hirsh, Vera; Hochmair, Maximilian J.; Levy, Benjamin Philip; De Marinis, Filippo; Mok, Tony; O´Byrne, Kenneth; Okamoto, Isamu; Schuler, Martin; Sebastian, Martin; Shah, Riyaz N. H; Tan, Eng-Huat; Yamamoto, Nobuyuki; Marten, Angela; Massey, Dan; Wind, Sven; Carbone, David Paul
    Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
    In: Journal of Clinical Oncology (JCO), Jg. 33, 2015, Nr. 15_suppl, S. 8073
    DOI, Online Volltext
  • Passaro, A.; Yang, J. C.; Ahn, M.; Dickgreber, N. J.; Halmos, B.; Hirsh, V.; Hochmair, M. J.; Levy, B. P.; de Marinis, F.; Mok, T.; OByrne, K.; Okamoto, I.; Schuler, Martin; Sebastian, M.; Shah, R.; Tan, E.; Yamamoto, N.; Marten, A.; Wind, S.; Carbone, D. P.
    Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
    In: Annals of Oncology, Jg. 26, 2015, Nr. S 6, S. vi73 – vi89
    DOI
  • Mühlenberg, Thomas; Grunewald, Susanne; Treckmann, Jürgen-Walter; Podleska, Lars; Schuler, Martin; Fletcher, Jonathan A.; Bauer, Sebastian
    Inhibition of KIT-Glycosylation by 2-Deoxyglucose Abrogates KIT-Signaling and Combination with ABT-263 Synergistically Induces Apoptosis in Gastrointestinal Stromal Tumor
    In: PLoS ONE, Jg. 10, 2015, Nr. 3, S. e0120531
    DOI (Open Access)
  • Stang, Andreas; Schuler, Martin; Kowall, Bernd; Darwiche, Kaid; Kühl, Hilmar; Jöckel, Karl-Heinz
    Lungenkrebsscreening mit Low-Dose-Computertomographie in Deutschland : Hochrechnung der Kennzahlen des National Lung Screening Trial
    In: Deutsches Ärzteblatt International, Jg. 112, 2015, Nr. 38, S. 637 – 644
    DOI (Open Access)
  • Pogorzelski, M.; Ting, Saskia; Gauler, Thomas; Breitenbücher, Frank; Vossebein, I.; Hoffarth, S.; Markowetz, J.; Lang, Stephan; Bergmann, Christoph; Brandau, Sven; Abu-Jawad, J.; Schmid, Kurt Werner; Schuler, Martin; Kasper, Stefan
    Molecular dissection of the impact of frequent genetic alterations on the response of head and neck cancers to anti-epidermal growth factor receptor-directed therapies
    In: Oral Oncology, Jg. 51, 2015, Nr. 5, S. e39
    DOI
  • Wu, Y. L.; Sequist, L. V.; Schuler, Martin; Yamamoto, N.; Zhou, C.; Hu, C. P.; OByrne, K.; Hirsh, V.; Mok, T.; Zazulina, V.; Yang, J. C. H.
    Overall survival (OS) with afatinib (A) vs chemotherapy (CT) in patients (pts) with NSCLC harboring EGFR mutations (mut) : Subgroup analyses by race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
    In: Annals of Oncology, Jg. 26, 2015, Nr. S 9: ESMO Asia Congress, 18-21 December 2015, Singapore : Submitted Abstracts, S. 136
    DOI
  • Janku, F.; Juric, D.; Cortes, J.; Rugo, H.; Burris, H. A.; Schuler, Martin; Deschler-Baier, B.; Middleton, M. R.; Gil-Martin, M.; Berlin, J.; Winer, E.; Bootle, D.; Blumenstein, L.; Demanse, D.; Coughlin, C.; Quadt, C.; Baselga, J.
    Phase I study of the PI3K alpha inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2-locally advanced or metastatic breast cancer
    In: Cancer Research, Jg. 75, 2015, Nr. S 9, S. 9 – 13
    DOI
  • Eberhardt, Wilfried; Pöttgen, Christoph; Gauler, Thomas; Friedel, Godehard; Veit, Stefanie; Heinrich, Vanessa; Welter, Stefan; Budach, Wilfried; Spengler, Werner; Kimmich, Martin; Fischer, Berthold; Schmidberger, Heinz; De Ruysscher, Dirk; Belka, Claus; Cordes, Sebastian; Hepp, Rodrigo; Lütke-Brintrup, Diana; Lehmann, Nils; Schuler, Martin; Jöckel, Karl-Heinz; Stamatis, Georgios; Stuschke, Martin
    Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)
    In: Journal of Clinical Oncology (JCO), Jg. 33, 2015, Nr. 35, S. 4194 – 4201
    DOI
  • Bauer, Sebastian; Herold, Thomas; Mühlenberg, Thomas; Reis, Anna-Carina; Falkenhorst, Johanna; Backs, Miriam; Ketzer, Julia; Breitenbücher, Frank; Schuler, Martin; Grunewald, Susanne
    Plasma sequencing to detect a multitude of secondary KIT resistance mutations in metastatic gastrointestinal stromal tumors (GIST)
    In: Journal of Clinical Oncology (JCO), Jg. 33, 2015, Nr. 15_suppl, S. 10518
    DOI, Online Volltext
  • Pöttgen, Christoph; Stuschke, Martin; Graupner, Britta; Theegarten, Dirk; Gauler, Thomas; Jendrossek, Verena; Freitag, Lutz; Abu Jawad, Jehad; Gkika, Eleni; Wohlschläger, Jeremias; Welter, Stefan; Hoiczyk, Matthias; Schuler, Martin; Stamatis, Georgios; Eberhardt, Wilfried
    Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors
    In: BMC Cancer, Jg. 15, 2015, Nr. 1, S. 363
    DOI (Open Access)
  • Gautschi, Oliver; Bluthgen, Marie-Virginia; Smit, Egbert F.; Wolf, Jürgen; Früh, Martin; Petersenn, Stephan; Schuler, Martin; Zalcman, Gérard; Milia, Julie; Mazieres, Julien
    Targeted Therapy for Patients with BRAF-Mutant Lung Cancer : Results from the European EURAF Cohort
    In: Annals of Oncology, Jg. 26, 2015, Nr. S 1: European Lung Cancer Conference (ELCC), Geneva, Switzerland, 15-18 April 2015 : Abstracts, S. i61
    DOI
  • Gautschi, Oliver; Milia, Julie; Cabarrou, Bastien; Bluthgen, Marie-Virginia; Besse, Benjamin; Smit, Egbert F.; Wolf, Jürgen; Peters, Solange; Früh, Martin; Koeberle, Dieter; Oulkhouir, Youssouf; Schuler, Martin; Curioni-Fontecedro, Alessandra; Huret, Benjamin; Kerjouan, Mallorie; Michels, Sebastian; Pall, Georg; Rothschild, Sacha I.; Schmid-Bindert, Gerald; Scheffler, Matthias; Veillon, Rémi; Wannesson, Luciano; Diebold, Joachim; Zalcman, Gérard; Filleron, Thomas; Mazières, Julien
    Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
    In: Journal of Thoracic Oncology, Jg. 10, 2015, Nr. 10, S. 1451 – 1457
    DOI (Open Access)
  • Hyman, David M.; Puzanov, Igor; Subbiah, Vivek; Faris, Jason E.; Chau, Ian; Blay, Jean‑Yves; Wolf, Jürgen; Raje, Noopur S.; Diamond, Eli L.; Hollebecque, Antoine; Gervais, Radj; Elez‑Fernandez, Maria Elena; Italiano, Antoine; Hofheinz, Ralf‑Dieter; Hidalgo, Manuel; Chan, Emily; Schuler, Martin; Lasserre, Susan Frances; Makrutzki, Martina; Sirzen, Florin; Veronese, Maria Luisa; Tabernero, Josep; Baselga, José
    Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations
    In: The New England Journal of Medicine, Jg. 373, 2015, Nr. 8, S. 726 – 736
    DOI, Online Volltext (Open Access)
  • Hoffmann, Gesine; Breitenbücher, Frank; Schuler, Martin; Ehrenhofer-Murray, Ann
    A Novel Sirtuin 2 (SIRT2) Inhibitor with p53-dependent Pro-apoptotic Activity in Non-small Cell Lung Cancer
    In: The Journal of Biological Chemistry (JBC), Jg. 289, 2014, Nr. 8, S. 5208 – 5216
    DOI
  • Wiesweg, M; Aydin, S; Köninger, Angela; Stein, Anja; Schara, Ulrike; van Roye, C; Hense, Jörg; Welt, Anja; Schuler, Martin
    Administration of Gemcitabine for Metastatic Adenocarcinoma during Pregnancy : A Case Report and Review of the Literature
    In: American Journal of Perinatology Reports, Jg. 4, 2014, Nr. 1, S. 017 – 022
    DOI (Open Access)
  • Christoph, Daniel; Reyna-Asuncion, Bernadette; Hassan, Biftu; Tran, Cindy; Maltzman, Julia D; O'Shannessy, Daniel J; Gauler, Thomas; Wohlschläger, Jeremias; Schuler, Martin; Eberhardt, Wilfried; Hirsch, Fred R
    Assessment of Folate Receptor-α and Epidermal Growth Factor Receptor Expression in Pemetrexed-Treated Non–Small-Cell Lung Cancer Patients
    In: Clinical Lung Cancer, Jg. 15, 2014, Nr. 5, S. 320 – 330.e3
    DOI
  • Shaw, A.; Mehra, R.; Tan, DSW; Felip, E.; Chow, LQM; Camidge, D. R.; Vansteenkiste, J.; Sharma, S.; De Pas, T.; Riely, G. J.; Solomon, B. J.; Wolf, J.; Thomas, M.; Schuler, Martin; Liu, G.; Santoro, A.; Geraldes, M.; Sen, P.; Boral, A. J.; Yovine, A.; Kim, D. W.
    Ceritinib (LDK378) for treatment of patients with ALK-rearranged (ALK plus) non small cell lung cancer (NSCLO) and brain metastases (BM) in the ascend-1 trial
    In: Neuro-Oncology, Jg. 16, 2014, Nr. Suppl. 5, S. v39
    DOI
  • Shaw, Alice T; Kim, Dong-Wan; Mehra, Ranee; Tan, Daniel S W; Felip, Enriqueta; Chow, Laura Q M; Camidge, D Ross; Vansteenkiste, Johan; Sharma, Sunil; De Pas, Tommaso; Riely, Gregory J; Solomon, Benjamin J; Wolf, Juergen; Thomas, Michael; Schuler, Martin; Liu, Geoffrey; Santoro, Armando; Lau, Yvonne Y; Goldwasser, Meredith; Boral, Anthony L; Engelman, Jeffrey A
    Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
    In: The New England Journal of Medicine, Jg. 370, 2014, Nr. 13, S. 1189 – 1197
    DOI, Online Volltext (Open Access)
  • Tan, DSW; Shaw, A. T.; Mehra, R.; Felip, E.; Chow, LQM; Camidge, D. R.; Vansteenkiste, J. F.; Sharma, S.; De Pas, T.; Riely, G. J.; Solomon, B. J.; Wolf, J.; Thomas, M.; Schuler, Martin; Liu, G.; Santoro, A.; Geraides, M.; Boral, A.; Yovine, A. J.; Kim, D. W.
    Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) NSCLC : Subgroup analysis of the ASCEND-1 trial
    In: Journal of Clinical Oncology (JCO), Jg. 32, 2014, Nr. 15 Suppl., S. 8078
    DOI
  • Kim, D. W.; Mehra, R.; Tan, DSW; Felip, E.; Chow, LQM; Camidge, D. R.; Vansteenkiste, J. F.; Sharma, S.; De Pas, T.; Riely, G. J.; Solomon, B. J.; Wolf, J.; Thomas, M.; Schuler, Martin; Liu, G.; Santoro, A.; Geraldes, M.; Boral, A.; Yovine, A. J.; Shaw, A. T.
    Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) : Results of the ASCEND-1 trial
    In: Journal of Clinical Oncology (JCO), Jg. 32, 2014, Nr. 15 Suppl., S. 8003
    DOI
  • Schuler, Martin; Yang, C. H.; Park, K.; Bennouna, J.; Chen, Y. M.; Chouaid, C.; De Marinis, F.; Feng, J. F.; Grossi, F.; Kim, D. W.; Liu, X. Q.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C. C.; Chand, V. K.; Wang, B. S.; Kim, J. H.; Planchard, D.; LUX-Lung 5 Investigators
    Continuation of afatinib beyond progression : Results of a randomized, open-label, phase III trial of afatanib plus paclitaxel (P) versus investigators choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed
    In: Journal of Clinical Oncology (JCO), Jg. 32, 2014, Nr. 15 Suppl., S. 8019
    DOI
  • Wu, Y. L.; Sequist, L.; Hu, C. P.; Feng, J. F.; Lu, S.; Huang, Y. C.; Li, W.; Hou, M.; Schuler, Martin; Mok, T.; Yamamoto, N.; OByrne, K.; Hirsh, V.; Gibson, N.; Massey, D.; Kim, M.; Yang, JCH
    Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in Circulating Cell-Free DNA in Two Phase III Studies (LUX-Lung 3 and LUX-Lung 6) of Afatinib vs Platinum-Based Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
    In: American Journal of Clinical Pathology, Jg. 142, 2014, Nr. Suppl. 1, S. A182
    DOI
  • Aktas, B.; Kasimir-Bauer, Sabine; Welt, Anja; Schuler, Martin; Kimmig, Rainer; Tewes, Mitra
    Detection of disseminated tumor cells in the bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer
    In: Journal of Clinical Oncology (JCO), Jg. 32, 2014, Nr. 15 Suppl., S. e22032
    DOI
  • Breitenbücher, Frank; Hoffarth, Sandra; Worm, Karl; Cortes-Incio, Diana; Gauler, Thomas; Köhler, Jens; Herold, Thomas; Kurt Werner, Schmid; Freitag, Lutz; Kasper, Stefan; Schuler, Martin
    Development of a Highly Sensitive and Specific Method for Detection of Circulating Tumor Cells Harboring Somatic Mutations in Non-Small-Cell Lung Cancer Patients
    In: PLoS ONE, Jg. 9, 2014, Nr. 1, e85350
    DOI (Open Access)
  • Schuler, Martin; Fischer, Jürgen R.; Grohé, Christian; Gütz, Sylvia; Thomas, Michael; Kimmich, Martin; Schneider, Claus-Peter; Laack, Eckart; Märten, Angela; for the Afatinib Compassionate Use Consortium
    Experience With Afatinib in Patients With Non-Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib
    In: The Oncologist, Jg. 19, 2014, Nr. 10, S. 1100 – 1109
    DOI, Online Volltext (Open Access)
  • Göbel, C.; Breitenbücher, Frank; Kalkavan, Halime; Hähnel, Patricia S.; Kasper, Stefan; Hoffarth, Christian; Merches, Katja; Schild, Hans-Jörg; Lang, Karl S.; Schuler, Martin
    Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity
    In: Cell Death and Disease, Jg. 5, 2014, Nr. 12, 1568
    DOI (Open Access)
  • Pogorzelski, M-; Ting, Saskia; Gauler, Thomas; Breitenbücher, Frank; Vossebein, I.; Hoffarth, S.; Markowetz, J.; Lang, S.; Bergmann, Christoph; Brandau, Sven; Abu Jawad, Jehad; Schmid, Kurt Werner; Schuler, Martin; Kasper, Stefan
    Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy
    In: Cell Death and Disease, Jg. 5, 2014, Nr. 2, e1091
    DOI (Open Access)
  • Köhler, Jens; Schuler, Martin
    LUX-Lung 3: redundancy, toxicity or a major step forward? : Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer
    In: Future Oncology, Jg. 10, 2014, Nr. 4, S. 533 – 540
    DOI
  • Wiesweg, Marcel; Schuler, Martin
    Molekulare Labordiagnostik bei gastrointestinalen Tumorerkrankungen
    In: Der Gastroenterologe, Jg. 9, 2014, Nr. 2, S. 127 – 137
    DOI
  • Yang, JCH; Sequist, L. V.; Schuler, Martin; Mok, T.; Yamamoto, N.; OByrne, K. J.; Hirsh, V.; Geater, S. L.; Zhou, C. C.; Massey, D.; Zazulina, V.; Wu, Y. L.
    Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut) : Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and
    In: Journal of Clinical Oncology (JCO), Jg. 32, 2014, Nr. 15 Suppl., S. 8004
    DOI
  • Sequist, L. V.; Cassier, P.; Varga, A.; Tabernero, J.; Schellens, J. H.; Delord, J. P.; LoRusso, P.; Camidge, D. R.; Medina, M. H.; Schuler, Martin; Campone, M.; Tian, G. G.; Wong, S.; Corral, J.; Isaacs, R.; Sen, S. K.; Porta, D. G.; Kulkarni, S. G.; Lefebvre, C.; Wolf, J.
    Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors
    In: Cancer Research, Jg. 74, 2014, Nr. 19 Suppl.
    DOI
  • Van Geel, R.; Elez, E.; Bendell, J. C.; Faris, J. E.; Lolkema, MPJK; Eskens, F.; Spreafico, A.; Kavan, P.; Delord, J. P.; Schuler, Martin; Wainberg, Z. A.; Yamada, Y.; Yoshino, T.; Demuth, T.; Avsar, E.; Chatterjee, A.; Zhu, P. J.; Bernards, R.; Tabernero, J.; Schellens, JHM
    Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer
    In: Journal of Clinical Oncology (JCO), Jg. 32, 2014, Nr. 15 Suppl., S. 3514
    DOI
  • Tabernero, J.; van Geel, R.; Bendell, J. C.; Spreafico, A.; Schuler, Martin; Yoshino, T.; Delord, J. P.; Yamada, Y.; Lolkema, M. P.; Fans, J. E.; Eskens, FALM; Sharma, S.; Yaeger, R.; Lenz, H. J.; Wainberg, Z.; Avsar, E.; Chatterjee, A.; Jaeger, S.; Demuth, T.; Schellens, JHM
    Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer
    In: European Journal of Cancer (EJC), Jg. 50, 2014, Nr. Suppl. 6, S. 199
    DOI
  • Eberhardt, Wilfried; Gauler, Thomas; Pöttgen, Christoph; Friedel, G.; Veit, S.; Heinrich, V.; Welter, Stefan; Spengler, W.; Kimmich, M.; Fischer, B.; Schmidberger, H.; Gkika, E.; Cordes, S.; Hepp, R.; Luetke-Brintrup, D.; Lehmann, Nils; Schuler, Martin; Jöckel, Karl-Heinz; Stamatis, Georgios; Stuschke, Martin; ESPATUE AIO ARO Clinical Trials
    Phase III study of surgery (S) versus definitive concurrent chemoradiotherapy boost (def ccCRTx-BOx) in patients (pts) with operable (OP+) stage IIIA(N2)/selected IIIb (sel IIIB) non-small cell lung cancer (NSCLC) following induction (IND) chemotherapy (CTx) and concurrent CRTx (ESPATUE)
    In: Journal of Clinical Oncology (JCO), Jg. 32, 2014, Nr. 15 Suppl., S. 7510
    DOI
  • Bauer, Sebastian; Hilger, Ralf A.; Mühlenberg, Thomas; Grabellus, Florian; Nagarajah, James; Hoiczyk, M.; Reichardt, A.; Ahrens, M.; Reichardt, P.; Grunewald, S.; Scheulen, Max Ernst; Pustowka, A.; Bock, E.; Schuler, Martin; Pink, D.
    Phase i study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
    In: British Journal of Cancer (BJC), Jg. 110, 2014, Nr. 5, S. 1155 – 1162
    DOI (Open Access)
  • Ahnert, J. R.; Schuler, Martin; Machiels, JPH; Hess, D.; Paz-Ares, L.; Awada, A.; von Moos, R.; Steeghs, N.; Zambrano, C. C.; De Mesmaeker, P.; Richly, Heike; Herremans, C.; Joerger, M.; Jaime, J. C.; Alsina, M.; Baffert, F.; Demanse, D.; Duval, V.; Morozov, A.; Dirix, L.
    Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC)
    In: Journal of Clinical Oncology (JCO), Jg. 32, 2014, Nr. 15 Suppl., S. 621
    DOI
  • Zambrano, C. C.; Schuler, Martin; Machiels, JPH; Hess, D.; Paz-Ares, L.; Awada, A.; von Moos, R.; Steeghs, N.; Ahnert, J. R.; De Mesmaeker, P.; Richly, Heike; Herremans, C.; Joerger, M.; Jaime, J. C.; Alsina, M.; Baffert, F.; Demanse, D.; Duval, V.; Morozov, A.; Dirix, L.
    Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC)
    In: Journal of Clinical Oncology (JCO), Jg. 32, 2014, Nr. 15 Suppl., S. 627
    DOI
  • Kuehnle, Marie-Christine; Attig, Sebastian; Britten, Cedrik Michael; Schulze-Bergkamen, Henning; Lordick, Florian; Von Wichert, Götz P. L .; Thuß-Patience, Peter C.; Stein, Alexander; Schuler, Martin; Bassermann, Florian; Şahin, Uǧur; Türeci, Özlem
    Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction
    In: Cancer Immunology, Immunotherapy, Jg. 63, 2014, Nr. 12, S. 1273 – 1284
    DOI
  • Schmidt, Lars Henning; Görlich, Dennis; Spieker, Tillmann; Rohde, Christian; Schuler, Martin; Mohr, Michael; Humberg, Julia; Sauer, Tim; Thoenissen, Nils; Huge, Andreas; Voss, Reinhard; Marra, Alessandro; Faldum, Andreas; Müller-Tidow, Carsten; Berdel, Wofgang E.; Wiewrodt, Rainer
    Prognostic impact of Bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non-small-cell lung cancer
    In: Journal of Thoracic Oncology, Jg. 9, 2014, Nr. 9, S. 1294 – 1304
    DOI
  • Kordelas, L.; Bauer, Sebastian; Schuler, Martin; Beelen, Dietrich; Gauler, Thomas
    Successful resuscitation of a patient with ventricular fibrillation due to hypomagnesemia under cetuximab therapy
    In: TumorDiagnostik & Therapie, Jg. 35, 2014, Nr. 1, S. 25 – 27
    DOI
  • Kasper, Stefan; Schuler, Martin
    Targeted therapies in gastroesophageal cancer
    In: European Journal of Cancer (EJC), Jg. 50, 2014, Nr. 7, S. 1247 – 1258
    DOI
  • Nogova, L.; Sequist, L. V.; Cassier, P. A.; Hidalgo, M.; Delord, J. P.; Schuler, Martin; Lim, W. T.; Camidge, D. R.; Buettner, R.; Heukamp, L. C.; Gardizi, M.; Scheffler, M.; Kambartel, K.; Ringeisen, F. P.; Sen, S.; Isaacs, R.; Joannaert, M.; Lefebvre, C.; Wolf, J.
    Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398
    In: Journal of Clinical Oncology (JCO), Jg. 32, 2014, Nr. 15 Suppl., S. 8034
    DOI
  • Pastille, Eva; Bardini, Katrin; Fleissner, Diana; Adamczyk, Alexandra; Frede, Annika; Wadwa, Munisch; Smolinski, Dorthe von; Kasper, Stefan; Sparwasser, Tim; Gruber, Achim D.; Schuler, Martin; Sakaguchi, Shimon; Roers, Axel; Müller, Werner; Hansen, Wiebke; Buer, Jan; Westendorf, Astrid
    Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancer
    In: Cancer Research, Jg. 74, 2014, Nr. 16, S. 4258 – 4269
    DOI
  • Köhler, J.; Schuler, Martin
    Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma : A Review
    In: Oncology Research and Treatment, Jg. 36, 2013, Nr. 9, S. 510 – 518
    DOI
  • Kasper, Stefan; Meiler, Johannes; Knipp, Heike; Hoehler, T.; Reimer, P.; Steinmetz, T.; Berger, W.; Linden, G.; Ting, Saskia; Markus, P.; Paul, Andreas; Schuler, Martin; Trarbach, Tanja
    Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) : An interim analysis of the CEBIFOX trial
    In: Journal of Clinical Oncology (JCO), Jg. 31, 2013, Nr. 15 Suppl., S. e14502
    DOI
  • Chen, Xiaofeng; Zhu, Quan; Zhu, Lingjun; Pei, Dong; Liu, Yiqian; Yin, Yongmei; Schuler, Martin; Shu, Yongqian
    Clinical perspective of afatinib in non-small cell lung cancer
    In: Lung Cancer, Jg. 81, 2013, Nr. 2, S. 155 – 161
    DOI
  • Juntermanns, Benjamin; Sotiropoulos, Georgios; Radunz, Sonia; Reis, Henning; Heuer, Matthias; Baba, Hideo Andreas; Canbay, Aliekber; Schuler, Martin; Gerken, Guido; Paul, Andreas; Kaiser, Gernot Maximil
    Comparison of the Sixth and the Seventh Editions of the UICC Classification for Perihilar Cholangiocarcinoma
    In: Annals of Surgical Oncology, Jg. 20, 2013, Nr. 1, S. 277 – 284
    DOI
  • Heusch, Philipp; Buchbender, Christian; Köhler, Jens; Nensa, Felix; Beiderwellen, Karsten; Kühl, Hilmar; Lanzman, Rotem S.; Wittsack, Hans-Jörg; Gomez, Benedikt; Gauler, Thomas; Schuler, Martin; Forsting, Michael; Bockisch, Andreas; Antoch, Gerald; Heusner, Till Alexander
    Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions : Initial results
    In: RöFo: Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, Jg. 185, 2013, Nr. 11, S. 1056 – 1062
    DOI
  • Simon, Susanne; Grabellus, Florian; Ferrera, Loretta; Galietta, Luis; Schwindenhammer, Benjamin; Mühlenberg, Thomas; Täger, Georg; Eilers, Grant; Treckmann, Jürgen-Walter; Breitenbücher, Frank; Schuler, Martin; Taguchi, Takahiro; Fletcher, Jonathan A.; Bauer, Sebastian
    DOG1 Regulates Growth and IGFBP5 in Gastrointestinal Stromal Tumors
    In: Cancer Research, Jg. 73, 2013, Nr. 12, S. 3661 – 3670
    DOI
  • Yang, JCH; Sequist, L.; OByrne, K.; Schuler, Martin; Mok, T.; Geater, S.; Massey, D.; OBrien, D.; Zazulina, V.; Wu, Y. L.
    Epidermal growth factor receptor (EGFR)-mediated adverse events (AEs) in patients (pts) with EGFR mutation positive (EGFR M plus ) non-small cell lung cancer treated with afatinib
    In: European Journal of Cancer (EJC), Jg. 49, 2013, Nr. Suppl. 2, S. 190
    DOI
  • Wiesweg, Marcel; Ting, Saskia; Reis, Henning; Worm, Karl; Kasper, Stefan; Tewes, Mitra; Welt, Anja; Richly, Heike; Meiler, Johannes; Bauer, Sebastian; Hense, Jörg; Gauler, Thomas; Köhler, Jens; Eberhardt, Wilfried; Darwiche, Kaid; Freitag, Lutz; Stamatis, Georgios; Breitenbücher, Frank; Wohlschläger, Jeremias; Theegarten, Dirk; Derks, Cordula; Cortes-Incio, Diana; Linden, Gabriele; Skottky, Silke; Lütkes, Peter; Dechene, Alexander; Paul, Andreas; Markus, Peter; Schmid, Kurt Werner; Schuler, Martin
    Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center
    In: European Journal of Cancer (EJC), Jg. 49, 2013, Nr. 15, S. 3076 – 3082
    DOI
  • Nel, I.; Gauler, Thomas; Eberhardt, Wilfried; Nickel, A. C.; Schuler, Martin; Thomale, Jürgen; Hoffmann, Andreas-Claudius
    Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment
    In: British Journal of Cancer (BJC), Jg. 109, 2013, Nr. 5, S. 1223 – 1229
    DOI (Open Access)
  • Rebmann, Vera; Gauler, Thomas; Schott, B.; Schott, P.; Bauer, Sebastian; Opalka, Bertram; Stamatis, Georgios; Eberhardt, Wilfried; Schuler, Martin; Horn, Peter
    Free soluble HLA-G molecules but not exosome-derived soluble HLA-G molecules are of prognostic relevance in lung cancer patients
    In: Tissue Antigens, Jg. 81, 2013, Nr. 5, S. 282 – 283
    DOI
  • Falkenhorst, J.; Mühlenberg, Thomas; Grunewald, S.; Marino-Enriquez, A.; Schuler, Martin; Fletcher, J.; Bauer, Sebastian
    IAP gene alterations and therapeutic modulation of IAPs by Smac mimetics in GIST
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,
    In: Onkologie, Jg. 36, 2013, Nr. Suppl. 7, S. 245 – 246
  • OByrne, K. J.; Sequist, L. V.; Schuler, Martin; Yamamoto, N.; Hirsh, V.; Mok, T.; Lungershausen, J.; Shahidi, M.; Palmer, M.; Yang, JCH
    LUX-Lung 3 : Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations
    In: Lung Cancer, Jg. 79, 2013, Nr. Suppl. 1, S. 11
    DOI
  • Kasper, Stefan; Breitenbücher, Frank; Reis, Henning; Brandau, Sven; Worm, K.; Köhler, J.; Paul, Andreas; Trarbach, Tanja; Schmid, Kurt Werner; Schuler, Martin
    Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade
    In: Oncogene, Jg. 32, 2013, Nr. 23, S. 2873 – 2881
    DOI
  • Sequist, Lecia V.; Yang, James Chih-Hsin; Yamamoto, Nobuyuki; O'Byrne, Kenneth; Hirsh, Vera; Mok, Tony; Geater, Sarayut Lucien; Orlov, Sergey; Tsai, Chun-Ming; Boyer, Michael; Su, Wu-Chou; Bennouna, Jaafar; Kato, Terufumi; Gorbunova, Vera; Lee, Ki Hyeong; Shah, Riyaz; Massey, Dan; Zazulina, Victoria; Shahidi, Mehdi; Schuler, Martin
    Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
    In: Journal of Clinical Oncology (JCO), Jg. 31, 2013, Nr. 27, S. 3327 – 3334
    DOI
  • Welt, Anja; Tewes, Mitra; Aktas, Bahriye; Hoffmann, Oliver; Wiesweg, Marcel; Ting, Saskia; Reis, Henning; Worm, Karl; Richly, Heike; Hense, Jörg; Palmer, Michael R.; Lee, Benjamin H.; Wendling, Johanna; Kossow, Josef; Scheulen, Max Ernst; Lehnerdt, Cathrin; Kohl, Marzena; Derks, Cordula; Skottky, Silke; Haus, Ulrike; Schmid, Kurt Werner; Kimmig, Rainer; Schuler, Martin; Kasper, Stefan
    Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients
    In: Breast Cancer Research and Treatment, Jg. 142, 2013, Nr. 1, S. 81 – 88
    DOI
  • Juric, D.; Gonzalez-Angulo, A. M.; Burris, H. A.; Schuler, Martin; Schellens, J.; Berlin, J.; Gupta, A.; Seggewiss-Bernhardt, R.; Adamo, B.; Gil-Martin, M.; Bootle, D.; Boehm, M.; De Buck, S.; Demanse, D.; Quadt, C.; Baselga, J.
    Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific P13K inhibitor in combination with fulvestrant : Results from a phase I study
    In: Cancer Research, Jg. 73, 2013, Nr. Suppl. 24
    DOI
  • Gonzalez-Angulo, A. M.; Juric, D.; Argiles, G.; Schellens, JHM; Burris, H. A.; Berlin, J.; Middleton, M. R.; Schuler, Martin; Van Geel, R.; Helgason, T.; Bootle, D.; Boehm, M.; Goggin, T. K.; Demanse, D.; Quadt, C.; Baselga, J.
    Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719 : Results from the first-in-human study
    In: Journal of Clinical Oncology (JCO), Jg. 31, 2013, Nr. 15 Suppl., S. 2531
    DOI
  • Schuler, Martin; Zvirbule, Z.; Lordick, F.; Krilova, A.; Helbig, U.; Schulze-Bergkamen, H.; Thuss-Patience, P. C.; von Wichert, G.; Schulmann, K.; Trarbach, Tanja; Bauer, Sebastian; Mueller, C.; Al-Batran, S. E.; Huber, C.; Sahin, U.; Tureci, O.
    Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas
    In: Journal of Clinical Oncology (JCO), Jg. 31, 2013, Nr. 15 Suppl., S. 4080
    DOI
  • Grunewald, S.; Mühlenberg, Thomas; Ketzer, J.; Backs, M.; Rubin, B.; Schuler, Martin; Fletcher, J.; Bauer, Sebastian
    Secondary KIT mutations negatively impact cell growth in a novel isogenic model of imatinib-resistance in GIST
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,
    In: Onkologie, Jg. 36, 2013, Nr. Suppl. 7, S. 178 – 179
  • Christoph, Daniel; Reyna-Asuncion, Bernadette; Hassan, Biftu; Tran, Cindy; Maltzman, Julia D.; O'Shannessy, Daniel J.; Wynes, Murry W.; Gauler, Thomas; Wohlschläger, Jeremias; Hoiczyk, M.; Schuler, Martin; Eberhardt, Wilfried; Hirsch, Fred R.
    Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed
    In: Journal of Thoracic Oncology, Jg. 8, 2013, Nr. 1, S. 19 – 30
    DOI
  • Molzan, M.; Kasper, Stefan; Röglin, L.; Skwarczynska, M.; Sassa, T.; Inoue, T.; Breitenbücher, Frank; Ohkanda, J.; Kato, N.; Schuler, Martin; Ottmann, C.
    Stabilization of Physical RAF/14-3-3 Interaction by Cotylenin A as Treatment Strategy for RAS Mutant Cancers
    In: ACS Chemical Biology, Jg. 8, 2013, Nr. 9, S. 1869 – 1875
    DOI
  • Yang, James Chih-Hsin; Hirsh, Vera; Schuler, Martin; Yamamoto, Nobuyuki; O'Byrne, Kenneth J.; Mok, Tony S.K.; Zazulina, Victoria; Shahidi, Mehdi; Lungershausen, Juliane; Massey, Dan; Palmer, Michael; Sequist, Lecia V.
    Symptom control and quality of life in lux-lung 3 : A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations
    In: Journal of Clinical Oncology (JCO), Jg. 31, 2013, Nr. 27, S. 3342 – 3350
    DOI
  • Hoiczyk, Mathias; Grabellus, Florian; Podleska, Lars; Ahrens, Marit; Schwindenhammer, Benjamin; Täger, Georg; Pöttgen, Christoph; Schuler, Martin; Bauer, Sebastian
    Trabectedin in metastatic soft tissue sarcomas : Role of pretreatment and age
    In: International Journal of Oncology, Jg. 43, 2013, Nr. 1, S. 23 – 28
    DOI
  • Schmidt, L. H.; Spieker, T.; Schuler, Martin; Marra, A.; Wiebe, K.; Berdel, W.; Mueller-Tidow, C.; Rainer, W.
    Tumor laterality influences the prognostic impact of Bcl-2 expression in curatively resected NSCLC patients
    In: European Respiratory Journal (ERJ), Jg. 42, 2013, Nr. Suppl. 57
    Online Volltext
  • Schuler, Martin
    Ärztliche Behandlung von an Krebs Erkrankten : Alles ganz anders?
    In: Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen (ZEFQ), Jg. 107, 2013, Nr. 2, S. 116 – 119
    DOI
  • Schuler, Martin; Awada, Ahmad; Harter, Philipp; Canon, Jean Luc; Possinger, Kurt; Schmidt, Marcus; De Grève, Jacques; Neven, Patrick; Dirix, Luc; Jonat, Walter; Beckmann, Matthias W.; Schütte, Jochen; Fasching, Peter A.; Gottschalk, Nina; Besse-Hammer, Tatiana; Fleischer, Frank; Wind, Sven; Uttenreuther-Fischer, Martina; Piccart, Martine; Harbeck, Nadia
    A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
    In: Breast Cancer Research and Treatment, Jg. 134, 2012, Nr. 3, S. 1149 – 1159
    DOI (Open Access)
  • Yang, J. C.; Schuler, Martin; Yamamoto, N.; OByrne, K. J.; Hirsh, V.; Mok, TSK; Massey, D.; Zazulina, V.; Shahidi, M.; Sequist, L. V.
    Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations in Lux-Lung 3, a phase III trial of afatinib or cisplatin/pemetrexed EGFR mutation-positive lung cancer
    In: Annals of Oncology, Jg. 23, 2012, Nr. Suppl. 9, S. 410 – 411
  • Kim, J. H.; Grossi, F.; De Marinis, F.; Cobo, M.; Yang, JCH; Ragulin, Y.; Bondarenko, I. N.; Chand, V. K.; Wang, B. S.; Gracien, E.; Schuler, Martin
    Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy : Interim subset analysis from a phase III trial
    In: Journal of Clinical Oncology (JCO), Jg. 30, 2012, Nr. Suppl. 15
  • Kasper, Stefan; Meiler, Johannes; Schuler, Martin
    Antikörper zur adoptiven Immuntherapie solider Tumoren
    In: Der Onkologe, Jg. 18, 2012, Nr. 9, S. 757 – 769
    DOI
  • Christoph, Daniel; Hoffmann, Andreas-Claudius; Gauler, Thomas; Asuncion, Bernadette Reyna; Loewendick, Heike; Peglow, Anja; Hassan, Biftu; Tran, Cindy; Wynes, Murry W.; Schuler, Martin; Eberhardt, Wilfried; Hirsch, Fred R.
    Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexed
    In: Journal of Thoracic Oncology, Jg. 7, 2012, Nr. 4, S. 766 – 767
    DOI (Open Access)
  • Wolf, J.; Nogova, L.; Heukamp, L. C.; Bos, M.; Schuler, Martin; Sequist, L.; Tian, G. G.; Ringeisen, F.; Buettner, R.; Thomas, R.
    Developments in targeted therapy : FGFR1 inhibition in lung cancer
    In: Journal of Thoracic Oncology, Jg. 7, 2012, Nr. Suppl. 6, S. 23
  • Drescher, O.; Eberhardt, Wilfried; Prittwitz, R.; Gkika, E.; Korfee, Sönke; Theegarten, Dirk; Welter, Stefan; Krbek, T.; Stamatis, Georgios; Pöttgen, Christoph; Schuler, Martin; Christoph, Daniel
    Distribution pattern of metastases and their associations with survival of malignant pleural mesothelioma patients undergoing different treatment modalities
    In: Onkologie, Jg. 35, 2012, Nr. Suppl. 6, S. 140
  • Nogova, L.; Gardizi, M.; Bos, MCA; Bitter, E.; Schildhaus, Hans-Ulrich; Heukamp, L. C.; Topelt, K.; Zander, T.; Scheffler, M.; Mattonet, C.; Gokkurt, E.; Risse, F.; Schuler, Martin; Sequist, L.; Tian, G. G.; Ringeisen, F.; Thomas, R.; Buttner, R.; Wolf, J.
    Early clinical evaluation of FGFR1 inhibition in lung cancer : Preliminary results of a phase I study in FGFR1 amplified lung cancer patients treated with BGJ398, a pan FGFR inhibitor
    In: Onkologie, Jg. 35, 2012, Nr. Suppl. 6, S. 137
  • Christoph, Daniel; Asuncion, Bernadette Reyna; Mascaux, Celine; Tran, Cindy; Lu, Xian; Wynes, Murry W.; Gauler, Thomas; Wohlschläger, Jeremias; Theegarten, Dirk; Neumann, Volker; Hepp, Rodrigo; Welter, Stefan; Stamatis, Georgios; Tannapfel, Andrea; Schuler, Martin; Eberhardt, Wilfried; Hirsch, Fred R.
    Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural Mesothelioma
    In: Journal of Thoracic Oncology, Jg. 7, 2012, Nr. 9, S. 1440 – 1448
    DOI (Open Access)
  • Welter, Stefan; Grabellus, Florian; Bauer, Sebastian; Schuler, Martin; Eberhardt, Wilfried; Tötsch, M.; Stamatis, Georgios
    Growth patterns of lung metastases from sarcoma : prognostic and surgical implications from histology
    In: Interactive Cardiovascular and Thoracic Surgery, Jg. 15, 2012, Nr. 4, S. 612 – 617
    DOI
  • Pogorzelski, M.; Ting, Saskia; Gauler, Thomas; Vossebein, I.; Breitenbucher, F.; Lang, Stephan; Hoffmann, T. K.; Bergmann, Christoph; Schmid, Kurt Werner; Schuler, Martin; Kasper, Stefan
    Impact of HPV status on the response of head and neck cancers to the anti-EGFR antibody cetuximab
    In: Onkologie, Jg. 35, 2012, Nr. Suppl. 6, S. 193 – 193
  • Meiler, Johannes; Guyot, M.; Hoffarth, S.; Wesarg, E.; Höhn, Y.; Breitenbücher, Frank; Schuler, Martin
    Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer
    In: Journal of Cancer Research and Clinical Oncology, Jg. 138, 2012, Nr. 8, S. 1385 – 1394
    DOI
  • Falkenhorst, J.; Mühlenberg, Thomas; Simon, S.; Grabellus, Florian; Breitenbucher, F.; Schuler, Martin; Fletcher, J. A.; Bauer, Sebastian
    Inhibitors of Apoptosis Proteins (IAPs) in gastrointestinal stromal tumors - a therapeutic target?
    In: Onkologie, Jg. 35, 2012, Nr. Suppl. 6, S. 249
  • Schuler, Martin; Planchard, D.; Yang, JCH; Kim, J. H.; De Marinis, F.; Chen, Y. M.; Zhou, C. C.; Bennouna, J.; Liu, X. Q.; Feng, J. F.; Bidoli, P.; Strausz, J.; Ou, SHI; Chand, V. K.; Wang, B. S.; Munzert, G. M.; Park, K.
    Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator's choice chemotherapy following progression on afatinib mono
    In: Journal of Clinical Oncology (JCO), Jg. 30, 2012, Nr. Suppl. 15, S. 7557
  • Schuler, Martin; Planchard, D.; Yang, JCH; Kim, J. H.; De Marinis, F.; Chen, Y. M.; Zhou, C. C.; Bennouna, J.; Liu, X. Q.; Feng, J. F.; Bidoli, P.; Strausz, J.; Ou, SHI; Chand, V. K.; Wang, B. S.; Munzert, G. M.; Park, K.
    Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigators choice chemotherapy following progression on afatinib monot
    In: Journal of Clinical Oncology (JCO), Jg. 30, 2012, Nr. Suppl. 15
  • Hoiczyk, Mathias; Iliodromitis, Konstantinos; Bauer, Sebastian; Konorza, Thomas; Philipp, Sebastian; Bankfalvi, Agnes; Gerl, Jan Mikael; Schuler, Martin; Erbel, Raimund
    Intimal sarcoma of the pulmonary artery with unusual findings : a case report
    In: Clinical Research in Cardiology, Jg. 101, 2012, Nr. 5, S. 397 – 401
    DOI
  • Christoph, Daniel; Asuncion, B. R.; Hassan, B.; Maltzman, J.; O'Shannessy, D.; Gauler, Thomas; Wynes, M. W.; Schuler, Martin; Eberhardt, Wilfried; Hirsch, F. R.
    Investigation of Folate Receptor alpha and Thymidylate Synthase Proteins Expression in metastatic Non-Small Cell Lung Cancer Patients treated with Pemetrexed-based Chemotherapy
    In: Journal of Thoracic Oncology, Jg. 7, 2012, Nr. 9, Suppl. 4, S. S211 – S212
  • Sequist, L.; Schuler, Martin; Yamamoto, N.; OByrne, K.; Hirsh, V.; Mok, T.; Massey, D.; Zazulina, V.; Shahidi, M.; Yang, J.
    LUX-Lung 3 : A Randomized, Open-Label, Phase III Study of Afatinib vs Pemetrexed and Cisplatin as First-Line Treatment for Patients with Advanced Adenocarcinoma of the Lung Harboring EGFR-Activating Mutations (Subgroup Analysis)
    In: Journal of Thoracic Oncology, Jg. 7, 2012, Nr. 9, Suppl. 4, S. 203
  • Yang, JCH; Schuler, Martin; Yamamoto, N.; OByrne, K. J.; Hirsh, V.; Mok, T.; Geater, S. L.; Orlov, S. V.; Tsai, C. M.; Boyer, M. J.; Su, W. C.; Bennouna, J.; Kato, T.; Gorbunova, V.; Lee, K. H.; Shah, RNH; Massey, D.; Lorence, R. M.; Shahidi, M.; Sequist, L. V.
    LUX-Lung 3 : A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations
    In: Journal of Clinical Oncology (JCO), Jg. 30, 2012, Nr. Suppl. 15, S. LBA7500
    DOI
  • Sequist, L. V.; Schuler, Martin; Yamamoto, N.; OByrne, K. J.; Hirsh, V.; Mok, TSK; Lungershausen, J.; Shahidi, M.; Palmer, M.; Yang, J. C.
    LUX-Lung 3 : Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations
    In: Annals of Oncology, Jg. 23, 2012, Nr. Suppl. 9, S. 402
  • OByrne, K.; Schuler, Martin; Yamamoto, N.; Hirsh, V.; Mok, T.; Massey, D.; Zazulina, V.; Shahidi, M.; Sequist, L.; Yang, J.
    Lux-Lung 3 : A randomized, open-label, phase III study of afatinib vs. pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR activating mutations
    In: Journal of Thoracic Oncology, Jg. 7, 2012, Nr. 7, S. 102
  • Boyer, M.; Schuler, Martin; Yamamoto, N.; OByrne, K.; Hirsh, V.; Mok, T.; Massey, D.; Zazulina, V.; Shahidi, M.; Sequist, L.; Yang, J. C.
    Lux-Lung 3 : a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harbouring EGFR-activating mutations
    In: Journal of Thoracic Oncology, Jg. 7, 2012, Nr. 9, Suppl. 3, S. 161
  • Yamamoto, N.; Schuler, Martin; OByrne, K.; Hirsh, V.; Mok, T.; Kato, T.; Yoshioka, H.; Okamoto, I.; Yokoyama, A.; Massey, D.; Jones, H.; Zazulina, V.; Shahidi, M.; Sequist, L.; Yang, JCH
    Lux-LungG 3 : Afatinib versus cisplatin and pemetrexed in Japanese patients with adenocarcinoma of the lung harboring an EGFR mutation
    In: Annals of Oncology, Jg. 23, 2012, Nr. Suppl. 11, S. 8
  • Köhler, Jens; Schuler, Martin
    Molekular zielgerichtete Tumortherapien : aktueller Stand und künftige Entwicklungen
    In: TumorDiagnostik & Therapie, Jg. 33, 2012, Nr. 6, S. 311 – 314
    DOI
  • Henze, Joern; Mühlenberg, Thomas; Simon, Susanne; Grabellus, Florian; Rubin, Brian; Täger, Georg; Schuler, Martin; Treckmann, Jürgen-Walter; Debiec-Rychter, Maria; Taguchi, Takahiro; Fletcher, Jonathan A.; Bauer, Sebastian
    P53 modulation as a therapeutic strategy in gastrointestinal stromal tumors
    In: PLoS ONE, Jg. 7, 2012, Nr. 5
    DOI (Open Access)
  • Markova, Boyka; Hähnel, Patricia S.; Kasper, Stefan; Herbertz, Stephan; Schuler, Martin; Breitenbücher, Frank
    Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer
    In: Journal of Cancer Research and Clinical Oncology, Jg. 138, 2012, Nr. 4, S. 545 – 554
    DOI
  • Ahnert, J. R.; Burris, H. A.; Schellens, JHM; Schuler, Martin; Goodman, O.; Britten, C.; Richards, D.; Demanse, D.; Silva, A.; Baselga, J.
    Phase I Dose-escalation Study of the Oral Dual MTOR/PI3K Inhibitor BEZ235, Solid Dispersion System (SDS) Sachet Formulation, in Patients with Advanced Solid Tumors
    In: European Journal of Cancer (EJC), Jg. 48, 2012, Nr. Suppl. 6, S. 112
    DOI
  • Bauer, Sebastian; Hilger, Ralf A.; Grabellus, Florian; Nagarajah, James; Hoiczyk, M.; Reichardt, A.; Ahrens, M.; Pink, D.; Mühlenberg, Thomas; Scheulen, Max Ernst; Schuler, Martin; Reichardt, P.
    Phase I trial of panobinostat (P) and imatinib (IM) in patients with treatment-refractory gastrointestinal stromal tumors (GIST)
    In: Journal of Clinical Oncology (JCO), Jg. 30, 2012, Nr. Suppl. 15, S. 10032
  • Dirix, L.; Schuler, Martin; Machiels, J.; Hess, D.; Awada, A.; Steeghs, N.; Paz-Ares, L.; von Moos, R.; Rabault, B.; Rodon, J.
    Phase IB dose-escalation study of BEZ235 or BKM 120 in combination with paclitaxel (PTX) in patients with advanced solid tumors
    In: Annals of Oncology, Jg. 23, 2012, Nr. Suppl. 9, S. 157 – 158
  • Schmidt, Markus; Rüttinger, Dominik; Sebastian, M.; Hanusch, Claus A.; Marschner, Norbert; Bäuerle, Patrick A.; Wolf, Andreas; Göppel, Gertrud; Oruzio, Daniel; Schlimok, Günter; Steger, Günther G.; Wolf, Christopher; Eiermann, Wolfgang; Lang, Alois; Schuler, Martin
    Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with epcampositive relapsed or refractory advanced-stage breast cancer
    In: Annals of Oncology, Jg. 23, 2012, Nr. 9, S. 2306 – 2313
    DOI (Open Access)
  • Hoiczyk, M.; Kuschel, P.; Grabellus, Florian; Geffken, M.; Ahrens, M.; Schuler, Martin; Bauer, Sebastian
    Rechallenge with ifosfamide-containing regimen as salvage option for patients with metastatic soft tissue sarcomas progressing after multiple pretreatments
    In: Journal of Clinical Oncology (JCO), Jg. 30, 2012, Nr. Suppl. 15
  • Christoph, Daniel; Asuncion, B. R.; Hassan, B.; Maltzman, J.; O'Shannessy, D.; Gauler, Thomas; Wohlschläger, Jeremias; Wynes, M. W.; Schuler, Martin; Eberhardt, Wilfried; Hirsch, F. R.
    Significance of Folate Receptor alpha (FRA) and Thymidylate Synthase (TS) expression in metastatic non-small cell lung cancer patients treated with pemetrexed-based chemotherapy
    In: Onkologie, Jg. 35, 2012, Nr. Suppl. 6, S. 34
  • Kasper, Stefan; Breitenbücher, Frank; Heidel, F.; Hoffarth, S.; Markova, B.; Schuler, Martin; Fischer, T.
    Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies
    In: Blood Cancer Journal, Jg. 2, 2012, Nr. 3, S. e60
    DOI (Open Access)
  • Kasper, Stefan; Reis, Henning; Breitenbücher, Frank; Markowetz, J.; Pogorzelski, M.; Trarbach, Tanja; Worm, K.; Schmid, Kurt Werner; Schuler, Martin
    Targeting the anti-apoptotic protein BCL-XL to overcome RAS mediated resistance to anti-EGFR antibody therapy in colorectal cancer
    In: Onkologie, Jg. 35, 2012, Nr. Suppl. 6, S. 253
  • Welt, Anja; Kossow, J.; Tewes, Mitra; Seeber, S.; Schuler, Martin
    Trends in survival of patients with metastatic breast cancer
    In: Onkologie, Jg. 35, 2012, Nr. Suppl. 6, S. 187
  • Wiesweg, Marcel; Kasper, Stefan; Wohlschläger, Jeremias; Ting, Saskia; Skottky, S.; Worm, K.; Derks, C.; Tewes, Mitra; Breitenbücher, Frank; Gauler, Thomas; Eberhardt, Wilfried; Ahrens, M.; Hoiczyk, M.; Meiler, Johannes; Hense, Jörg; Welt, Anja; Theegarten, Dirk; Freitag, Lutz; Kimmig, Rainer; Schmid, Kurt Werner; Schuler, Martin
    VVTZ-Tumorprofil - First results of a preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer Center
    In: Onkologie, Jg. 35, 2012, Nr. Suppl. 6, S. 204 – 204
  • Christoph, Daniel; Kasper, Stefan; Gauler, Thomas; Loesch, Christian; Engelhard, Marianne; Theegarten, Dirk; Pöttgen, Christoph; Hepp, Rodrigo; Peglow, Anja; Loewendick, Heike; Welter, Stefan; Stamatis, Georgios; Hirsch, Fred R.; Schuler, Martin; Eberhardt, Wilfried; Wohlschläger, Jeremias
    Βv-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer
    In: British Journal of Cancer (BJC), Jg. 107, 2012, Nr. 5, S. 823 – 830
    DOI (Open Access)
  • Aktas, B.; Kasimir-Bauer, Sabine; Kasper, Stefan; Derks, C.; Kimmig, Rainer; Schuler, Martin; Tewes, Mitra
    Comparison of PIK3CA Hot Spot Mutations in the Primary Tumor or Metastases with PIK3CA Mutations or PIK3CA Over-Expression in Circulating Tumor Cells of Metastatic Breast Cancer Patients under Sequential Palliative Therapy
    In: Cancer Research, Jg. 71, 2011, Nr. Suppl. 24
    DOI
  • Livingstone, Elisabeth; Trarbach, Tanja; Zimmer, Lisa; Schuler, Martin; Schadendorf, Dirk
    EGFR-Inhibitoren und Multityrosinkinaseinhibitoren : Interdisziplinäre Behandlung der kutanen Nebenwirkungen
    In: Deutsche Medizinische Wochenschrift - DMW, Jg. 136, 2011, Nr. 1-2, S. 39 – 44
    DOI
  • Schmidt, Marcus; Petry, Ilka Brigitte; Böhm, Daniel; Lebrecht, Antje; Törne, Christian von; Gebhard, Susanne; Gerhold-Ay, Aslihan; Cotarelo, Cristina; Battista, Marco; Schormann, Wiebke; Freis, Evgenia; Selinski, Silvia; Ickstadt, Katja; Rahnenführer, Jörg; Sebastian, Martin; Schuler, Martin; Koelbl, Heinz; Gehrmann, Mathias; Hengstler, Jan G.
    Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer
    In: Breast Cancer Research and Treatment, Jg. 125, 2011, Nr. 3, S. 637 – 646
    DOI
  • Christoph, DanielC; Kasper, Stefan; Gauler, ThomasC; Breitenbücher, Frank; Engelhard, Marianne; Theegarten, Dirk; Pöttgen, Christoph; Hepp, Rodrigo; Peglow, Anja; Loewendick, Heike; Hirsch, FredR; Schuler, Martin; Eberhardt, Wilfried; Wohlschläger, Jeremias
    Evaluation of Betav-Tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancer
    In: Journal of Thoracic Oncology, Jg. 6, 2011, Nr. Suppl. 6, S. 1078
  • Christoph, Daniel; Gauler, Thomas; Engelhard, M.; Theegarten, Dirk; Pöttgen, Christoph; Hepp, R.; Schuler, Martin; Hirsch, F.; Eberhardt, Wilfried; Wohlschläger, Jeremias
    Evaluation of betaV-tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancer (NSCLC)
    In: European Journal of Cancer (EJC), Jg. 47, 2011, Nr. Suppl. 4, S. 14
  • Becker, Silvan; Markova, Boyka; Wiewrodt, Rainer; Hoffarth, Sandra; Hähnel, Patricia S.; Pleiner, Sina; Schmidt, Lars Hennig; Breitenbücher, Frank; Schuler, Martin
    Functional and Clinical Characterization of the Putative Tumor Suppressor WWOX in Non-small Cell Lung Cancer
    In: Journal of Thoracic Oncology, Jg. 6, 2011, Nr. 12, S. 1976 – 1983
    DOI (Open Access)
  • Christoph, DanielC; Wohlschläger, Jeremias; Neumann, Volker; Gauler, ThomasC; Pöttgen, Christoph; Peglow, Anja; Tannapfel, Andrea; Schuler, Martin; Hirsch, FredR; Eberhardt, Wilfried; Theegarten, Dirk
    Impact of dihydrofolate reductase expression for clinical benefit from pemetrexed in malignant pleural mesothelioma
    In: Journal of Thoracic Oncology, Jg. 6, 2011, Nr. Suppl. 6, S. S1052 – S1053
  • Lambertz, Nicole; Köhler, Jens; Schulte, D.M.; Kühl, Hilmar; Wohlschläger, Jeremias; Hense, Jörg; Schuler, Martin; Müller, Oliver
    Multivisceral systemic metastases from an intracranial anaplastic meningioma : A case report and review of literature
    In: Clinical Neurology and Neurosurgery, Jg. 113, 2011, Nr. 7, S. 592 – 595
    DOI
  • Köhler, Jens; Schuler, Martin
    Personalisierte medikamentöse Therapie des fortgeschrittenen nichtkleinzelligen Lungenkarzinoms : Der Pfeil des Wilhelm Tell?
    In: Der Onkologe, Jg. 17, 2011, Nr. 8, S. 702 – 708
    DOI
  • Kasper, Stefan; Breitenbücher, Frank; Even, A.; Pogorzelski, M.; Hoffarth, S.; Stergar, S. L.; Trarbach, Tanja; Schuler, Martin
    Pharmacological Inhibition of NF-k and PLK-1 to the Opening of the RAS-mediated Resistance to anti-EGFR Antibody therapies in Colorectal cancer *
    In: Der Internist, Jg. 52, 2011, Nr. 6, S. 726 – 726
  • Christoph, Daniel; Schuler, Martin
    Polo-like kinase 1 inhibitors in mono- and combination therapies : A new strategy for treating malignancies
    In: Expert Review of Anticancer Therapy, Jg. 11, 2011, Nr. 7, S. 1117 – 1132
    DOI
  • Christoph, DanielC; Mascaux, Celine; Wynes, MurryW; Asuncion, Bernadette; Wohlschläger, Jeremias; Theegarten, Dirk; Gauler, Thomas; Neumann, Volker; Pöttgen, Christoph; Tran, Cindy; Tannapfel, Andrea; Schuler, Martin; Eberhardt, Wilfried; Hirsch, FredR
    Predictive value of thymidylate synthase and Folypoly-Glutamate Synthease for clinical benefit from pemetrexed in malignant pleural mesothelioma
    In: Journal of Thoracic Oncology, Jg. 6, 2011, Nr. Suppl. 6, S. S1092 – S1093
  • Christoph, Daniel; Mascaux, C.; Wynes, M. W.; Reyna Asuncion, B.; Wohlschläger, Jeremias; Theegarten, Dirk; Gauler, Thomas; Schuler, Martin; Eberhardt, Wilfried; Hirsch, F. R.
    Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesothelioma
    In: Journal of Clinical Oncology (JCO), Jg. 29, 2011, Nr. 15_suppl, S. 7024
    DOI
  • Schuler, Martin; Breitenbücher, Frank; Trarbach, Tanja; Brandau, Sven; Schmid, Kurt Werner; Kasper, Stefan
    Simultaneous protection against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR-signaling blockade by oncogenic RAS
    In: Journal of Clinical Oncology (JCO), Jg. 29, 2011, Nr. Suppl. 4, S. 440
    DOI
  • Schütt, Philipp; Stattaus, Jörg; Schuler, Martin
    Solitärer Lungenrundherd - Weitere Abklärung erforderlich?
    In: TumorDiagnostik & Therapie, Jg. 32, 2011, Nr. 1, S. 33 – 37
    DOI
  • Koeppen, Susanne; Hense, Jörg; Nolte, K. W.; Weis, J.; Schuler, Martin
    Treatable Bortezomib-related peripheral neuropathy in multiple myeloma
    In: Journal of the Peripheral Nervous System, Jg. 16, 2011, Nr. Suppl. 3, S. 68
  • Christoph, Daniel; Wittkowski, Lukas; Stattaus, Jörg; Pöttgen, Christoph; Keyvani, Kathy; Gauler, Thomas; Schuler, Martin; Eberhardt, Wilfried
    Very Late and Isolated Leptomeningeal Relapse of a Pulmonary Adenocarcinoma Presenting as Dementia
    In: Onkologie, Jg. 34, 2011, Nr. 6, S. 316 – 320
    DOI
  • Schütt, Philipp; Müller, Stefan; Matuszczyk, Anna; Schmid, Kurt Werner; Bockisch, Andreas; Schuler, Martin; Mann, Klaus
    Zielgerichtete Therapie für Patienten mit Schilddrüsenkarzinom
    In: TumorDiagnostik & Therapie, Jg. 32, 2011, Nr. 5, S. 269 – 276
    DOI
  • Schmidt, Martina; Scheulen, Max Ernst; Dittrich, C.; Obrist, P.; Marschner, N.; Dirix, L.; Schmidt, M.; Rüttinger, D.; Schuler, Martin; Reinhardt, C.; Awada, A.
    An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer
    In: Annals of Oncology, Jg. 21, 2010, Nr. 2, S. 275 – 282
    DOI
  • Schuler, Martin; Uttenreuther-Fischer, M. M.; Piccart-Gebhart, M. J.; Harbeck, N.; on behalf of the study group and trial team
    BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies
    In: Journal of Clinical Oncology (JCO), Jg. 28, 2010, Nr. Suppl. 15, S. 1065
    DOI
  • Petry, I. B.; Fieber, E.; Schmidt, Marcus; Gehrmann, M.; Gebhard, S.; Hermes, M.; Schormann, W.; Selinski, S.; Freis, E.; Schwender, H.; Brulport, M.; Ickstadt, K.; Rahnenführer, J.; Maccoux, L.; West, J.; Kölbl, H.; Schuler, Martin; Hengstler, J. G.
    ERBB2 Induces an Antiapoptotic Expression Pattern of Bcl-2 Family Members in Node-Negative Breast Cancer
    In: Clinical Cancer Research, Jg. 16, 2010, Nr. 2, S. 451 – 460
    DOI
  • Mühlenberg, Thomas; Fletcher, J. A.; Grabellus, Florian; Schuler, Martin; Bauer, Sebastian
    Effective therapeutic sensitization of gastrointestinal stromal tumors by a BH3 mimetic
    In: European Journal of Cancer / EJC Supplements, Jg. 8, 2010, Nr. 7, S. 69 – 70
    DOI
  • Köhler, Jens; Breitenbücher, Frank; Schuler, Martin
    Individualisierte Therapie für Patienten mit fortgeschrittenen Lungenkarzinomen
    In: TumorDiagnostik & Therapie, Jg. 31, 2010, Nr. 2, S. 79 – 87
    DOI
  • Nguyen, B.; Grabellus, Florian; Hoiczyk, M.; Täger, Georg; Schuler, Martin; Bauer, Sebastian
    Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib (IM)
    In: Journal of Clinical Oncology (JCO), Jg. 28, 2010, Nr. Suppl. 15, S. 10047
    DOI
  • Hoffmann, Andreas-Claudius; Wild, Peter; Leicht, Christina; Bertz, Simone; Danenberg, Kathleen D.; Danenberg, Peter V.; Stöhr, Robert; Stöckle, Michael; Lehmann, Jan; Schuler, Martin; Hartmann, Arndt
    MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy
    In: Neoplasia: An International Journal for Oncology Research, Jg. 12, 2010, Nr. 8, S. 628 – 636
    DOI (Open Access)
  • Waldner, Maximilian J.; Wirtz, Stefan; Becker, Christoph; Seidel, Daniel; Tubbe, Ingrid; Cappel, Kyra; Hähnel, Patricia S.; Galle, Peter R.; Schuler, Martin; Neurath, Markus F.
    Perforin deficiency attenuates inflammation and tumor growth in colitis-associated cancer
    In: Inflammatory Bowel Diseases, Jg. 16, 2010, Nr. 4, S. 559 – 567
    DOI
  • Schütt, Philipp; Schütt, Birgit; Switala, Magdalena; Bauer, Sebastian; Stamatis, Georgios; Opalka, Bertram; Eberhardt, Wilfried; Schuler, Martin; Horn, Peter; Rebmann, Vera
    Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients
    In: Human Immunology, Jg. 71, 2010, Nr. 5, S. 489 – 495
    DOI
  • Advani, Anjali; Coiffier, Bertrand; Czuczman, Myron S.; Dreyling, Martin; Foran, James; Gine, Eva; Gisselbrecht, Christian; Ketterer, Nicolas; Nasta, Sunita; Rohatiner, Ama; Schmidt-Wolf, Ingo G. H.; Schuler, Martin; Sierra, Jorge; Smith, Mitchell R.; Verhoef, Gregor; Winter, Jane N.; Boni, Joseph; Vandendries, Erik; Shapiro, Mark; Fayad, Luis
    Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma : results of a phase I study
    In: Journal of Clinical Oncology (JCO), Jg. 28, 2010, Nr. 12, S. 2085 – 2093
    DOI
  • Köhler, Jens; Schuler, Martin
    Targeted Therapies in der Behandlung solider und hämatologischer Neoplasien
    In: TumorDiagnostik & Therapie, Jg. 31, 2010, Nr. 3, S. 133 – 142
    DOI
  • Sebastian, Martin; Reck, Martin; Waller, Cornelius F.; Kortsik, Cornelius; Frickhofen, Norbert; Schuler, Martin; Fritsch, Holger; Gaschler-Markefski, Birgit; Hanft, Gertraud; Munzert, Gerd; Pawel, Joachim von
    The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy : Results from an open-label, randomized phase ii clinical trial
    In: Journal of Thoracic Oncology, Jg. 5, 2010, Nr. 7, S. 1060 – 1067
    DOI (Open Access)
  • Bauer, Sebastian; Mühlenberg, Thomas; Leahy, Michael; Hoiczyk, Mathias; Gauler, Thomas; Schuler, Martin; Looijenga, Leendert
    Therapeutic Potential of Mdm2 Inhibition in Malignant Germ Cell Tumours
    In: European Urology, Jg. 57, 2010, Nr. 4, S. 679 – 687
    DOI
  • Mühlenberg, Thomas; Zhang, Yixiang; Wagner, Andrew J.; Grabellus, Florian; Bradner, James; Täger, Georg; Lang, Hauke; Taguchi, Takahiro; Schuler, Martin; Fletcher, Jonathan A.; Bauer, Sebastian
    Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors
    In: Cancer Research, Jg. 69, 2009, Nr. 17, S. 6941 – 6950
    DOI (Open Access)
  • Thaler, Sonja; Hähnel, Patricia S.; Schad, Arno; Dammann, Reinhard; Schuler, Martin
    RASSF1A mediates p21Cip1/Waf1- dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt
    In: Cancer Research, Jg. 69, 2009, S. 1748 – 1757
    Online Volltext
  • Hähnel, Patricia S.; Thaler, Sonja; Antunes, Edite; Huber, Christoph; Theobald, Matthias; Schuler, Martin
    Targeting AKT signaling sensitizes cancer to cellular immunotherapy
    In: Cancer Research, Jg. 68, 2008, S. 3899 – 3906
    Online Volltext
  • Stolz, Claudia; Hess, Georg; Hähnel, Patricia S.; Grabellus, Florian; Hoffarth, Sandra; Schmid, Kurt Werner; Schuler, Martin
    Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis
    In: Blood, Jg. 112, 2008, Nr. 8, S. 3312 – 3321
    DOI, Online Volltext (Open Access)
  • Bargou, R.; Leo, E.; Zugmeier, G.; Klinger, M.; .Goebeler, M.; Knop, S.; Noppeney, Richard; Viardot, A.; Hess, G.; Schuler, Martin; Einsele, H.; Brandl, C.; Wolf, A.; Kirchinger, P.; Klappers, P.; Schmidt, Markus; Riethmüller, G.; Reinhardt, C.; Baeuerle, P.A.; Kufer, P.
    Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.
    In: Science, Jg. 5891, 2008, Nr. 321, S. 974 – 977
  • Hoffarth, Sandra; Zitzer, Alexander; Wiewrodt, Rainer; Hähnel, Patricia S.; Beyer, Vera; Kreft, Andreas; Biesterfeld, Stefan; Schuler, Martin
    pp32/PHAPI determines the apoptosis response of non-small-cell lung cancer
    In: Cell Death and Differentiation, Jg. 15, 2008, S. 161 – 170
    Online Volltext

    • Vorworte / Nachworte

  • Schuler, Martin; Pogorzelski, Michael; Bruns, Christiane
    Kleinzelliges Lungenkarzinom
    In: Die Onkologie. Berlin: Springer, Jg. 30, 2024, Nr. 9, S. 776 – 779
    DOI (Open Access)
  • Reinmuth, Niels; Schuler, Martin
    Shall we use steroids when treating patients with lung cancer with checkpoint inhibitors?
    In: European Journal of Cancer (EJC). Amsterdam: Elsevier, Jg. 145, 2021, S. 255 – 257
    DOI
  • Schuler, Martin
    Inhibiting fibroblast growth factor receptors in cancer – the next generation
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 31, 2020, Nr. 10, S. 1285 – 1286
    DOI (Open Access)
  • Höffken, K.; Heiss, M.M.; Schuler, Martin
    Tumorimmunologie : Beginn einer neuen Ära?
    In: Der Onkologe. Berlin: Springer, Jg. 18, 2012, S. 754 – 756
    DOI

    • Abstracts

  • Ramalingam, S.; Velcheti, V.; Altan, M.; de Castro, G.; Thomas, M.; Sanborn, R.E.; Maziéres, J.; Spigel, D.R.; Schuler, Martin; Isaksson, J.; Schenker, M.; Macedo-Pérez, E.O.; Poddubskaya, E.; Kim, Y.J.; Parakh, S.; Liu, W.; Whipple Neibauer, M.; Aghera, V.; Chiu, G.; Peters, S.
    A Randomized Phase 3 Study of Niraparib Plus Pembrolizumab as Maintenance Therapy for Advanced/Metastatic NSCLC : ZEAL-1L
    2025 World Conference on Lung Cancer, 6-9 September 2025, Barcelona, Spain,
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 20, 2025, Nr. 10, Supplement 1, S. S20 – S21
    DOI
  • Le Tourneau, Christophe; Schuler, Martin; Di Nicola, Massimo A.; Justina Lam, Yick Ching; Kuboki, Yasutoshi; Lin, Chia-Chi; Machiels, Jean-Pascal; Gainor, Justin F.; Wainberg, Zev A.; Patel, Manish R.; Otero, Javier A.; Kornbluth, Kimberly Ann.; Bsharat, Rebhi; Pisupati, Jaya; Ramkumar, Thiruvamoor; Chaudhury, Anwesha; Oberoi, Arjun
    A first-in-human, first-in-class, phase 1 trial of QEQ278 in patients with advanced solid tumors
    In: Molecular Cancer Therapeutics. Philadelphia: American Association for Cancer Research (AACR), Jg. 24, 2025, Nr. 10 (Supplement), B002
    DOI (Open Access)
  • Küper, Alina; Kersting, David; Welt, Anja; Vaz, Sofia; Moraitis, Alexandros; Djaileb, Loic; Seifert, Robert; Umutlu, Lale; Schuler, Martin; Herrmann, Ken; Fendler, Wolfgang; Kümmel, Sherko; Ciuciulkaite, Ieva
    Clinical value of [68Ga]Ga-FAPI-46 PET in Comparison to [18F]FDG PET in Triple-negative Breast Cancer and Possible Theranostic Applications
    In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 66, 2025, Nr. Supplement 1, 251520
    Online Volltext (Open Access)
  • Michels, Sebastian Yves Friedrich; Frank, Julia; Chen, Zhendong; Felip, Enriqueta; Sebastian, Martin; Schuler, Martin; Wermke, Martin; Rosell, Rafael; Nogova, Lucia; Ruge, Lea; Scheffler, Matthias; Fischer, Rieke Nila; Riedel, Richard; Terjung, Inken; Scharpenseel, Heather; Merkelbach-Bruse, Sabine; Fassunke, Jana; Buettner, Reinhard; Fuhr, Uwe; Wolf, Juergen
    EATON : A phase I trial of nazartinib (EGF816) and trametinib in EGFR-mutant (EGFRmut) non-small cell lung cancer (NSCLC)
    Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), MAY 30-JUN 03, 2025, Chicago, IL,
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 43, 2025, Nr. 16_Suppl, S. 8619
    DOI
  • Rudin, Charles M.; Mountzios, Giannis Socrates; Sun, Longhua; Cho, Byoung Chul; Demirci, Umut; Baka, Sofia; Gumus, Mahmut; Lugini, Antonio; Ciuleanu, Tudor-Eliade; Ahn, Myung-Ju; Rocha, Pedro; Zhu, Bo; Blackhall, Fiona Helen; Yoshida, Tatsuya; Owonikoko, Taofeek K.; Paz-Ares, Luis G.; Huang, Shuang; Gauto, Diana Maria; Recondo, Gonzalo; Schuler, Martin
    Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC) : Primary analysis of Ph3 DeLLphi-304
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 43, 2025, Nr. Suppl. 17
    DOI
  • Dörr, F.; Grapatsas, G.; Baldes, N.; Oezkan, F.; Theegarten, Dirk; Darwiche, Kaid; Eberhardt, Wilfried; Stuschke, Martin; Hautzel, H.; Herrmann, Ken; Taube, Christian; Forsting, Michael; Schuler, Martin; Bölükbas, S.
    Deciphering Destiny : Is Curation of NSCLC Limited to Stage IA?
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 19, 2024, Nr. Suppl. 10, S. S552
  • Melero Bermejo, Ignacio; de Miguel, Maria J.; de Velasco, Guillermo; Garralda, Elena; Martin-Liberal, Juan; Joerger, Markus; Alonso, Guzman; Goebeler, Maria-Elisabeth; Schuler, Martin H.; König, David; Reig, Maria; Rodriguez-Ruiz, Maria E.; Calvo, Emiliano; Esteban Villarrubia, Jorge; Sàbat, Paula; Koster, Kira-Lee; Sayehli, Cyrus; Gromke, Tanja; Klar, Kathrin; Leo, Eugen
    Effects of neutralization of tumor-derived immunosuppressant GDF-15 on anti-PD-1 activity in anti-PD-(L)1 relapsed/refractory non-squamous NSCLC, urothelial, and hepatocellular cancer
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 42, 2024, Nr. Suppl. 16, 2513
    DOI (Open Access)
  • Schuler, Martin H.; Tabernero, Josep; Carranza, Omar; Loriot, Yohann; Pant, Shubham; Arnold, Dirk; Folprecht, Gunnar; Palmer, Daniel H.; Prenen, Hans; Zibetti Dal Molin, Graziela; Lugowska, Iwona A.; Cervantes, Andres; Sweiti, Hussein; Hammond, Constance; Najmi, Saltanat; Thomas, Shibu; Triantos, Spyros; Xia, Karen; Gutierrez, Martin
    Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 42, 2024, Nr. Suppl. 16, 8515
    DOI (Open Access)
  • Carranza, Omar; Schuler, Martin H.; Tabernero, Josep; Loriot, Yohann; Arnold, Dirk; Folprecht, Gunnar; Palmer, Daniel; Zibetti Dal Molin, Graziela; Gutierrez, Martin; Prenen, Hans; Lugowska, Iwona A.; Cervantes, Andres; Sweiti, Hussein; Hammond, Constance; Najmi, Saltanat; Thomas, Shibu; Triantos, Spyros; Crow, Lauren; Pant, Shubham
    Efficacy and safety of erdafitinib in adults with breast cancer and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 42, 2024, Nr. Suppl. 16, 1088
    DOI (Open Access)
  • Pant, Shubham; Park, Joon Oh; Su, Wu-Chou; Schuler, Martin H.; Loriot, Yohann; Iyer, Gopa; Doi, Toshihiko; Qin, Shukui; Tabernero, Josep; Prenen, Hans; Folprecht, Gunnar; Winter, Helen; Zibetti Dal Molin, Graziela; Sweiti, Hussein; Najmi, Saltanat; Hammond, Constance; Liao, Huimin; Thomas, Shibu; Triantos, Spyros; Feng, Yin-Hsun
    Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations : Pooled analysis of RAGNAR and LUC2001 studies
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 42, 2024, Nr. Suppl. 16, 4121
    DOI (Open Access)
  • Lugowska, Iwona A.; Schuler, Martin H.; Loriot, Yohann; Carranza, Omar; Iyer, Gopa; Doi, Toshihiko; Qin, Shukui; Tabernero, Josep; Reardon, David A.; Massard, Christophe; Arnold, Dirk; Gutierrez, Martin; Winter, Helen; Sweiti, Hussein; Xia, Karen; Najmi, Saltanat; Hammond, Constance; Thomas, Shibu; Triantos, Spyros; Pant, Shubham
    Efficacy of erdafitinib in adults with advanced solid tumors and non-prespecified fibroblast growth factor receptor mutations in the phase 2 RAGNAR trial : Exploratory cohort
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 42, 2024, Nr. Suppl. 16, 3119
    DOI (Open Access)
  • Mavroeidi, I.; Seyed Mohammad, T.W.; Webersinke, G.; Burghofer, J.; Piringer, G.; Kasper-Virchow, S.; Liffers, S-T.; Reichinger, A.; Kirchweger, P.; Heibl, S.; Hamacher, R.W.; Petzer, A.L.; Schuler, Martin H. H.; Prager, G.; Kersting, David M.; Treckmann, Jürgen-Walter; Schildhaus, Hans-Ulrich; Rumpold, H.; Siveke, Jens T.; Doleschal, B.
    Homologous recombination repair (HRR) deficiency in biliary tract cancers : Clinical implications in subsequent therapy lines and correlation with platinum sensitivity
    ESMO Gastrointestinal Cancers Congress 2024, 26-29 June 2024, Munich, Germany,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Supplement 1, S. S127
    DOI
  • Grapatsas, K.; Doerr, F.; Oezkan, F.; Baldes, N.; Darwiche, Kaid; Theegarten, Dirk; Eberhardt, Wilfried; Gauler, Thomas; Stuschke, Martin; Hautzel, H.; Herrmann, Ken; Taube, Christian; Forsting, Michael; Schuler, Martin; Bölükbas, S.
    Impact of Preoperative Pulmonary Function on Survival Following Lobectomy for Stage I and II Lung Cancer
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 19, 2024, Nr. Suppl. 10, S. S531
  • Oezkan, F.; Webendoerfer, M.; Winantea, Jane; Wiesweg, Marcel; Metzenmacher, M.; Theegarten, Dirk; Darwiche, Kaid; Bölükbas, S.; Dörr, F.; Taube, Christian; Stuschke, Martin; Opitz, Marcel; Schuler, Martin; Eberhardt, Wilfried
    Lung Cancer in Young Adults is Associated with Advanced Disease at Diagnosis and Increased Frequency of Targetable Mutations
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 19, 2024, Nr. Suppl. 10, S. S84 – S85
  • Cobb, P.W.; Hochmair, M.; Schuler, Martin; Riely, G.J.; Rojas, C.I.; Kim, S.J.; Chen, X.; Lara-Guerra, H.; Felip, E.
    Phase III study of pembrolizumab plus MK-1084 vs pembrolizumab plus placebo as first-line treatment for metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 tumour proportion score (TPS) ≥50%: MK-1084-004
    ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Suppl. 2, S. S871 – S872
    DOI
  • Sauer, Christopher Martin; Brehmer, Alexander; Rostalski, Till; Schuler, Martin H.; Nensa, Felix; Reinhardt, Hans Christian; Kleesiek, Jens; Pucher, Gernot
    Predicting persistent fever in patients with cancer using machine learning
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 42, 2024, Nr. 16_suppl, e13552
    DOI (Open Access)
  • Kasper-Virchow, Stefan; Hofheinz, R.D.; Stintzing, S.; Dechow, T.N.; Ettrich, T.J.; Sinn, M.; Roderburg, C.; Fischer von Weikersthal, L.; Graeven, U.; Mueller, C.; Meiler, J.; Stein, A.; Modest, D.P.; Pauligk, C.; Virchow, I.; Siveke, Jens T.; Al-Batran, S-E.; Schuler, Martin; Goetze, T.O.
    Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer : The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)
    ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Suppl. 2: Abstract Book of the ESMO Congress 2024, 13-17 September 2024, S. S1218
    DOI
  • Schuler, Martin
    Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer : DeLLphi-305 Phase 3 Trial
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 19, 2024, Nr. Suppl. 10, S. S206 – S207
  • Grapatsas, K.; Dörr, F.; Oezkan, F.; Baldes, N.; Theegarten, Dirk; Darwiche, Kaid; Eberhardt, Wilfried; Gauler, Thomas; Stuschke, Martin; Hautzel, H.; Herrmann, Ken; Taube, Christian; Forsting, Michael; Schuler, Martin; Bölükbas, S.
    The Influence of Smoking on Morbidity and Early Mortality after Anatomical Lung Resections for Stage I-IIIA NSCLC
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 19, 2024, Nr. Suppl. 10, S. S143 – S144
  • Wiesweg, Marcel; Alaffas, A.; Rasokat, A.; Saalfeld, F.C.; Rost, M.; Assmann, C.; Herster, F.; Hilbrandt, M.; Griesinger, F.; Kropf-Sanchen, C.; Reck, M.; Kulhavy, J.; Stenzinger, A.; Sebastian, M.; Schuler, Martin; Wermke, M.; Frost, N.; Kopp, H-G.; Christopoulos, P.; Scheffler, M.
    Treatment sequences in BRAF-V600-mutant non-small cell lung cancer : First-line targeted therapy versus first-line (chemo-) immunotherapy
    ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Suppl. 2, S. S827 – S828
    DOI
  • Kersting, David; Lazaridis, Lazaros; Barbato, Francesco; Kebir, Sied; Kümmel, Sherko; Welt, Anja; Umutlu, Lale; Milosevic, Aleksandar; Nader, Michael; Fragoso Costa, Pedro; Schmidt, T.; Oster, Christoph; Deuschl, Cornelius; Sure, Ulrich; Stuschke, Martin; Kleinschnitz, Christoph; Scheffler, Björn; Hautzel, Hubertus; Schuler, Martin; Glas, Martin; Fendler, Wolfgang; Herrmann, Ken
    68Ga-NeoB PET for Glioma and Breast Cancer : First Results from a Prospective Observational Trial
    Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,
    In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. 1 supplement, S. S265
    DOI
  • Kersting, David; Sandach, Patrick; Sraieb, Miriam; Wiesweg, Marcel; Metzenmacher, Martin; Darwiche, Kaid; Özkan, Filiz; Bölükbas, Servet; Stuschke, Martin; Umutlu, Lale; Nader, Michael; Hamacher, Rainer; Fendler, Wolfgang; Wienker, Johannes; Eberhardt, Wilfried; Schuler, Martin; Herrmann, Ken; Hautzel, H.
    68Ga-SSO-120 versus 18F-FDG PET in the Initial Staging of Small-Cell Lung Cancer Patients
    In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. Suppl. 1, Annual Congress of the European Association of Nuclear Medicine September 9–13, 2023 Vienna, Austria, S. 488 – S489
    DOI
  • Kersting, David; Sandach, Patrick; Sraieb, Miriam; Wiesweg, Marcel; Metzenmacher, Martin; Darwiche, Kaid; Oezkan, Filiz; Bolukbas, Servet; Stuschke, Martin; Umutlu, Lale; Nader, Michael; Fendler, Wolfgang; Wienker, Johannes; Eberhardt, Wilfried; Schuler, Martin; Herrmann, Ken; Hautzel, Hubertus
    68Ga-Satoreotide PET for Staging of Small-Cell Lung Cancer Patients
    In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 64, 2023, Nr. Suppl. 1, P165
  • Schuler, Martin; de Langen, A. J.; Paz-Ares, L.; Skoulidis, F.; et al.
    Biomarker subgroup analyses of the Phase III study CodeBreaK 200 comparing sotorasib to docetaxel in pretreated patients with KRAS G12C-mutated non-small cell lung cancer
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 148 – 149
    DOI (Open Access)
  • Pabst, Kim; Hamacher, Rainer; Schaarschmidt, Benedikt; Kessler, Lukas; Cheung, Phyllis; Liffers, Sven-Thorsten; Miera, Monika; Kostbade, Karina; Lanzafame, Helena; Mavroeidi, Ilektra; Hirmas, Nader; Costa, Pedro Fragoso; Nader, Michael; Bartel, Timo; Schuler, Martin; Bauer, Sebastian; Herrmann, Ken; Siveke, Jens; Schildhaus, Hans-Ulrich; Fendler, Wolfgang
    Fibroblast activation protein alpha (FAPα) directed imaging and radioligand therapy in patients with solitary fibrous tumor (SFT)
    55th Annual Conference of the Society of Nuclear Medicine (SNMICON), November 16-19, 2023, Jodhpur, India,
    In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 64, 2023, Nr. Suppl. 1, P714
  • Stockey, M.; Treckmann, Jürgen-Walter; Rink, A.; Schmidt, H.; Markus, Peter; Albers, David; Zaun, G.; Kostbade, K.; Hilser, T.; Pogorzeslki, M.; Baba, Hideo Andreas; Wiesweg, Marcel; Schuler, Martin; Kasper, Stefan; Virchow, I.
    HER2-low as potential prognostic biomarker in patients (pts) with metastatic or recurrent Gastric Cancer (GC) or esophageal-gastric junction (AEG) adenocarcinoma
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 117 – 118
    DOI (Open Access)
  • Schuler, Martin; Cassier, P. A.; Dooms, C.; de Miguel, M. J.; et al.
    KontRASt-01 update : safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 147 – 148
    DOI (Open Access)
  • Richlitzki, Cedric; Pöttgen, Christoph; Wiesweg, Marcel; Metzenmacher, Martin; Guberina, Nika; Gauler, Thomas; Hautzel, Hubertus; Eberhardt, Wilfried; Darwiche, Kaid; Theegarten, Dirk; Bölükbas, Servet; Schuler, Martin; Stuschke, Martin; Guberina, Maja
    Kreuzvalidierte Prognoseparameter C-reaktives Protein und Blutbild-Parameter im Verlauf der kurativ intendierten Radiochemotherapie bei Patienten mit nichtkleinzelligem Lungenkarzinom (NSCLC) im Stadium IIIA-C
    In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics. Heidelberg: Springer, Jg. 199, 2023, Nr. Suppl. 1, S. S100 – S101
    DOI (Open Access)
  • Stuschke, Martin; Pöttgen, Christoph; Gauler, Thomas; Cordes, Sebastian; Metzenmacher, Martin; Brintrup, Diana Luetke; Guberina, Maja; Filiz, Özkan; Darwiche, Kaid; Schuler, Martin; Jöckel, Karl-Heinz; Aigner, Clemens; Stamatis, Georgios; Eberhardt, Wilfried
    Langzeitüberleben und konkurrierende Risiken von Patienten einer randomisierten Studie zur defnitiven vs. neoadjuvanten Radiochemotherapie + Resektion mit einem nach der Induktion resektablen NSCLC im Stadium III
    In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics. Heidelberg: Springer, Jg. 199, 2023, Nr. Suppl. 1, S. S7 – S8
    DOI (Open Access)
  • Guberina, Maja; Pöttgen, Christoph; Wiesweg, Marcel; Metzenmacher, Martin; Richlitzki, Cedric; Plönes, Till; Guberina, Nika; Forsting, Michael; Herrmann, Ken; Gauler, Thomas; Hoffmann, Christian; Theegarten, Dirk; Darwiche, Kaid; Garcia, Alina Santiago; Stuschke, Martin; Schuler, Martin
    Long-term Survival in Patients with oligometastatic Lung Cancer (cT4 or cN2-3, cM1a-c) after thoracic Chemoradiation, Metastasis-directed and Systemic Therapy compared with the Outcome in locally advanced Lung Cancer (cT4 or cN2-3, cM0)
    In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics. Heidelberg: Springer, Jg. 199, 2023, Nr. Suppl. 1, S. S101 – S102
    DOI (Open Access)
  • Mavroeidi, I. A.; Reissig, T.; Kalbourtzis, S.; Liffers, S.-T.; Herold, T.; Treckmann, Jürgen-Walter; Schildhaus, Hans-Ulrich; Schuler, Martin; Siveke, Jens T.
    Molecular characterization of biliary tract cancer at a single comprehensive cancer center focusing on DNA damage repair genes
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 62
    DOI (Open Access)
  • Fink, M.; Schmidt, K.; Tewes, Mitra; Schuler, Martin; Müller, B. W.; Schadendorf, Dirk; Scherbaum, Norbert; Kowalski, A.; Skoda, E.-M.; Teufel, Martin
    RCT to Test the Efficacy of an EEG Neurofeedback Intervention in Cancer Patients and Cancer Survivors
    Deutscher Kongress für Psychosomatische Medizin und Psychotherapie, 03.-05.05.2023, Berlin,
    In: Zeitschrift für Psychosomatische Medizin und Psychotherapie. Göttingen: Vandenhoeck & Ruprecht, Jg. 69, 2023, Nr. 2, S. 148 – 149
    DOI
  • Lanzafame, H.; Hirmas, N.; Schuler, Martin; Darwiche, Kaid; Eberhardt, Wilfried E. E.; Aigner, Clemens; Stuschke, Martin; Kessler, Lukas; Pabst, K. M.; Barbato, F.; Rischpler, Christoph; Hautzel, H.; Herrmann, Ken; Fendler, Wolfgang
    68GA-FAPI PET/CT in the evaluation of Non-Small Cell Lung Cancer (NSCLC)
    EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,
    In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S107
    DOI (Open Access)
  • Schuler, Martin H. H.; Cuppens, K.; Ploenes, T.; Vanbockrijck, M.; Wiesweg, Marcel; Darwiche, Kaid; Schramm, Alexander; Maes, B.; Hegedus, B.; Schildhaus, Hans-Ulrich; Hautzel, H.; Theegarten, Dirk; Baas, P.; Hartemink, K.; Du Pont, B.; Aigner, Clemens
    A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)
    ESMO Congress 2022, 9 - 13 September 2022, Paris, France,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 33, 2022, Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S1404
    DOI (Open Access)
  • Petzold, A.; Dujardin, P.; Oeck, S.; Wiesweg, Marcel; Hegedüs, B.; Schuler, Martin; Grüner, Barbara M.; Schramm, Alexander
    Combining Patient-Derived Xenografts and Barcoding Technology to Evaluate Response to Targeted Therapies in ALK+NSCLC
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 17, 2022, Nr. 9, S. 611
    DOI
  • Schuler, Martin; Loriot, Y.; Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Tabernero, J.; Reardon, D. A.; Massard, C.; Palmer, D. H.; Lugowska, I.; Coward, J.; Corassa, M.; Stuyckens, K.; Liao, H.; Najmi, S.; Hammond, C.; Santiago-Walker, A. E.; Sweiti, H.; Pant, S.
    Entitäten-unabhängige Sicherheit und Wirksamkeit von Erdafitinib bei Patienten mit fortgeschrittenen soliden Tumoren mit präspezifizierten genomischen FGFR- Aberrationen (RAGNAR Interimanalyse)
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 45, 2022, Nr. Supplement 2, S. 27 – 28
    DOI (Open Access)
  • Hegedüs, Luca; Okumus, Ö.; Mairinger, Fabian; Plönes, Till; Reuter, Sebastian; Schuler, Martin; Theegarten, Dirk; Bankfalvi, Agnes; Aigner, Clemens; Hegedüs, Balazs
    Expression and SN38 Antitumor Activity in Malignant Pleural Mesothelioma Cells
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 17, 2022, Nr. 9, S. 118
    DOI
  • Schuler, Martin; Tan, D. S.; Shimizu, T.; Cassier, P. A.; et al.
    KontRASt-01 : eine Phase Ib/II Dosiseskalationsstudie von JDQ443 in Patienten mit fortgeschrittenen, KRAS G12C-mutierten soliden Tumoren
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie 07. bis 10. Oktober 2022, Wien, Austria,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 45, 2022, Nr. Supplement 2, S. 29
    DOI (Open Access)
  • Eberhardt, Wilfried; Pöttgen, Christoph; Gauler, Thomas; Schulte, C; Friedel, G.; Kopp, H.-G.; Fischer, B.; Schmidberger, H.; Kimmich, M.; Budach, W.; Cordes, S.; Metzenmacher, M.; de Los Rios, R. Hepp; Spengler, W.; De Ruysscher, D.; Belka, C.; Welter, S.; Brintrup, D. Luetke; Guberina, M.; Oezkan, F.; Darwiche, Kaid; Schuler, Martin; Jöckel, Karl-Heinz; Aigner, Clemens; Stamatis, Georgios; Stuschke, Martin
    Long-term Survival and Competing Risks of Death in the ESPATUE Randomized Phase-III Trial in Stage III NSCLC
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 17, 2022, Nr. 9, S. 65
    DOI
  • Miura, Satoru; Schuler, Martin; Popat, Sanjay; Park, Keunchil; Passaro, Antonio; De Marinis, Filippo; Solca, Flavio; Märten, Angela; Kim, Edward S.; Chih-Hsin Yang, James
    MO29-3 A database of 1023 patients with NSCLC and uncommon EGFR mutations treated with afatinib : Focus on Asian patients
    The 19th Annual Meeting of JSMO (Japanese Society of Medical Oncology), 17.–19.02.2022, Kyoto,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 33, 2022, Nr. Suppl. 6: 2022 the Japanese Society of Medical Oncology Annual Meeting 17–19 February 2022, Kyoto, Japan, S. 500
    DOI (Open Access)
  • Okumus, O.; Mardanzai, K.; Ploenes, T.; Theegarten, Dirk; Darwiche, Kaid; Schuler, Martin; Nensa, Felix; Hautzel, H.; Stuschke, Martin; Hegedues, B.; Aigner, Clemens
    Preoperative PET-SUVmax and Volume Based PET Metrics of the Tumor Fail to Predict Nodal Upstaging in Early-Stage Lung Cancer
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 17, 2022, Nr. 9, S. 203
    DOI
  • Maier, D.; Vehreschild, J. J.; Uhl, B.; Grünwald, Viktor; Hadaschik, Boris; Palm, S.; Stuschke, Martin; Esins, M.; Ressing, F.; Schuler, Martin; Serve, H.; et al.
    Profil der multizentrischen Kohorte der Klinischen Kommunicationsplattform des Deutschen Konsortiums für Translationale Krebsforschung (DKTK)
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 45, 2022, Nr. Supplement 2, S. 13
    DOI (Open Access)
  • Guberina, M.; Pöttgen, Christoph; Guberina, N.; Gauler, Thomas; Metzenmacher, M.; Wiesweg, Marcel; Richlitzki, C.; Plönes, T.; Forsting, Michael; Wetter, Axel; Herrmann, Ken; Hautzel, H.; Darwiche, Kaid; Theegarten, Dirk; Aigner, Clemens; Schuler, Martin; Eberhardt, Wilfried E. E.; Stuschke, Martin
    Robuste und lang-andauernde Wirksamkeit der Durvalumab-Konsolidierung bei NSCLC im Stadium III nach Induktionschemotherapie und definitiver Radiochemotherapie : Fokus auf Behandlungsauswahl und prognostische Faktoren
    28. Kongress der Deutschen Gesellschaft für Radioonkologie ; DEGRO 2022 ; 26. bis 28.05.2022, Stuttgart, Germany,
    In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics. Heidelberg: Springer, Jg. 198, 2022, Nr. Supplement 1, S. S15
    DOI (Open Access)
  • Hamacher, R.W.; Pabst, K.M.; Kessler, Lukas; Costa, Pedro Fragoso; Ferdinandus, J.; Weber, Manuel; Lippert, M.; Lückerath, Katharina; Hirmas, N.; Kostbade, K.; Mavroeidi, I.A.; Schuler, Martin H. H.; Ahrens, M.; Rischpler, Christoph; Bauer, Sebastian; Herrmann, Ken; Siveke, Jens T.; Fendler, Wolfgang P.
    Safety and efficacy of [90Y]Y-FAPI-46 radioligand therapy in patients with advanced sarcomas and other cancer entities
    ESMO Congress 2022, 9 - 13 September 2022, Paris, France,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 33, 2022, Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S1231 – S1232
    DOI (Open Access)
  • Martens, U.M.; Schröder, J.; Sellmann, Ludger; Reiser, M.; Frank-Gleich, S.; Decker, T.; Schneeweiss, A.; Schuler, Martin; Grebhardt, S.; Woerner, S.; Zacharias, S.; Marschner, N.W.; Kasenda, B.; Vannier, C.
    Second interim analysis of INFINITY : A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 33, 2022, S. 575 – S576
    DOI
  • Johnson, M.L.; de Langen, A.J.; Waterhouse, D.M.; Mazieres, J.; Dingemans, A-M.C.; Mountzios, G.; Pless, M.; Wolf, J.; Schuler, Martin; Lena, H.; Skoulidis, F.; Okamoto, I.; Kim, S-W.; Linardou, H.; Novello, S.; Chen, Y.; Solomon, B.; Obiozor, C.; Wang, Y.; Paz-Ares, L.
    Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation : CodeBreaK 200 phase III study
    ESMO Congress 2022, 9 - 13 September 2022, Paris, France,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 33, 2022, Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S1417 – S1418
    DOI (Open Access)
  • Tüns, A.I.; Ho, C.S.L.; Schildhaus, Hans-Ulrich; Wiesweg, Marcel; Grüner, Barbara M.; Hegedüs, B.; Schuler, Martin; Schramm, Alexander; Oeck, S.
    Targeting SHP2 Reverts Oncogenic Mediated Resistance to KRAS-G12C Inhibition
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 17, 2022, Nr. 9, S. S586 – S587
    DOI
  • Loriot, Yohann; Schuler, Martin; Iyer, Gopa; Witt, Olaf; Doi, Toshihiko; Qin, Shukui; Tabernero, Josep; Reardon, David A.; Massard, Christophe; Palmer, Daniel; Lugowska, Iwona; Coward, Jermaine; Corassa, Marcelo; Stuyckens, Kim; Liao, Huimin; Najmi, Saltanat; Hammond, Constance; Santiago-Walker, Ademi E.; Sweiti, Hussein; Pant, Shubham
    Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR : Interim analysis (IA) results
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 40, 2022, Nr. 16_Suppl., S. 3007
    DOI (Open Access)
  • Martens, U.; Schröder, J.; Sellmann, Ludger; Reiser, M.; Frank-Gleich, S.; Decker, T.; Schneeweiss, A.; Schuler, Martin; Grebhardt, S.; Woerner, S.; Zacharias, S.; Marschner, N.; Kasenda, B.; Vannier, C.
    Zweite Interimsanalyse zu INFINITY : ein Register zur Entscheidungsfindung in der Biomarker-basierten Präzisionsonkologie und deren klinische Bedeutung
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 45, 2022, Nr. Supplement 2, S. 11 – 12
    DOI (Open Access)
  • Kessler, Lukas; Ferdinandus, J.; Costa, P. F.; Weber, Manuel; Hirmas, N.; Kostbade, K.; Bauer, Sebastian; Dirksen, U.; Zarrad, F.; Nader, M.; Grafe, Hong; Chodyla, M.; Milosevic, A.; Umutlu, Lale; Schuler, Martin; Ahrens, M.; Podleska, Lars E.; Schildhaus, Hans-Ulrich; Rischpler, Christoph; Siveke, Jens T.; Herrmann, Ken; Fendler, Wolfgang P.; Hamacher, R.
    A novel theranostic approach for sarcoma : Insights on diagnostic and therapeutic use of FAP-radioligands
    Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 44, 2021, Nr. Supplement 2, S. 11 – 12
    DOI (Open Access)
  • Melero, Ignacio; Calvo, Emiliano; Goebeler, Maria-Elisabeth; Garralda, Elena; Dummer, Reinhard; Rodríguez-Ruiz, María; Miguel, Maria de; Sayehli, Cyrus Michael; Casal, Guzman Alonso; Ramelyte, Egle; Schuler, Martin; Gromke, Tanja; Sanmamed, Miguel; Moreno, Irene; Bargou, Ralf; Lostes, Maria; Maul, Julia-Tatjana; Eggenschwiler, Corinne; Richly, Heike; Fettes, Petra; Klar, Kathrin; Schuberth-Wagner, Christine; Haake, Markus; Wischhusen, Jörg; Leo, Eugen
    A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)
    SITC 36th Anniversary Annual Meeting (SITC 2021), 10-14 November 2021, Washington & virtually,
    In: Journal for ImmunoTherapy of Cancer. London: BMJ, Jg. 9, 2021, Nr. Suppl. 2, S. A536 – A536
    DOI (Open Access)
  • Melero, Ignacio; Calvo, Emiliano; Dummer, Reinhard; Garralda, Elena; Schuler, Martin; Goebeler, Maria-Elisabeth; Bargou, Ralf C.; Gromke, Tanja; Tabernero, Josep; Ramelyte, Egle; De Miguel, Maria; Sanmamed, Miguel F.; Rodriguez-Ruiz, Maria E.; Fettes, Petra; Klar, Kathrin; Ruediger, Manfred; Schuberth-Wagner, Christine; Haake, Markus; Wischhusen, Joerg; Leo, Eugen
    A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER).
    2021 Genitourinary Cancers Symposium, 11 - 13 Feb 2021, online,
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 39, 2021, Nr. 15_suppl, S. TPS2658
    DOI (Open Access)
  • Pant, Shubham; Tabernero, Josep; Massard, Christophe; Iyer, Gopa; Witt, Olaf; Doi, Toshihiko; Qin, Shukui; Lu-Emerson, Christine; Hargrave, Darren R.; García-Corbacho, Javier; Little, Shonda Marie; Xia, Qi; Santiago-Walker, Ademi E.; Moy, Christopher; Hammond, Constance; Sweiti, Hussein; Schuler, Martin
    A phase II open-label study in adult and adolescent patients (pts) with advanced solid tumors harboring fibroblast growth factor receptor (FGFR) gene alterations
    2021 Gastrointestinal Cancers Symposium, 15-17 January 2021, online,
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 39, 2021, Nr. 3, Supplement, S. TPS480
    DOI (Open Access)
  • Yang, J.Y.C-H.; Schuler, Martin; Popat, Sanjay; Miura, Satoru; Park, Kyungrae; Passaro, Antonio; de Marinis, Filippo; Solca, Flavio F.; Märten, Angela; Kim, Edward S.
    Afatinib for the treatment of NSCLC with uncommon EGFR mutations : An updated database of 1023 cases
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 32, 2021, Nr. Suppl. 5, S. 965
    DOI (Open Access)
  • Subbiah, Vivek; Cassier, Philippe A.; Siena, Salvatore; Alonso, Guzman; Paz-Ares, Luis G.; Garrido, Pilar; Nadal, Ernest; Curigliano, Giuseppe; Vuky, Jacqueline; Lopes, Gilberto; Kalemkerian, Gregory Peter; Bowles, Daniel W.; Seetharam, Mahesh; Chang, Jianhua; Zhang, Hui; Ye, Chaoyang; Green, Jennifer; Zalutskaya, Alena; Schuler, Martin; Fan, Yun
    Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors : Update from the ARROW trial
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 39, 2021, Nr. 15_Suppl, S. 3079 – 3079
    DOI (Open Access)
  • Subbiah, Vivek; Hu, Mimi I-Nan; Gainor, Justin F.; Mansfield, Aaron Scott; Alonso, Guzman; Taylor, Matthew H.; Zhu, Viola Weijia; Garrido, Pilar; Amatu, Alessio; Doebele, Robert C; Cassier, Philippe; Keam, Bhumsuk; Schuler, Martin; Zhang, Hui; Clifford, Corinne; Palmer, Michael; Green, Jennifer; Turner, Christopher D.; Curigliano, Giuseppe
    Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion–positive solid tumors
    2021 Gastrointestinal Cancers Symposium, 15-17 January 2021, online,
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 39, 2021, Nr. 3, Supplement, S. 467 – 467
    DOI (Open Access)
  • Guberina, M.; Herrmann, Ken; Pöttgen, Christoph; Guberina, N.; Hoffmann, C.; Ploenes, T.; Gauler, Thomas; Wetter, Axel; Umutlu, Lale; Hautzel, H.; Theegarten, Dirk; Schuler, Martin; Eberhardt, Wilfried; Metzenmacher, M.; Wiesweg, Marcel; Aigner, Clemens; Darwiche, Kaid; Karpf-Wissel, Rüdiger; Stuschke, Martin
    EBUS-TBNA and [F-18] FDG-PET/CT for precise Target Volume Definition prior to Chemoradiotherapy : Lymphonodular Spreading Patterns in Stage III NSCLC
    In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics. Heidelberg: Springer, Jg. 197, 2021, Nr. Suppl. 1, S. 142
  • Decker, T.; Fasching, P.A.; Nusch, A.; Hartkopf, A.; Heinrich, B.J.; Kurbacher, C.M.; Fuchs, R.; Tesch, H.; Krabisch, P.; Huober, J.; Kümmel, Sherko; Brucker, S.Y.; Janni, W.; Schneeweiss, A.; Schuler, Martin; Fehm, T.N.; Lüftner, D.; C. Quiering; Kreuzeder, J.; Reinisch, M.
    Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptor–positive advanced breast cancer (ABC) : Secondary and exploratory results of phase 3b RIBECCA study
    ESMO Congress 2021, 16 – 21 September 2021, Virtual,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 32, 2021, Nr. Supplement 5, S. S467 – S468
    DOI (Open Access)
  • Müller, S.; Fink, M.; Schuler, Martin; Hense, Jörg; Przyborek, M.; Teufel, Martin; Tewes, Mitra
    Influence of external and self-assessment in symptom burden of cancer patients in a palliative care outpatient clinic of a Comprehensive Cancer Center
    Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 44, 2021, Nr. Supplement 2, S. 92
    DOI (Open Access)
  • Ferdinandus, J.; Fragoso Costa, Pedro; Kessler, Lukas; Weber, Manuel; Hirmas, N.; Kostbade, Karina; Bauer, Sebastian; Schuler, Martin; Ahrens, M.; Schildhaus, Hans-Ulrich; Rischpler, Christoph; Siveke, Jens T.; Herrmann, Ken; Fendler, Wolfgang P.; Hamacher, R.
    Initial clinical experience with [Y-90]Y-FAPI-46 radioligand therapy for advanced stage solid tumors
    Annual Congress of the European Association of Nuclear Medicine, October 20-23, 2021, Virtual,
    In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 48, 2021, Nr. Suppl. 1, S. S290
    DOI (Open Access)
  • Skoulidis, Ferdinandos; Li, Bob T.; Govindan, Ramaswamy; Dy, Grace K.; Shapiro, Geoffrey; Bauml, Joshua; Schuler, Martin; Addeo, Alfredo; Kato, Terufumi; Besse, Benjamin; Anderson, Abraham; Ang, Agnes; Ngarmchamnanrith, Gataree; Tran, Qui; Velcheti, Vamsidhar
    Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 39, 2021, Nr. 15_Suppl, S. 9003 – 9003
    DOI (Open Access)
  • Massard, Christophe; Pant, Shubham; Iyer, Gopa; Schuler, Martin; Witt, Olaf; Qin, Shukui; Tabernero, Josep; Doi, Toshihiko; Hargrave, Darren R.; Hammond, Constance; Little, Shonda Marie; Xia, Qi; Cao, Jing; Santiago-Walker, Ademi E.; Sweiti, Hussein
    Preliminary results of molecular screening for FGFR alterations (alts) in the RAGNAR histology-agnostic study with the FGFR-inhibitor (FGFRi) erdafitinib
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 39, 2021, Nr. 15_Suppl, S. 4081 – 4081
    DOI (Open Access)
  • Kasper, Stefan; Goetze, Thorsten Oliver; Stintzing, Sebastian; Hofheinz, Ralf Dieter; Sinn, Marianne; Dechow, Tobias Nicolaas; Ettrich, Thomas Jens; Keitel, Verena; Graeven, Ullrich; Fischer von Weikersthal, Ludwig; Kolov, Alexander; Edelmann, Thomas; Stein, Alexander; Trarbach, Tanja; Junge, Sabine; Pauligk, Claudia; Virchow, Isabel; Siveke, Jens T.; Al-Batran, Salah-Eddin; Schuler, Martin
    RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer : Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316)
    2021 ASCO Annual Meeting, June 4-8, 2021, virtual,
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 39, 2021, Nr. 15_Suppl, 3566
    DOI (Open Access)
  • Pöttgen, Christoph; Gauler, Thomas; Guberina, M.; Pierscianek, D.; Wrede, Karsten; Wiesweg, Marcel; Eberhardt, Wilfried; Schuler, Martin; Stuschke, Martin
    Re-Irradiation of cerebral Metastases after prophylactic Brain Skull irradiation in small-cell neuroendocrine Lung Cancer (SCLC)
    In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics. Heidelberg: Springer, Jg. 197, 2021, Nr. Suppl. 1, S. 176
  • Schuler, Martin; Wolf, J.
    Registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC : first disclosure of the CodeBreaK 100 primary analysis
    In: Pneumologie. Stuttgart: Thieme, Jg. 75, 2021, Nr. Suppl. 1, 61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V. Leipzig digital, 02.–05.06.2021, S. S38
    DOI
  • Lauri, F.; Hilser, T.; Hense, Jörg; Ting, S. C.; Kansy, B.; Laue, K.; Gauler, Thomas C.; Stuschke, Martin; Schmid, K. W.; Lang, Stephan; Grünwald, Viktor; Schuler, Martin; Kasper, S.
    Systemic inflammatory response parameters as prognostic markers in patients with recurrent or metastatic head and neck cancer treated with immunotherapy
    Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 44, 2021, Nr. Supplement 2, S. 58
    DOI (Open Access)
  • Lopez, Juanita S.; Camidge, Ross; Iafolla, Marco; Rottey, Sylvie; Schuler, Martin; Hellmann, Matthew; Balmanoukian, Ani; Dirix, Luc; Gordon, Michael; Sullivan, Ryan; Henick, Brian S.; Drake, Charles; Wong, Kit; LoRusso, Patricia; Ott, Patrick; Fong, Lawrence; Schiza, Aglaia; Yachnin, Jeffery; Ottensmeier, Christian; Braiteh, Fadi; Bendell, Johanna; Leidner, Rom; Fisher, George; Jerusalem, Guy; Molenaar-Kuijsten, Laura; Schmidt, Marcus; Laurie, Scott A.; Aljumaily, Raid; Rittmeyer, Achim; Gort, Eelke; Melero, Ignacio; Mueller, Lars; Sabado, Rachel; Twomey, Patrick; Huang, Jack; Yadav, Manesh; Zhang, Jingbin; Mueller, Felicitas; Derhovanessian, Evelyna; Sahin, Ugur; Türeci, Özlem; Powles, Thomas
    Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors
    Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, USA,
    In: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 80, 2020, Nr. 16: Supplement, S. CT301
    DOI (Open Access)
  • Yang, J. C-H.; Schuler, Martin; Popat, S.; Miura, S.; Heeke, S.; Passaro, A.; de Marinis, F.; Park, K.; Kim, E. S.
    Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations
    ESMO Asia Virtual Congress 2020 ; 20-22 November 2020,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 31, 2020, Nr. Supplement 6, S. S1396
    DOI (Open Access)
  • Yang, J.C-H.; Schuler, Martin; Popat, Sanjay; Miura, S.; Heeke, S.; Passaro, A.; de Marinis, Filippo; Park, K.; Kim, E.S.
    Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC harboring uncommon mutations
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 31, 2020, Nr. Suppl. 4, S. S860 – S861
    DOI (Open Access)
  • Subbiah, Vivek; Hu, Mimi I-Nan; Gainor, Justin F.; Mansfield, Aaron Scott; Alonso, Guzman; Taylor, Matthew H.; Zhu, Viola Weijia; Garrido Lopez, Pilar; Amatu, Alessio; Doebele, Robert C; Cassier, Philippe Alexandre; Keam, Bhumsuk; Schuler, Martin; Zhang, Hui; Clifford, Corinne; Palmer, Michael; Green, Jennifer; Turner, Christopher D.; Curigliano, Giuseppe
    Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 38, 2020, Nr. 15_Suppl., S. 109
    DOI (Open Access)
  • Peuker, CA; Yaghobramzi, S; Lüftner, D.; Brucker, S; Decker, T; Fasching, P; Fehm, T; Janni, W; Kümmel, Sherko; Schneeweiss, A; Schuler, Martin; Busse, A
    Einfluss des CDK4/6-Inhibitors Ribociclib auf die periphere Immunantwort beim Hormonrezeptor-positiven Mammakarzinom
    40. Jahrestagung der Deutschen Gesellschaft für Senologie, 25.–27. Juni 2020, München, Germany,
    In: Geburtshilfe und Frauenheilkunde. Stuttgart: Thieme, Jg. 80, 2020, Nr. 6, S. e53
    DOI
  • Martens, U.; Reiser, M.; Schirrmacher-Memmel, S.; Sellmann, L.; Decker, T.; Schneeweiss, A.; Schuler, Martin; Bengsch, F.; Vannier, C.; Potthoff, K.; Marschner, N.; Kasenda, B.
    First results from INFINITY - A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice
    Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 43, 2020, Nr. Suppl. 4, S. 251 – 252
    DOI (Open Access)
  • Peuker, C. A.; Yaghobramzi, S.; Grunert, C.; Keilholz, L.; Henning, S.; Schaper, S.; Brucker, S.; Decker, T.; Fasching, P.; Fehm, T.; Janni, W.; Kümmel, Sherko; Schneeweiss, A.; Schuler, Martin; Lüftner, D.; Busse, A.
    Influence of CDK4/6 inhibitors on the peripheral immune response in hormone receptor-positive breast cancer
    Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 43, 2020, Nr. Suppl. 4, S. 159
    DOI (Open Access)
  • Guberina, Marko; Pöttgen, Christoph; Guberina, Nika; Hautzel, Hubertus; Herrmann, Ken; Theegarten, Dirk; Aigner, Clemens; Plones, Till; Gauler, Thomas; Eberhardt, Wilfried; Schuler, Martin; Karpf-Wissel, Rüdiger; Darwiche, Kaid; Stuschke, Martin
    Lymphknoten-Staging von lokal fortgeschrittenen, nicht kleinzelligen Lungenkarzinomen (NSCLC) : Wert von [18F] FDG-PET/CT und EBUS/TBNA zur Festlegung des Zielvolumens bei definitiver Radiotherapie in kurativer Intention
    26. Jahrestagung der Deutschen Gesellschaft für Radioonkologie (DEGRO) ; 24. Juni - 28. Juni 2020, Wiesbaden, Germany,
    In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics. Heidelberg: Springer, Jg. 196, 2020, Nr. 1 Supplement: Abstracts DEGRO 2020, S. S143
    DOI (Open Access)
  • Pöttgen, Christoph; Plajer, D.; Gauler, Thomas; Guberina, Marko; Santiago, Alina; Guberina, Nika; Eberhardt, Wilfried; Schuler, Martin; Darwiche, Kaid; Plönes, Till; Aigner, Clemens; Stuschke, Martin
    Optimierung prognostischer Modelle für das Überleben von Patienten mit lokal fortgeschrittenen kleinzelligen Lungenkarzinomen nach definitiver Radiochemotherapie mittels künstlicher Intelligenz
    26. Jahrestagung der Deutschen Gesellschaft für Radioonkologie (DEGRO) ; 24. Juni - 28. Juni 2020, Wiesbaden, Germany,
    In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics. Heidelberg: Springer, Jg. 196, 2020, Nr. 1 Supplement: Abstracts DEGRO 2020, S. S57 – S58
    DOI (Open Access)
  • Röhrig, T.; Oechsel, K.; Schuler, U.; Rosenbruch, J.; Neukirchen, M.; Hense, Jörg; Weber, M.; Nauck, F.; Junghanß, C.; Kramer, T.; Oorschot, B. van; Ostgathe, C.; Thuss-Patience, P.; Schweda, Adam; Ullrich, A.; Teufel, Martin; Schuler, Martin; Tewes, Mitra
    Palliative knowledge and self-efficacy expectation of residents before and after palliative care unit rotation - A national study project
    Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 43, 2020, Nr. Suppl. 4, S. 210
    DOI (Open Access)
  • Kraskowski, O.; Eberhardt, Wilfried; Metzenmacher, Martin; Zaun, Gregor; McCutcheon, A.; Schmid, Kurt Werner; Schildhaus, Hans-Ulrich; Darwiche, Kaid; Aigner, Clemens; Kasper, Stefan; Hense, Jörg; Gruenwald, Viktor; Wiesweg, Marcel; Schuler, Martin; Pogorzelski, Michael
    Patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC) show highly favorable outcomes with treatment sequences provided at a comprehensive cancer center
    Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 43, 2020, Nr. Suppl. 4, S. 137
    DOI (Open Access)
  • Janku, Filip; Elez, Elena; Iyer, Gopa; Yamamoto, Noboru; Tan, Daniel Shao-Weng; Stathis, Anastasios; Stammberger, Uz M.; Evans, Helen; Seroutou, Abdelkader; Mais, Anna; Schuler, Martin
    Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 38, 2020, Nr. 15_Suppl., S. 3640
    DOI (Open Access)
  • Schuler, Martin; Tabernero, J.; Massard, C.; Iyer, G. Vasudeva; Witt, Olaf; Doi, T.; Qin, S.; Lu-Emerson, C.; Hargrave, D.; Garcia-Corbacho, J.; Little, S.; Xia, Q.; Santiago-Walker, A.; Moy, C.H.; Hammond, C.; Lau, Y.Y.; Sweiti, H.; Pant, S.
    Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterations
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 31, 2020, Nr. Suppl. 4, S. 502 – S503
    DOI (Open Access)
  • Thomas, M.; Griesinger, F.; Schuler, Martin; Gainor, J. F.; Curigliano, G.; Kim, D.-W.; Lee, D. H.; Besse, B.; Baik, C. S.; Doebele, R. C.; Cassier, P.; Lopes, G.; Tan, D. S.-W.; Garralda, E.; Paz-Ares, L.; Chul Cho, B.; Gadgeel, S. M.; Liu, S. V.; Turner, C. D.; Subbiah, V.
    Registrational dataset from the phase 1/2 ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion plus non-small-cell lung cancer (NSCLC)
    Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 43, 2020, Nr. Suppl. 4, S. 141 – 142
    DOI (Open Access)
  • Keam, B.; Hu, M. I.; Subbiah, V.; Wirth, L.; Schuler, Martin; Mansfield, A. S.; Brose, M. S.; Curigliano, G.; Leboulleux, S.; Zhu, V. W.; Matos, I.; Adkins, D.; Baik, C. S.; Lopes, G.; Godbert, Y.; Sarker, D.; Zhang, H.; Turner, C. D.; Taylor, M. H.; Lin, C.-C.
    Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
    ESMO Asia Virtual Congress 2020 ; 20-22 November 2020,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 31, 2020, Nr. Supplement 6, S. S1413 – S1414
    DOI (Open Access)
  • Hu, M.; Subbiah, V.; Wirth, L.J.; Schuler, Martin; Mansfield, A.S.; Brose, M.S.; Curigliano, G.; Leboulleux, S.; Zhu, Viola W.; Keam, Bhumsuk; Matos, I.; Lin, C-C.; Adkins, Douglas R.; Baik, C.S.; Lopes, G.; Godbert, Y.; Sarker, Debashis; Zhang, H.; Turner, C.; Taylor, M.
    Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 31, 2020, Nr. Suppl. 4, S. S1084
    DOI (Open Access)
  • Darwiche, Kaid; Theegarten, Dirk; Schildhaus, Hans-Ulrich; Schuler, Martin; Wiesweg, Marcel; Aigner, Clemens; Karpf-Wissel, Rüdiger
    The impact of needle choice on molecular analysis of ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in NSCLC
    In: European Respiratory Journal (ERJ). Sheffield: European Respiratory Society, Jg. 56, 2020, Nr. Suppl. 64
    DOI (Open Access)
  • Stockhammer, P.; Ho, C.S.L.; Bankfalvi, Agnes; Plönes, T.; Hegedus, L.; Schuler, Martin; Aigner, Clemens; Schramm, Alexander; Hegedus, B.
    A Novel Patient Derived Synchronous Cell Pair with Different Mutations in an ALK-Rearranged Lung Adenocarcinoma Underlines Tumor Heterogeneity
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 14, 2019, Nr. 10, Supplement, S. S571 – S572
    DOI (Open Access)
  • Kasper, Stefan; zur Hausen, Gerrit; Stein, Alexander; Stintzing, Sebastian; Berger, Andreas; Loges, Sonja; Hofheinz, Ralf; Trarbach, Tanja; Graeven, Ullrich; Fischer von Weikersthal, Ludwig; Goetze, Thorsten Oliver; Hagen, Volker A.; Burock, Susen; Hoffmeister, Albrecht; Dechow, Tobias Nicolaas; Pauligk, Claudia; Virchow, Isabel; Siveke, Jens T.; Al-Batran, Salah-Eddin; Schuler, Martin
    A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients : The RAMTAS trial of the German AIO (KRK-0316)
    2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, Ill., USA,
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 37, 2019, Nr. 15, TPS3617
    DOI (Open Access)
  • Zaatar, M.; Stork, T.; Fangmann, L.; Martens, A.; Collaud, S.; Mardanzai, K.; Plönes, T.; Valdivia, D.; Schuler, Martin; Stuschke, Martin; Darwiche, Kaid; Hegedus, B.; Aigner, Clemens
    Advanced Age and High Modified Glasgow Prognostic Score Are Associated with Increased Complications After Pneumonectomy
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 14, 2019, Nr. 10, Supplement, S. S677
    DOI (Open Access)
  • Tewes, Mitra; Goette, M.; Frikkel, J.; Guyot, M.; Kasper, S.; Metzenmacher, M.; Hense, Jörg; Teufel, Martin; Schuler, Martin; Beckmann, M.
    Barriers and motivation of physical activitiy (PA) in patients with cancer related fatigue (CRF)
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 42, 2019, Nr. Supplement 4: Abstracts, S. 165
    DOI (Open Access)
  • Michels, Sebastian Yves Friedrich; Nogova, Lucia; Deschler-Baier, Barbara; Felip, Enriqueta; Rodriguez-Abreu, Delvys; Rosell, Rafael; Sebastian, Martin; Schuler, Martin; Wermke, Martin; Fischer, Rieke Nila; Koleczko, Sophia; Abdulla, Diana S.Y.; Riedel, Richard; Scheffler, Matthias; Fassunke, Jana; Hellmich, Martin; Merkelbach-Bruse, Sabine; Buettner, Reinhard; Wolf, Juergen
    EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer – preliminary data on safety and tolerability
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 37, 2019, Nr. 15, S. e20577 – e20577
    DOI (Open Access)
  • Joerger, Markus; Cho, Byoung Chul; Mach, Nicolas; Caballero, Cristina; Soo, Ross A.; Wirth, Manfred; Sayehli, Cyrus; Navarro, Alejandro; Keam, Bhumsuk; Piciu, Ana-Maria; Bender, Sebastian; Nogai, Hendrik; Ellinghaus, Peter; Schuler, Martin
    Early clinical experience with the pan-FGFR inhibitor rogaratinib in patients with non-small cell lung cancer selected based on FGFR mRNA expression levels
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 37, 2019, Nr. 15, S. e20661 – e20661
    DOI (Open Access)
  • Schuler, Martin
    Integration of immune checkpoint inhibitors in the treatment of early stage lung cancer
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 42, 2019, Nr. Supplement 4: Abstracts, S. 13
    DOI (Open Access)
  • Nothdurft, S.; Breitenbücher, Frank; Okimoto, R.; Bivona, T.; Grüner, Barbara M.; Hoelzel, M.; Forster, J.; Kalmbach, S.; Schramm, Alexander; Schuler, Martin
    MA17.07 Identification of AHR as a Novel Regulator of Lung Cancer Metastasis
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 14, 2019, Nr. 10, Supplement, S. S319
    DOI (Open Access)
  • O'Byrne, K.; Yang, J.C.; Wu, Y.; Hirsh, V.; Yamamoto, N.; Popat, S.; Tamiya, A.; Märten, A.; Schuler, Martin
    P2.14-60 Afatinib in EGFR Mutation-Positive NSCLC : Activity in Patients with Brain Metastases, and Impact on CNS Progression/Spread
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 14, 2019, Nr. 10, S. 855
    DOI (Open Access)
  • Guberina, M.; Stuschke, Martin; Eberhardt, Wilfried; Gauler, Thomas; Aigner, Clemens; Schuler, Martin; Stamatis, Georgios; Dirk, T.; Jentzen, Walter; Herrmann, Ken; Pöttgen, Christoph
    Prognostic Value of Metabolic Tumor Volume after Induction Chemotherapy in Stage IIIA/B Non-Small-Cell Lung Cancer : Secondary Analysis of a Randomized Phase 3 Trial
    61st Annual Meeting of the American Society for Radiation Oncology ; September 15-18, 2019, Chicago, IL, USA,
    In: International Journal of Radiation Oncology, Biology, Physics. New York: Elsevier, Jg. 105, 2019, Nr. 1, Supplement, S. S146 – S147
    DOI (Open Access)
  • Nusch, Arnd; Decker, Thomas; Reinisch, Mattea; Hartkopf, Andreas D.; Heinrich, Bernhard; Kurbacher, Christian M.; Fuchs, Roswitha Dorothea; Tesch, Hans; Krabisch, Petra; Brucker, Sara; Fehm, Tanja N.; Janni, Wolfgang; Kümmel, Sherko; Luftner, Diana; Schneeweiss, Andreas; Schuler, Martin; Voges, Claudia; Schubert, Joerg; Fasching, Peter A.
    RIBECCA: A phase IIIb, multicenter, open label study for women with estrogen receptor-positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole—Results of the second interim analysis.
    2019 ASCO Annual Meeting, May 31 through June 4, 2019, Chicago, Ill., USA,
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 37, 2019, Nr. 15, S. 1061 – 1061
    DOI (Open Access)
  • Sebastian, M.; Schuler, Martin; Schulz, C.; Deschler-Baier, B.; Kimmich, M.; Hilgert-Daute, K.; Griesinger, F.
    Adverse events self-reported by patients with advanced non-small cell lung cancer treated with osimertinib or chemotherapy in the AURA3 trial
    33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 1, S. 111
    DOI (Open Access)
  • O'Byrne, K.; Yang, JCH; Wu, Y. L.; Hirsh, V.; Yamamoto, N.; Popat, S.; Tamiya, A.; Maerten, A.; Schuler, Martin
    Afatinib for patients with EGFR mutation-positive (EGFRm plus ) NSCLC : Activity in patients with baseline brain metastases and impact on the rate of central nervous system (CNS) progression or spread
    COSA's 45th Annual Scientific Meeting, Mesothelioma and Gastro‐Intestinal Cancers: Technology and Genomics, 13–15 November 2018, Perth Australia,
    In: Asia-Pacific Journal of Clinical Oncology: Wiley, Jg. 14, 2018, Nr. Suppl. 7, S. 159 – 160
    DOI
  • O'Byrne, K.; Yang, J. C-H; Wu, Y-L; Hirsh, V.; Yamamoto, N.; Popat, S.; Tamiya, A.; Maerten, A.; Schuler, Martin
    Central Nervous System or Systemic Progression Analysis for EGFR Mutation-Positive NSCLC Patients Receiving Afatinib in LUX-Lung 3, 6, and 7
    Konferenz Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, New Directions in Personalised Cancer Therapy; 1–3 August 2018; Adelaide, Australia,
    In: Asia-Pacific Journal of Clinical Oncology: Wiley, Jg. 14, 2018, Nr. Supplement 3, S. 69
    DOI
  • Bogner, Simon; Schmid, Kurt Werner; Metzenmacher, Martin; Hager, Thomas; Herrmann, Ken; Walter, Robert; Hegedues, Balazs; Herold, Thomas; Eberhardt, Wilfried; Reis, Henning; Goetz, Moritz; Mairinger, Fabian Dominik; Wiesweg, Marcel; Darwiche, Kaid; Aigner, Clemens; Schuler, Martin
    Development of predictors for PD-1/PD-L1-directed therapy of non-small cell lung cancer (NSCLC) by gene expression profiling of small diagnostic biopsies (DBX)
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 36, 2018, Nr. 15 Suppl., S. e15121
    DOI (Open Access)
  • Cao, J.; Wiesweg, Marcel; Fuchs, M.; Stein, A.; Karthaus, M.; Lettmaier, S.; Kretzschmar, A.; Draube, A.; Ettrich, T.; Rüssel, J.; Müller, C.; Rafiyan, M.-R.; Borchert, K.; Schuler, Martin; Kasper, Stefan
    Efficacy and safety of Trifluridin/Tipiracil (FTD/TPI) (Lonsurf (R)) in patients with metastatic colorectal cancer (CRC) in clinical-routine use
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 4, S. 289
    DOI (Open Access)
  • Slaski, C.; Kasper, Stefan; Paul, Andreas; Gerken, G.; Schmid, Kurt Werner; Meiler, Johannes; Teckelnborg, K.; Dechene, Alexander; Schumacher, B.; Markus, P.; Schuler, Martin; Virchow, I.
    Evaluation of prognostic markers in patients (pts) with advanced gastric cancer (GC) and adenocarcinoma of the gastroesophageal junction (AEG) treated with systemic chemothearpy (ctx) at the West German Cancer Center
    33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 1, S. 67
    DOI (Open Access)
  • Exner, J.-P.; Nadjm, S.; Gauler, Thomas; Pöttgen, Christoph; Krebs, B.; Cheufou, D.; Darwiche, Kaid; Metzenmacher, M.; Theegarten, Dirk; Umutlu, Lale; Hoffmann, Andreas-Claudius; Oezkan, F.; Aigner, Clemens; Taube, Christian; Schuler, Martin; Stamatis, Georgios; Stuschke, Martin; Eberhardt, Wilfried
    Long-term Survival (LT-S) and Survivorship Program (SS-P) of Lung Cancer (LC) Patients (Pts) - B : Implications for Follow-up (F-up) and Surveillance (SV)
    33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 1, S. 109 – 110
    DOI (Open Access)
  • Nadjm, S.; Exner, J. P.; Gauler, Thomas; Pöttgen, Christoph; Darwiche, Kaid; Cheufou, D.; Krebs, B.; Metzenmacher, M.; Oezkan, F.; Rebmann, Vera; Umutlu, Lale; Deuschl, C.; Li, Y.; Lahner, Harald; Christoph, Daniel; Hoiczyk, M.; Witzke, Oliver; Hoffmann, Andreas-Claudius; Aigner, Clemens; Theegarten, Dirk; Taube, Christian; Schuler, Martin; Stamatis, Georgios; Stuschke, Martin; Eberhardt, Wilfried
    Long-term Survival(LTS) and Survivorship Program(SS-P) of Lung Cancer(LC) Patients(Pts). Investigations(Invest) on LT-toxicities(Tox) and late morbidities(Morb)
    33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 1, S. 108
    DOI (Open Access)
  • Waberer, Lisa; Homann, Nils; Wirtz, Ralph M.; Schmalenberg, Harald; Haag, Georg Martin; Schuler, Martin; Kasper, Stefan; Goetze, Thorsten Oliver; Pauligk, Claudia; Hofheinz, Ralf; Al-Batran, Salah-Eddin
    PD-L1 mRNA expression in patients with resectable gastric cancer and adenocarcinoma of the oesophago-gastric junction undergoing perioperative chemotherapy : Results from the FLOT4 phase III trial of the AIO
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 36, 2018, Nr. Suppl. 15, S. e24277 – e24277
    DOI (Open Access)
  • Reis, Henning; Niedworok, Christian; Wiesweg, Marcel; Schuler, Martin; Rübben, Herbert; Hadaschik, Boris; Schmid, Kurt Werner; Szarvas, Tibor
    Potentially Targetable Molecular Alterations in 70 Cases of Urachal Cancer
    Geared to Learn ; USCAP 107th Annual Meeting ; March 17–23, 2018, Vancouver,
    In: Modern Pathology. Amsterdam: Elsevier, Jg. 31, 2018, Nr. Suppl. 2, S. 378
    DOI (Open Access)
  • Fasching, Peter A.; Nusch, Arnd; Heinrich, Bernhard; Brucker, Sara; Decker, Thomas; Kurbacher, Christian M.; Tesch, Hans; Krabisch, Petra; Mundhenke, Christoph; Fehm, Tanja N.; Janni, Wolfgang; Lueftner, Diana; Schneeweiss, Andreas; Schuler, Martin; Guderian, Gernot; Voges, Claudia; Schubert, Joerg; Kümmel, Sherko
    RIBECCA: A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole : Results of the first interim analysis
    2018 ASCO Annual Meeting, June 1-5, 2018, Chicago, Ill., USA,
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 36, 2018, Nr. 15, Supplement, 1051
    DOI (Open Access)
  • Joerger, Markus; Cassier, Philippe Alexandre; Penel, Nicolas; Cathomas, Richard; Richly, Heike; Schostak, Martin; Janitzky, Andreas; Wermke, Martin; Nogova, Lucia; Tai, David Wai-Meng; Sayehli, Cyrus; Grüllich, Carsten; Grande, Enrique; Navarro, Alejandro; Park, Se Hoon; Nogai, Hendrik; Bender, Sebastian; Ellinghaus, Peter; Schuler, Martin
    Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 36, 2018, Nr. Suppl. 15, S. 4513 – 4513
    DOI (Open Access)
  • Schuler, Martin; Cassier, P.; Penel, N.; Cathomas, R.; Richly, Heike; Schostak, M.; Janitzky, A.; Wermke, M.; Nogova, L.; Tai, D.; Sayehli, C.; Grüllich, C.; Grande, E.; Navarro, A.; Park, S. H.; Nogai, H.; Bender, S.; Ellinghaus, P.; Joerger, M.
    Rogaratinib in patients with advanced urothelial carcinomas selected for tumor FGFR mRNA expression and impact of mutations in the FGFR signaling pathway
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; Wien, 28. September - 2. Oktober 2018,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 4, S. 321
    DOI (Open Access)
  • Sayehli, Cyrus; Nogova, Lucia; Nogai, Hendrik; Park, Se Hoon; Richly, Heike; Cathomas, Richard; Wermke, Martin; Bender, Sebastian; Navarro, Alejandra; Schostak, Martin; Grande, Enrique; Cassier, Philippe; Janitzky, Andreas; Penel, Nicolas; Ellinghaus, Peter; Tai, David Wai-Meng; Gillessen, Silke; Grüllich, Carsten; Joerger, Markus; Schuler, Martin
    Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression.
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 36, 2018, Nr. 6 Suppl., S. 494
    DOI (Open Access)
  • Wiesweg, Marcel; Reis, Henning; Köster, T.; Goetz, M.; Worm, K.; Herold, T.; Paul, Andreas; Dechene, Alexander; Schumacher, B.; Markus, P.; Virchow, I.; Kostbade, K.; Wolf, N.; Zaun, G.; Metzenmacher, M.; Schmid, Kurt Werner; Schuler, Martin; Kasper, Stefan
    Signaling network activation in colorectal cancer : p70S6K phosphorylation as a prognostic marker
    33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 1, S. 55
    DOI (Open Access)
  • Stein, G.; Stelmach, Patrick; Kasper, Stefan; Paul, Andreas; Wedemeyer, Heiner H.; Schmid, Kurt Werner; Schumacher, B.; Markus, P.; Siffert, Winfried; Schuler, Martin; Bachmann, Hagen Sjard; Virchow, I.
    The prognostic impact of UDP-glucuronyltransferase 1A1*1 (UGT1A1*1) polymorphism in patients with advanced colorectal and non-colorectal cancer treated with irinotecan-based systemic chemotherapies
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 4, S. 122 – 123
    DOI (Open Access)
  • Schuler, Martin; Nogova, L.; Heidenreich, A.; Tai, D.; Cassier, P.; Richly, Heike; Cho, B. C.; Sayehli, C. M.; Navarro, A.; Bender, Stefan; Ocker, M.; Nogai, H.; Wagner, A.; Ince, S.; Ellinghaus, P.; Joerger, M.
    Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 28, 2017, Nr. Suppl. 5
  • Schuler, Martin
    Liquid Biopsies for Dynamic Monitoring of EGFR Mutations in Lung Cancer
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 12, 2017, Nr. 1, Suppl., S. 85
  • Schmidt-Wetzel, S; Decker, T; Kuemmel, Sherko; Lueftner, D; Fasching, PA; Schneeweiss, A; Brucker, S; Schuler, Martin; Janni, W; Guderian, G; Fehm, T; Schubert, J; Reiners, R
    RIBECCA - A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole
    2016 San Antonio Breast Cancer Symposium, December 6-10, 2016, San Antonio, Texas, USA,
    In: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 77, 2017, Nr. 4, Supplement, OT2-01-18
    DOI
  • Lückerath, M.; Kasper, Stefan; Paul, Andreas; Gerken, Guido; Schmid, Kurt Werner; Meiler, Johannes; Wiesweg, M.; Neuhaus, I.; Dechene, Alexander; Mende, B.; Schumacher, B.; Markus, P.; Schuler, Martin; Virchow, I.
    Evaluation of prognostic markers in patients (pts) with metastatic colorectal cancer (mCRC) treated with a bevacizumab (bev) based chemotherapy (ctx) at the West German Cancer Center
    Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 39, 2016, Nr. Suppl. 1, S. 77
    DOI
  • Pogorzelski, M.; Hilser, T.; Ting, Saskia; Vossebein, I.; Gauler, Thomas; Abendroth, A.; Lang, Stephan; Stuck, Boris; Abu-Jawad, J.; Stuschke, Martin; Schmid, Kurt Werner; Schuler, Martin; Kasper, Stefan
    Evaluation of systemic inflammatory response (SIR) markers in recurrent or metastatic head and neck squamous cell carcinoma (r/m HNSCC)
    In: Oncology Research and Treatment. Basel: Karger, Jg. 39, 2016, Nr. Suppl. 3, S. 307 – 308
    DOI
  • Abendroth, A.; Markus, M.; Abramczyk, M.; Noureddine, R.; Paul, Andreas; Gerken, Guido; Schmid, Kurt Werner; Markus, P.; Schumacher, B.; Meiler, Johannes; Wiesweg, M.; Kaiser, Gernot Maximil; Dechene, Alexander; Trarbach, Tanja; Schuler, Martin; Kasper, Stefan
    Evaluation of systemic inflammatory response (SIR) markers in advanced biliary tract cancer (ABTC)
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 38, 2015, Nr. Suppl. 5, S. 5 – 6
    DOI
  • Markus, M.; Kasper, Stefan; Noureddine, R.; Abramczyk, M.; Paul, Andreas; Gerken, Guido; Schmid, Kurt Werner; Markus, P.; Schumacher, B.; Meiler, Johannes; Wiesweg, M.; Kaiser, Gernot Maximil; Dechene, Alexander; Trarbach, Tanja; Schuler, Martin; Abendroth, A.
    Evaluation of systemic inflammatory response (SIR) markers in pancreatic ductal adenocarcinoma (PDAC)
    In: Oncology Research and Treatment. Basel: Karger, Jg. 38, 2015, Nr. S 5, Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz, S. 4 – 5
    DOI
  • Thomas, M.; Schuler, Martin; Potzner, M.; Szczudlo, T.; Sutradhar, S.; Yovine, A.; Wolf, J.
    Experience from the ASCEND-1 trial : Ceritinib in patients (Pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) and brain metastases
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 38, 2015, Nr. Suppl. 5, S. 270
    DOI
  • Pöttgen, Christoph; Stuschke, Martin; Gauler, Thomas; Welter, Stefan; Schuler, Martin; Stamatis, Georgios; Eberhardt, Wilfried
    Hirnmetastasen bei Patienten mit lokal fortgeschrittenem NSCLC nach multimodaler kurativer Therapie in einem randomisierten Protokoll : prognostische Faktoren
    21. Jahrestagung der Deutschen Gesellschaft für Radioonkologie, 25. Juni 2015, Hamburg,
    In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics. Heidelberg: Springer, Jg. 191, 2015, Nr. Suppl. 1, S. 36 – 37
    DOI
  • Falkenhorst, J.; Treckmann, Jürgen-Walter; Nguyen, B. P.; Podleska, Lars; Reis, A. C.; Virchow, I.; Schuler, Martin; Bauer, Sebastian
    Longitudinal analysis of the impact of the introduction of tyrosine kinase inhibitor therapy on overall survival of patients with gastrointestinal stromal tumors treated at the West German Cancer Center
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 38, 2015, Nr. Suppl. 5, S. 167 – 167
    DOI
  • Abendroth, A.; Noureddine, R.; Abramczyk, M.; Paul, Andreas; Gerken, Guido; Schmid, Kurt Werner; Markus, P.; Meiler, Johannes; Wiesweg, M.; Dechene, Alexander; Schumacher, B.; Kaiser, Gernot Maximil; Schuler, Martin; Kasper, Stefan
    Prognostische Faktoren bei Patienten mit fortgeschrittenen Pankreaskarzinomen, die am Westdeutschen Tumorzentrum (WTZ) sequentielle Chemotherapien erhalten haben
    121. Kongress der Deutschen Gesellschaft für Innere Medizin ; DGIM 2015 ; 18. - 21. April 2015, Mannheim, Germany,
    In: Der Internist. Berlin: Springer Medizin, Jg. 56, 2015, Nr. Supplement 1: Abstracts zum 121. Kongress der Deutschen Gesellschaft für Innere Medizin e.V., S. 38 – 39
    DOI
  • Abendroth, A.; Abramczyk, M.; Noureddine, R.; Paul, Andreas; Gerken, Guido; Schmid, Kurt Werner; Baba, Hideo Andreas; Meiler, Johannes; Wiesweg, M.; Kaiser, Gernot Maximil; Bockisch, Andreas; Dechene, Alexander; Forsting, Michael; Schuler, Martin; Kasper, Stefan
    Prognostische Faktoren bei Patienten mit fortgeschrittenen cholangiozellulären Karzinomen, die am Westdeutschen Tumorzentrum (WTZ) sequentielle Chemotherapien erhalten haben
    121. Kongress der Deutschen Gesellschaft für Innere Medizin ; DGIM 2015 ; 18. - 21. April 2015, Mannheim, Germany,
    In: Der Internist. Berlin: Springer Medizin, Jg. 56, 2015, Nr. Supplement 1: Abstracts zum 121. Kongress der Deutschen Gesellschaft für Innere Medizin e.V., S. 37
    DOI
  • Pöttgen, Christoph; Graupner, B.; Theegarten, Dirk; Gauler, Thomas; Jendrossek, Verena; Freitag, Lutz; Abu Jawad, Jehad; Gkika, E.; Wohlschläger, Jeremias; Welter, Stefan; Hoiczyk, M.; Schuler, Martin; Stamatis, Georgios; Eberhardt, Wilfried; Stuschke, Martin
    Rekursive Partitions-Analyse prognostischer Faktoren für das Langzeit-Überleben nach trimodaler Therapie von Patienten mit lokal fortgeschrittenem NSCLC
    21. Jahrestagung der Deutschen Gesellschaft für Radioonkologie, 25. Juni 2015, Hamburg,
    In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics. Heidelberg: Springer, Jg. 191, 2015, Nr. Suppl. 1, S. 23
    DOI
  • Virchow, I.; Podleska, Lars; Pöttgen, Christoph; Reis, A. C.; Steinau, H. U.; Täger, Georg; Farzaliyev, F.; Schuler, Martin; Bauer, Sebastian
    Solitary fibrous tumors/haemangiopericytoma : Analysis of prognostic factors of 28 patients from a high volume sarcoma center
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 38, 2015, Nr. Suppl. 5, S. 246
    DOI
  • Mertins, S.; Virchow, I.; Farzaliyev, F.; Geismar, Dirk; Podleska, Lars; Pöttgen, Christoph; Reis, A. C.; Steinau, H. U.; Stuschke, Martin; Täger, Georg; Treckmann, Jürgen-Walter; Schuler, Martin; Bauer, Sebastian
    TNM-classification for clear cell sarcomas - is it useful?
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 38, 2015, Nr. Suppl. 5, S. 247 – 248
    DOI
  • Hoiczyk, M.; Herbrik, M.; Grabellus, Florian; Podleska, Lars; Pöttgen, Christoph; Schwindenhammer, B.; Bekas, V.; Schuler, Martin; Bauer, Sebastian
    Brain metastases in sarcoma patients : Incidence and outcome
    2014 ASCO Annual Meeting, 30 May to 3 June 2014, Chicago, Ill., USA,
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 32, 2014, Nr. 15, Suppl., 10591
    DOI
  • Kasper, Stefan; Meiler, Johannes; Knipp, Heike; Hohler, T.; Reimer, P.; Steinmetz, T.; Berger, W.; Linden, G.; Ting, Saskia; Markus, P.; Paul, Andreas; Dechene, Alexander; Kostbade, K.; Schuler, Martin; Trarbach, Tanja
    Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) - Primary endpoint analysis of the CEBIFOX trial
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 5, S. 99 – 100
    DOI
  • Köhler, Jens; Schuler, Martin; Gauler, Thomas; Nopel-Dunnebacke, S.; Hoffmann, Andreas-Claudius; Kasper, Stefan; Nensa, Felix; Gomez, Benedikt; Hahnemann, M.; Breitenbücher, Frank; Cheufou, D.; Ozkan, F.; Darwiche, Kaid; Hoiczyk, M.; Welter, Stefan; Eberhardt, Wilfried; Teschler, Helmut; Stamatis, Georgios; Hahn, S. A.; Baraniskin, A.
    Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 5, S. 226 – 227
    DOI
  • Gauler, Thomas; Nel, I.; Bublitz, K.; Lazaridis, L.; Schuler, Martin; Hoffmann, Andreas-Claudius
    Circulating tumor cell composition and molecular markers in metastasized renal cell carcinoma (mRCC)
    31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 1, S. 131
    DOI
  • Jehn, U.; Nel, I.; Schuler, Martin; Gauler, Thomas; Hoffmann, Andreas-Claudius
    Circulating tumor cell subgroups and outcome in patients with non-small-cell-lung-cancer receiving platinum based treatment
    31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 1, S. 89
    DOI
  • Thomas, M.; Wolf, J.; Schuler, Martin; Goldwasser, M.; Boral, A.; Shaw, A. T.
    Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC
    31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 1, S. 89 – 90
    DOI
  • Gauler, Thomas; Espenhain, Lydia; Hoiczyk, Mathias; Nel, Ivonne; Parr, Annette; Roder, Joanna; Schuler, Martin H.; Eberhardt, Wilfried E. E.; Roder, Heinrich; Hoffmann, Andreas-Claudius
    Correlation of proteomics and first-line platinum-based chemotherapy in stage NSCLC in a large single-center cohort
    50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30-June 3, 2014, Chicago, Illinois, USA,
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 32, 2014, Nr. 15 Suppl.
    DOI
  • Stuschke, Martin; Pöttgen, Christoph; Gauler, Thomas; Friedel, G.; Veit, S.; Heinrich, V.; Welter, Stefan; Spengler, W.; Schmidberger, H.; Lutke-Brintrup, D.; Lehmann, Nils; Jöckel, Karl-Heinz; Schuler, Martin; Stamatis, Georgios; Eberhardt, Wilfried
    Definitive Hyperfractionated Accelerated (AHF) Radiochemotherapy (CRT) Versus Neoadjuvant AHF-CRT and Surgery (S) for Patients (pts) With Operable Stage IIIA(N2)/Selected IIIB Non-small-Cell Lung Cancer (NSCLC) Following Induction Chemotherapy (IND-C) : Results From a Multicenter Phase III Study
    56th Annual Meeting of the American Society for Radiation Oncology ; 14-17 September 2014, San Francisco, CA, USA,
    In: International Journal of Radiation Oncology, Biology, Physics. New York: Elsevier, Jg. 90, 2014, Nr. 1, Supplement, S. S146 – S147
    DOI
  • Stuschke, Martin; Pöttgen, Christoph; Gauler, Thomas; Friedel, G.; Veit, S.; Heinrich, V.; Gkika, E.; Hepp, R.; Welter, Stefan; Spengler, W.; Schmidberger, H.; Lutke-Brintrup, D.; Lehmann, Nils; Jöckel, Karl-Heinz; Schuler, Martin; Stamatis, Georgios; Eberhardt, Wilfried
    Definitive accelerated-hyperfractionated (AHF) Chemoradiotherapy (CRT) vs. neoadjuvant AHF-CRT and Surgery (S) for Patients with operable NSCLC in Stage IIIA(N2)/IIIB after Induction Chemotherapy (IND-C) : Results of a randomized Multicentre Study
    20. Jahreskongress der Deutschen Gesellschaft für Radioonkologie (DEGRO), 3. bis 6. Juli 2014, Düsseldorf,
    In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics. Heidelberg: Springer, Jg. 190, 2014, Nr. Suppl. 1, S. 5 – 6
    DOI
  • Grunewald, Susanne; Mühlenberg, Thomas; Rubin, B.; Schuler, Martin; Fletcher, J. A.; Bauer, Sebastian
    Effect of secondary KIT mutations on growth of GIST cells in the absence of selective pressure by imatinib in isogenic models of imatinib resistance
    2014 ASCO Annual Meeting, 30 May to 3 June 2014, Chicago, Ill., USA,
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 32, 2014, Nr. 15, Suppl., 10555
    DOI
  • Kim, D.; Mehra, R.; Tan, DSW; Felip, E.; Chow, LQM; Camidge, D. R.; Vansteenkiste, J.; Sharma, S.; De Pas, T.; Riely, G. J.; Solomon, B. J.; Wolf, J.; Thomas, M.; Schuler, Martin; Liu, G.; Santoro, A.; Geraldes, M.; Boral, A. L.; Yovine, A.; Shaw, A. T.
    Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) : An Update of ASCEND-1: Metastatic Non-Small Cell Lung Cancer
    2014 Chicago Multidisciplinary Symposium in Thoracic Oncology ; 30 October-1 November 2014, Chicago, Illinois, USA,
    In: International Journal of Radiation Oncology, Biology, Physics. New York: Elsevier, Jg. 90, 2014, Nr. 5, Supplement, S. S33 – S34
    DOI
  • Wu, Y.; Geater, S. L.; Mok, T.; OByrne, K. J.; Schuler, Martin; Sequist, L. V.; Yang, J. C.; Massey, D.; OBrien, D.; Zazulina, V.
    Epidermal Growth Factor Receptor (EGFR)-Mediated Adverse Events (AEs) in Patients (pts) With EGFR-Mutation Positive (EGFR M+) Non-Small Cell Lung Cancer (NSCLC) Treated With Afatinib (A) : Metastatic Non-Small Cell Lung Cancer
    2014 Chicago Multidisciplinary Symposium in Thoracic Oncology ; 30 October-1 November 2014, Chicago, Illinois, USA,
    In: International Journal of Radiation Oncology, Biology, Physics. New York: Elsevier, Jg. 90, 2014, Nr. 5, Supplement, S. S41
    DOI
  • Gauler, Thomas; Pogorzelski, M.; Ting, Saskia; Breitenbücher, Frank; Vossebein, I.; Hoffarth, S.; Lang, Stephan; Bergmann, Christoph; Abu Jawad, Jehad; Markowetz, J.; Schmid, Kurt Werner; Schuler, Martin; Kasper, Stefan
    Impact of human papilloma virus infection on the response of head and neck cancers (HNSCC) to anti-epidermal growth factor receptor (EGFR) antibody therapy
    31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 1, S. 76
    DOI
  • Kasper, Stefan; Ting, Saskia; Meiler, Johannes; Knipp, Heike; Hohler, T.; Reimer, P.; Steinmetz, T.; Berger, W.; Linden, G.; Worm, K.; Schmid, Kurt Werner; Markus, P.; Paul, Andreas; Dechene, Alexander; Forsting, Michael; Kostbade, K.; Trarbach, Tanja; Schuler, Martin
    Molecular and clinical predictors of the efficacy of cetuximab in combination with mFOLFOX6 in 1st line treatment of patients (pts) with metastatic colorectal cancer (mCRC) : subgroup analyses of the CEBIFOX trial
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 5, S. 100 – 101
    DOI
  • Kasper, Stefan; Abendroth, A.; Abramczyk, M.; Noureddine, R.; Paul, Andreas; Gerken, Guido; Schmid, Kurt Werner; Markus, P.; Meiler, Johannes; Wiesweg, M.; Kaiser, Gernot Maximil; Dechene, Alexander; Schuler, Martin
    Outcome of patients (pts) with advanced pancreaticobiliary cancers treated with sequential chemotherapies at the West German Cancer Center (WTZ)
    Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 1, S. 51
    DOI
  • Sequist, L.; Wu, Y.; Schuler, Martin; OByrne, K.; Sebastian, M.; Popat, S.; Boyer, M.; Mok, T.; Yamamoto, N.; Hirsh, V.; Geater, S. L.; Zhou, C.; Massey, D.; Zazulina, V.; Jones, H.; Yang, J.
    Overall Survival (OS) With Afatinib Versus Chemotherapy in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Common (Del19/L858R) Epidermal Growth Factor Receptor Mutations (EGFR Mut) : Results of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6): Metastatic Non-Small Cell Lung Cancer
    2014 Chicago Multidisciplinary Symposium in Thoracic Oncology ; 30 October-1 November 2014, Chicago, Illinois, USA,
    In: International Journal of Radiation Oncology, Biology, Physics. New York: Elsevier, Jg. 90, 2014, Nr. 5, Supplement, S. S5 – S6
    DOI
  • Welt, Anja; Kasper, Stefan; Tewes, Mitra; Aktas, B.; Hoffmann, Oliver; Wiesweg, M.; Ting, Saskia; Reis, Henning; Worm, K.; Richly, Heike; Hense, Jörg; Palmer, M. R.; Lee, B. H.; Wendling, J.; Kossow, J.; Scheulen, Max Ernst; Lehnerdt, C.; Kohl, M.; Derks, C.; Slottky, S.; Haus, U.; Schmid, Kurt Werner; Kimmig, Rainer; Schuler, Martin
    Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 1: 31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie Berlin, 19.-22. Februar 2014: Abstracts, S. 19
    DOI (Open Access)
  • Abendroth, A.; Abramczyk, M.; Nourredine, R.; Paul, A.; Gerken, Guido; Schmid, Kurt Werner; Baba, Hideo Andreas; Meiler, Johannes; Wiesweg, M.; Kaiser, Gernot Maximil; Dechene, Alexander; Bockisch, Andreas; Forsting, Michael; Schuler, Martin; Kasper, Stefan
    Prognostic factors in patients (pts) with advanced cholangiocellular carcinoma (CCC) receiving sequential chemotherapies (CTX) at the West German Cancer Center (WTZ)
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 5, S. 122 – 123
    DOI
  • Abendroth, A.; Nourredine, R.; Abramczyk, M.; Paul, A.; Gerken, Guido; Schmid, Kurt Werner; Markus, P.; Meiler, Johannes; Wiesweg, M.; Kaiser, Gernot Maximil; Dechene, Alexander; Schuler, Martin; Kasper, Stefan
    Prognostic factors in patients with pancreatic cancer receiving sequential chemotherapies (CTX) at the West German Cancer Center (WTZ), one of the 12 Oncology Centers of Excellence in Germany
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 5, S. 123 – 124
    DOI
  • Pöttgen, Christoph; Graupner, B.; Theegarten, Dirk; Gauler, Thomas; Kleinhans, J.; Jendrossek, Verena; Freitag, Lutz; Abu Jawad, Jehad; Gkika, E.; Wohlschläger, Jeremias; Welter, Stefan; Hoiczyk, M.; Schuler, Martin; Stamatis, Georgios; Eberhardt, Wilfried; Stuschke, Martin
    Prognostisches Modell für das Langzeit-Überleben von Patienten mit lokal fortgeschrittenem nicht-kleinzelligen Lungenkarzinom (NSCLC) nach neoadjuvanter Radiochemotherapie (RT/CT) und Resektion
    20. Jahreskongress der Deutschen Gesellschaft für Radioonkologie (DEGRO), 3. bis 6. Juli 2014, Düsseldorf,
    In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics. Heidelberg: Springer, Jg. 190, 2014, Nr. Suppl 1, S. 17
    DOI
  • Schuler, Martin; Sequist, L. V.; Yang, J. C.; Yamamoto, N.; OByrne, K. J.; Mok, T.; Geater, S. L.; Massey, D.; Wind, S.; OBrien, D.; Lorence, R.; Wu, Y. L.
    Safety profile of afatinib in first-line therapy of patients with metastatic EGFR mutation-positive (M plus ) non-small cell lung cancer (NSCLC) : Comparative analysis of Asian and non-Asian patients from two randomized trials
    31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 1, S. 90
    DOI
  • Richly, Heike; Scheulen, Max Ernst; Wiesweg, Marcel; Abendroth, A.; Schuler, Martin; Bauer, Sebastian
    Systemic treatment of metastatic uveal melanoma - a silver lining on the horizon?
    31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin, Germany,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 1, 31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie Berlin, 19.-22. Februar 2014: Abstracts, S. 118 – 119
    DOI
  • Nogova, L.; Gardizi, M.; Bos, M.; Scheffler, M.; Papachristou, I.; Wompner, C.; Heukamp, L.; Schildhaus, H. U.; Fuhr, U.; Sos, M.; Eberhardt, Wilfried; Wiesweg, Marcel; Schmid, Kurt Werner; Schuler, Martin; Thomas, R.; Buttner, R.; Wolf, J.
    TRY : A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation
    31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 1, S. 92
    DOI
  • Nogova, Lucia; Gardizi, Masyar; Bos, Marc Christiaan Allardt; Scheffler, Matthias; Mattonet, Christian; Heukamp, Lukas Carl; Schildhaus, Hans-Ulrich; Fuhr, Uwe; Eberhardt, Wilfried; Reis, Henning; Wiesweg, Marcel; Schmid, Kurt Werner; Schoch, Gernot; Ko, Yon-Dschun; Serke, Monika Heidi; Schuler, Martin H.; Büttner, Reinhard; Wolf, Jürgen
    TRY : A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 32, 2014, Nr. 15, Suppl., S. 8109
    DOI
  • Mühlenberg, T.; Grunewald, S.; Schuler, Martin; Bauer, Sebastian
    Targeting glucose metabolism by 2-deoxyglucose in gastrointestinal stromal tumors
    In: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 74, 2014, Nr. 19, Suppl., 3375
    DOI
  • Pöttgen, Christoph; Graupner, B.; Theegarten, Dirk; Gauler, Thomas; Freitag, Lutz; Abu Jawad, Jehad; Gkika, E.; Wohlschläger, Jeremias; Welter, Stefan; Hoiczyk, M.; Schuler, Martin; Stamatis, Georgios; Eberhardt, Wilfried; Stuschke, Martin
    Vergleich von pCR und mediastinalem Downstaging als Surrogat- Marker für das Langzeit-Überleben von Patienten mit lokal fortgeschrittenem nicht-kleinzelligen Lungenkarzinom (NSCLC) nach neoadjuvanter Radiochemotherapie (RT/CT) und Resektion (Trimodalität)
    20. Jahreskongress der Deutschen Gesellschaft für Radioonkologie (DEGRO), 3. bis 6. Juli 2014, Düsseldorf,
    In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics. Heidelberg: Springer, Jg. 190, 2014, Nr. Suppl. 1, S. 17
    DOI
  • Wiesweg, Marcel; Ting, Saskia; Reis, Henning; Worm, K.; Kasper, Stefan; Bauer, Sebastian; Gauler, Thomas; Welt, Anja; Richly, Heike; Tewes, Mitra; Meiler, Johannes; Hense, Jörg; Eberhardt, Wilfried; Derks, Christian; Cortes-Incio, D.; Skottky, S.; Wohlschläger, Jeremias; Breitenbucher, F.; Freitag, Lutz; Stamatis, Georgios; Schmid, Kurt Werner; Schuler, Martin
    WTZ-Tumorprofil-A preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer Center : Two years experience
    31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin, Germany,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 1, S. 2 – 3
    DOI
  • Yang, J. C.; Sequist, L. V.; Geater, S. L.; Tsai, C. M.; Mok, TSK; Schuler, Martin; Yamamoto, N.; Massey, D.; Zazulina, V.; Wu, Y. L.
    Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations : findings from three trials of afatinib in EGFR mutation-positive lung cancer
    15th World Conference on Lung Cancer, October 27 - 30 2013, Sydney, Australia,
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 8, 2013, Nr. Suppl. 2, S. 141
    DOI
  • Hoiczyk, M.; Herbrik, M.; Grabellus, Florian; Podleska, Lars; Pöttgen, Christoph; Schuler, Martin; Bauer, Sebastian
    Brain metastases in soft tissue sarcoma patients - incidence, prognosis and outcome
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,
    In: Onkologie. Basel: Karger, Jg. 36, 2013, Nr. Suppl. 7, S. 181
    DOI
  • Sequist, L. V.; Yang, J. C.; Yamamoto, N.; OByrne, K.; Schuler, Martin; Mok, T.; Geater, S. L.; Massey, D.; Wind, S.; OBrien, D.; Lorence, R.; Wu, Y. L.
    Comparative safety profile of afatinib in asian and non-asian patients with EGFR mutation-positive (EGFR M plus) non-small cell lung cancer (NSCLO)
    15th World Conference on Lung Cancer, October 27 - 30 2013, Sydney, Australia,
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 8, 2013, Nr. Suppl. 2, S. 1197
    DOI (Open Access)
  • Schuler, Martin; Yang, J. C.; Sequist, L. V.; Hirsh, V.; OByrne, K.; Yamamoto, N.; Massey, D.; Shahidi, M.; Zazulina, V.; Mok, T.
    Effiacy of afatinib vs. chemotherapy in treatment-naive patients with non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations with or without metastatic brain disease
    15th World Conference on Lung Cancer, October 27 - 30 2013, Sydney, Australia,
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 8, 2013, Nr. Suppl. 2, S. S299 – S300
    DOI (Open Access)
  • Kasper, Stefan; Breitenbücher, Frank; Markowetz, J.; Reis, Henning; Ting, Saskia; Worm, K.; Meiler, Johannes; Schmid, Kurt Werner; Trarbach, Tanja; Schuler, Martin
    Molecular dissection of effector mechanisms of RAS-induced resistance to monoclonal anti-EGFR antibodies
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,
    In: Onkologie. Basel: Karger, Jg. 36, 2013, Nr. Suppl. 7, S. 116 – 117
    DOI
  • Abendroth, A.; Abramczyk, M.; Paul, Andreas; Gerken, Guido; Schmid, Kurt Werner; Markus, P.; Meiler, Johannes; Tometten, M.; Wiesweg, Marcel; Kaiser, Gernot Maximil; Dechene, Alexander; Trarbach, Tanja; Schuler, Martin; Kasper, Stefan
    Outcome of patients (pts) with advanced pancreaticobiliary cancers treated with sequential chemotherapies at the West German Cancer Center (WTZ), one of the 11 Oncology Centers of Excellence in Germany
    17 Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,
    In: Onkologie. Basel: Karger, Jg. 36, 2013, Nr. Suppl. 7, S. 263
    DOI
  • Tewes, Mitra; Kasper, Stefan; Aktas, B.; Hoffmann, A.; Wiesweg, M.; Ting, Saskia; Reis, Henning; Worm, K.; Richly, Heike; Hense, Jörg; Kern, P.; Scheulen, Max Ernst; Skottky, S.; Peters, M.; Schlegel, R.; Lee, B. H.; Palmer, M. R.; Monahan, J. E.; Haus, U.; Schmid, Kurt Werner; Kimmig, Rainer; Schuler, Martin; Welt, Anja
    Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastastic breast cancer patients
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 36, 2013, Nr. Suppl. 7, S. 157
    DOI
  • Nel, I.; Gauler, Thomas; Nickel, A.; Eberhardt, Wilfried; Thomale, Jürgen; Schuler, Martin; Hoffmann, A.
    Prä-therapeutische ex-vivo Reparatur Kinetiken von Cisplatin-DNA-Addukten in Zirkulierenden Tumorzellen als Platin-Resistenz Test
    119. Kongress der Deutschen Gesellschaft für Innere Medizin e.V., 06. - 09. April 2013, Wiesbaden,
    In: Der Internist. Berlin: Springer Medizin, Jg. 54, 2013, Nr. Suppl. 1, S. 95 – 96
    DOI
  • Nogova, L.; Gardizi, M.; Bos, MCA; Scheffler, M.; Papachristou, I.; Wompner, C.; Heukamp, L. C.; Schildhaus, H. U.; Fuhr, U.; Sos, M. L.; Eberhardt, Wilfried; Wiesweg, Marcel; Schmid, Kurt Werner; Schuler, Martin; Thomas, R. K.; Buttner, R.; Wolf, J.
    TRY : A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation
    In: Onkologie. Basel: Karger, Jg. 36, 2013, Nr. Suppl. 7, S. 30
    DOI
  • Mühlenberg, Thomas; Grunewald, S.; Schuler, Martin; Bauer, Sebastian
    Targeting glucose metabolism by 2-Deoxyglucose in Gastrointestinal Stromal Tumors
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,
    In: Onkologie. Basel: Karger, Jg. 36, 2013, Nr. Suppl. 7, S. 246
    DOI
  • Nogova, L.; Bos, M.; Gardizi, M.; Scheffler, M.; Papachristou, I.; Wompner, C.; Heukamp, L. C.; Schildhaus, H.; Fuhr, U.; Sos, M. L.; Eberhardt, Wilfried; Wiesweg, Marcel; Schmid, Kurt Werner; Schuler, Martin; Buttner, R.; Wolf, J.
    Try : a phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 8, 2013, Nr. Suppl. 2, S. S914 – S915
    DOI (Open Access)
  • Wolf, Jürgen; LoRusso, Patricia M.; Camidge, Ross D.; Perez, Jose Manuel; Tabernero, Josep; Hidalgo, Manuel; Schuler, Martin; Tian, Gary G.; Soria, Jean Charles; Delord, Jean Pierre; Campone, Mario; Bachelot, Thomas; van der Noll, Ruud; Ringeisen, Francois P.; Nogova, Lucia; Sequist, Lecia V.; Schellens, Jan H. M.
    A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors
    In: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 72, 2012, Nr. 8, Suppl., S. LB – 122
    DOI
  • Scheulen, Max Ernst; Richly, Heike; Kalkavan, H.; Hoffmann, Andreas-Claudius; Virchow, I.; Hilger, Ralf A.; Koeppen, Susanne; Sure, Ulrich; Schuler, Martin; Hense, Jörg
    An investigator-initiated monocentric phase I dose escalation trial of temsirolimus and irinotecan (TEMIR) in patients with relapsing glioblastoma multiforme (reGBM)
    48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, 2012, Chicago, Ill., USA,
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 30, 2012, Nr. 15, Suppl., 2086
    DOI
  • Ölschläger, K.; Grabellus, Florian; Schnell, R.; Geffken, M.; Hoiczyk, M.; Ahrens, M.; Podleska, Lars; Täger, G.; Treckmann, Jürgen-Walter; Pöttgen, Christoph; Schuler, Martin; Bauer, Sebastian
    Chemotherapy in resectable sarcomas with complex karyotypes - a single center retrospective analysis
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 19.-23. Oktober 2012, Stuttgart, Germany,
    In: Onkologie. Basel: Karger, Jg. 35, 2012, Nr. Suppl. 6, S. 150 – 150
    DOI
  • Christoph, Daniel C.; Asuncion, Bernadette Reyna; Wynes, Murry; Gauler, Thomas C.; Wohlschläger, Jeremias; Theegarten, Dirk; Welter, Stefan; Tran, Cindy; Hassan, Biftu; Loewendick, Heike; Peglow, Anja; Schuler, Martin; Eberhardt, Wilfried; Hirsch, Fred R.
    Folylpoly-α-glutamate synthetase and thymidylate synthase are associated with clinical outcome from pemetrexed-based therapy in advanced non-small cell lung cancer (NSCLC)
    In: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 72, 2012, Nr. 8, Suppl., S. 1713
    DOI
  • Simon, Susanne; Fererra, Loretta; Galietta, Luis; Grabellus, Florian; Breitenbücher, Frank; Schuler, Martin; Fletcher, Jonathan; Bauer, Sebastian
    Functional characterization of DOG1 in Gastrointestinal Stromal Tumors (GIST)
    In: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 72, 2012, Nr. 8, Suppl., S. 1824
    DOI
  • Köhler, Jens; Worm, K.; Gauler, Thomas; Hoiczyk, M.; Theegarten, Dirk; Eberhardt, Wilfried; Hense, Jörg; Breitenbücher, Frank; Schmid, Kurt Werner; Schuler, Martin
    Impact of EGFR mutation status on clinical benefit from BIBW 2992 in patients (PTS) with advanced non-small lung cancer (NSCLC) progressing after chemotherapy (CTX) and erlotinib (E) or gefitinib (G) : a single center experience
    37th ESMO Congress, 28 September - 2 October 2012, Vienna, Austria,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 23, 2012, Nr. Suppl. 9, S. 437 – 438
    DOI
  • Falkenhorst, Johanna; Mühlenberg, Thomas; Simon, Susanne; Ecken, Sonja; Henze, Jörn; Grabellus, Florian; Breitenbücher, Frank; Schuler, Martin; Fletcher, Jonathan A.; Bauer, Sebastian
    Inhibitors of apoptosis (IAPs) in gastrointestinal stromal tumors
    In: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 72, 2012, Nr. 8, Suppl., S. 3855 – 3855
    DOI
  • Schuler, Martin; Yang, James Chih-Hsin; Yamamoto, Nobuyuki; O’Byrne, Ken; Hirsh, Vera; Mok, Tony; Massey, Dan; Zazulina, Victoria; Shahidi, Mehdi; Sequist, Lecia
    LUX-lung 3 : A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations
    In: Lung Cancer. Amsterdam: Elsevier, Jg. 77, 2012, Nr. Suppl. 1, S. S25 – S26
    DOI
  • Philipps, E. S.; Mühlenberg, Thomas; Simon, S.; Ecken, S.; Grabellus, Florian; Täger, Georg; Schuler, Martin; Bauer, Sebastian
    Inhibition of the Ras/Raf/MAPK-pathway in GIST : Therapeutic potential?
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 30.09.–04.10. 2011, Basel, Switzerland,
    In: Onkologie. Basel: Karger, Jg. 34, 2011, Nr. Suppl. 6, S. 235 – 235
    DOI
  • Hoiczyk, M.; Grabellus, Florian; Täger, Georg; Schuler, Martin; Bauer, Sebastian
    Trabectedin in heavily pretreated and elderly metastatic soft tissue sarcomas - a single center experience
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 30.09.–04.10. 2011, Basel, Switzerland,
    In: Onkologie. Basel: Karger, Jg. 34, 2011, Nr. Suppl. 6, S. 237 – 237
    DOI
  • Markova, B.; Hahnel, P. S.; Herbertz, S.; Schuler, Martin; Breitenbücher, Frank
    Influence of Everolimus and Pemetrexed on Thymidylate Synthase expression as well as on Proliferation and survival of non-small cell ling Cancer Cells
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 5, 2010, Nr. Suppl. 1, S. S56 – S57
    DOI
  • Nguyen, B. P.; Grabellus, Florian; Hoiczyk, M.; Täger, Georg; Schuler, Martin; Bauer, Sebastian
    Metastasectomy in patients with GIST in the era of imatinib - improved survival?
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 1.–5. Oktober 2010, Berlin, Germany,
    In: Onkologie. Basel: Karger, Jg. 33, 2010, Nr. Suppl. 6, S. 108
    DOI
  • Even, A.; Kasper, Stefan; Breitenbucher, F.; Pogorzelski, M.; Hoffarth, S.; Trarbach, Tanja; Schuler, Martin
    Targeting NF-kappa B and PLK-1 to overcome RAS-mediated resistance to anti-EGFR antibody therapy in colorectal cancer
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,
    In: Onkologie. Basel: Karger, Jg. 33, 2010, Nr. Suppl. 6, S. 33
    DOI
  • Hoffmann, Andreas-Claudius; Gauler, Thomas; Parr, A.; Eberhardt, Wilfried; Schuler, Martin
    Use of ERCC1 expression levels in circulating tumor cells to predict to response to platinum-based chemotherapy in patients with non-small cell lung cancer
    2010 ASCO Annual Meeting, June 4-8, 2010, Chicago, Ill., USA,
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 28, 2010, Nr. 15, Suppl., 7512

    • Beiträge in Sammelwerken und Tagungsbänden

  • Taube, Christian; Schuler, Martin
    Apoptosis in the Physiology and Diseases of the Respiratory Tract
    In: Apoptosis: Physiology and Pathology / Reed, John; Green, Douglas R.. Cambridge: Cambridge University Press, 2011, S. 221 – 230
    DOI

    • Poster / Posterbeiträge

  • Doerr, F.; Grapatsas, K.; Baldes, N.; Oezkan, F.; Opitz, Marcel; Forsting, Michael; Wiesweg, Marcel; Metzenmacher, Martin; Theegarten, Dirk; Taube, Christian; Hautzel, H.; Herrmann, Ken; Stuschke, Martin; Schuler, Martin; Bölükbas, S.
    Enhancing Lung Cancer Screening : A Comparative Evaluation of Predictive Models for Malignancy in Pulmonary Nodules
    2025 World Conference on Lung Cancer, 6-9 September 2025, Barcelona, Spain,
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 20, 2025, Nr. 10, Supplement 1, S. S666 – S667
    DOI
  • Schott, I.; Achilleos, N.; Doerr, F.; Grapatsas, K.; Baldes, N.; Taube, Christian; Theegarten, Dirk; Guberina, N.; Stuschke, Martin; Wiesweg, Marcel; Schuler, Martin; Bölükbas, S.
    European Single-Center Validation of the 9Th TNM Staging System in over 3,300 Surgically treated NSCLC Patients
    2025 World Conference on Lung Cancer, 6-9 September 2025, Barcelona, Spain,
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 20, 2025, Nr. 10, Supplement 1, S. S285 – S286
    DOI
  • Richter, K.M.; Lueong, S.; Kemper, M.; Angenendt, A.; Hansen, U.; Finkemeier, I.; Eirich, J.; Evers, G.; Mohr, M.; Lenz, G.; Hegedus, B.; Metzenmacher, Martin; Schuler, Martin; Menck, K.; Bleckmann, A.
    Improved liquid biopsy sensitivity with large extracellular vesicle-associated DNA
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 36, 2025, Nr. Suppl. 2, S. S281
    DOI (Open Access)
  • Lanzafame, Helena; Hamacher, Rainer; Mavroeidi, Ilektra-Antonia; Pabst, Kim; Hirmas, Nader; Kessler, Lukas; Bartel, Timo; Leyser, Stephan; Barbato, Francesco; Schuler, Martin; Bauer, Sebastian; Siveke, Jens T.; Herrmann, Ken; Fendler, Wolfgang P.
    68Ga-FAPI PET/CT novel diagnostic tool in sarcoma
    Annual Congress of the European Association of Nuclear Medicine, 9-13 September, 2023, Vienna, Austria,
    In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. 1 supplement, S. S414 – S415
    DOI
  • Mavroeidi, I.; Reissig, T.; Kalbourtzis, S.; Liffers, S-T.; Herold, T.; Kasper-Virchow, S.; Schildhaus, Hans-Ulrich; Schuler, Martin H. H.; Siveke, Jens
    DNA damage repair pathways in biliary tract cancer : A new target for precision medicine?
    ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 34, 2023, Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S223
    DOI (Open Access)
  • Pant, S.; Arnold, D.; Tabernero, J.; Loriot, Y.; Folprecht, G.; Haag, G.M.; Palmer, D.; Prenen, H.; Coward, J.; Lugowska, I.; Goeminne, J-C.; Cervantes, A.; Gutierrez, M.; Sweiti, H.; Hammond, C.; Najmi, S.; Thomas, S.; Triantos, S.; Crow, L.; Schuler, Martin H. H.
    Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label : Single-arm RAGNAR trial
    ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 34, 2023, Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S898
    DOI (Open Access)
  • Loriot, Y.; Pant, S.; Witt, O.; Reardon, D.A.; Doi, T.; Qin, S.; Tabernero, J.; Iyer, G.; Massard, C.; Arnold, D.; Lugowska, I.; Carranza, O.; Gutierrez, M.; Winter, H.; Sweiti, H.; Thomas, S.; Gormley, M.; Zhang, J.; Triantos, S.; Schuler, Martin H. H.
    Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial
    ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 34, 2023, Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S273
    DOI (Open Access)
  • Wiesweg, Marcel; Küter, C.; Schnorbach, J.; Keyl, J.; Plönes, T.; Metzenmacher, M.; Cvetkovic, J.; Eberhardt, Wilfried E.E.; Oezkan, F.; Theegarten, Dirk; Stenzinger, A.; Darwiche, Kaid; Herth, F.J.F.; Bölükbas, S.; Winter, H.; Weykamp, F.; Stuschke, Martin; Thomas, M.; Schuler, Martin H. H.; Christopoulos, P.
    Oligometastatic non-small cell lung cancer : Impact of local and systemic treatment approaches on clinical outcome
    ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 34, 2023, Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S828
    DOI
  • Pogorzelski, M.; Fendler, Wolfgang; Berliner, C.; Hussain, T.; Lang, Stephan; Ting, Saskia; Schmid, Kurt Werner; Schildhaus, Hans-Ulrich; Gauler, Thomas; Stuschke, Martin; Laue, K.; Herrmann, Ken; Grünwald, Viktor; Schuler, Martin; Kasper-Virchow, S.
    Immuntherapie eines Mikrosatelliten-instabilen metastasierten Talgdrüsenkarzinoms der Glandula submandibularis mit Pembrolizumab
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 45, 2022, Nr. Supplement 2, S. 230 – 231
    DOI (Open Access)
  • Hu, M.I.; Subbiah, V.; Mansfield, A.S.; Taylor, M.; Schuler, Martin H. H.; Zhu, V.; Hadoux, J.; Curigliano, G.; Wirth, L.J.; Garralda, E.; Adkins, D.R.; Godbert, Y.; Ahn, M-J.; Cassier, P.A.; Cho, B.C.; Lin, C-C.; Barata, T.; Zalutskaya, A.; Scalori, A.; Brose, M.S.
    Updated ARROW data : Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC)
    ESMO Congress 2022, 9 - 13 September 2022, Paris, France,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 33, 2022, Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S1298 – S1299
    DOI (Open Access)
  • Pogorzelski, M.; Lauri, F.; Hilser, T.; Hense, Jörg; Ting, Saskia; Kansy, B.; Gauler, Thomas; Stuschke, Martin; Schmid, Kurt Werner; Lang, Stephan; Zaun, G.; Grünwald, Viktor; Schuler, Martin; Kasper, Stefan
    Efficacy of immunotherapy (IO) and subsequent systemic treatment after failure of IO in patients with recurrent or metastatic head and neck cancer in a real-world setting
    ESMO Congress 2021, 16 – 21 September 2021, Virtual,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 32, 2021, Nr. Suppl. 5, S. S812
    DOI (Open Access)
  • Martens, U.; Schröder, J.; Sellmann, Ludger; Frank-Gleich, S.; Zaiss, M.; Decker, T.; Schneeweiss, A.; Schuler, Martin; Grebhardt, S.; Vannier, C.; Marschner, N.; Kasenda, B.
    First interim analysis of INFINITY : A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice
    Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 44, 2021, Nr. Supplement 2, S. 295
    DOI (Open Access)
  • Reinisch, Mattea; Nusch, Arndt; Decker, Thomas; Hartkopf, Andreas; Heinrich, Bernhard J.; Kurbacher, Christian M.; Fuchs, Roswitha; Tesch, Hans; Krabisch, Petra; Brucker, Sara Y.; Fehm, Tanja; Janni, Wolfgang; Kuemmel, Sherko; Lüftner, Diana; Schneeweiss, Andreas; Schuler, Martin; Voges, Claudia; Schubert, Jörg; Fasching, Peter A.
    Ribecca - a phase 3b, multi-center, open label study for women with estrogen receptor positive, locally advanced or metastatic breast cancer treated with ribociclib (lee011) in combination with letrozole : Final results
    San Antonio Breast Cancer Virtual Symposium ; December 8-11, 2020; San Antonio, Texas,
    In: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 81, 2021, Nr. 4, Supplement, PS10 - 31
    DOI (Open Access)
  • Kasper, Stefan; Hofheinz, R.D.; Stintzing, S.; Götze, T.O.; Sinn, M.; Dechow, T.; Ettrich, T.J.; Keitel, V.; Graeven, U.; Fischer von Weikersthal, L.; Kolov, A.; Edelmann, T.; Stein, A.; Trarbach, T.; Junge, S.; Pauligk, C.; Virchow, I.; Siveke, Jens; Al-Batran, S-E.; Schuler, Martin
    Interim safety analysis of the phase IIb study of ramucirumab in combination with TAS102 vs. TAS102 monotherapy in metastatic colorectal cancer : The RAMTAS trial of the German AIO
    ESMO Virtual Congress 2020, 19 – 21 September / 16 – 18 October 2020,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 31, 2020, Nr. Suppl. 4, S. S427 – S428
    DOI (Open Access)
  • Hartkopf, Andreas; Nusch, Arnd; Decker, Thomas; Reinisch, Mattea; Heinrich, Bernhard J; Kurbacher, Christian; Fuchs, Roswitha; Tesch, Hans; Krabisch, Petra; Brucker, Sara; Fehm, Tanja N; Janni, Wolfgang; Kümmel, Sherko; Lüftner, Diana; Schneeweiss, Andreas; Schuler, Martin; Voges, Claudia; Schubert, Jörg; Fasching, Peter A
    RIBECCA - A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole : Results of the third interim analysis
    San Antonio Breast Cancer Symposium, December 10-14, 2019, San Antonio, Texas, USA,
    In: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 80, 2020, Nr. 4
    DOI (Open Access)
  • Grünwald, Viktor; Schuler, Martin H.; Schöffski, Patrick; Kopp, Hans-Georg; Bauer, Sebastian; Kasper, Bernd; Lindner, Lars H.; Chemnitz, Jens M.; Crysandt, Martina; Stein, Alexander; Steffen, B.; Richter, Stephan; Kneba, Michael; Egerer, Gerlinde; Zimmermann, S.; Karch, Annika; Kunitz, Annegret
    Health-related quality of life (HR-QoL) in elderly soft tissue sarcoma (STS) patients from the randomized phase II EPAZ study comparing pazopanib (PAZ) and doxorubicin (DOX) in first line
    43rd ESMO Congress (ESMO 2018), 19–23 October 2018, Munich, Germany,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 29, 2018, Nr. Suppl. 8, S. viii577
    DOI (Open Access)
  • Sahin, U.; Schuler, Martin; Bauer, S.; Krilova, A.; Utsch, M.; Huber, C.; Tureci, O.
    First-in-human study of IMAB362, an anti-claudin 18.2 monoclonal antibody, in patients with advanced gastroesophageal cancer
    42nd ESMO Congress (ESMO 2017), 8-12 September 2017, Madrid, Spain,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 28, 2017, Nr. Suppl. 5, S. v224 – v225
    DOI
  • Hamacher, R.; Kampfe, D.; Ahrens, M.; Reuter-Jessen, K.; Schuler, Martin; Schildhaus, H. U.; Bauer, Sebastian
    PD-L1 inhibition - a new therapeutic opportunity in cutaneous angiosarcoma?
    42nd ESMO Congress (ESMO 2017), 8-12 September 2017, Madrid, Spain,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 28, 2017, Nr. Suppl. 5, S. v532 – v533
    DOI
  • Köhler, Jens; Schuler, Martin; Kasper, Stefan; Nensa, Felix; Hense, Jörg; Forsting, Michael; Kühl, Hilmar
    Formation of multiple pneumatoceles during anti-angiogenic treatment for metastatic colorectal cancer
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.–14. Oktober 2014, Hamburg, Germany,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 5, S. 84 – 85
    DOI
  • Nell, I.; Gauler, Thomas; Nickel, A. C.; Alotaibi, S.; Thomale, Jürgen; Schuler, Martin; Hoffmann, Andreas-Claudius
    Pre-therapeutic ex-vivo repair kinetics of cisplatin-DNA-adducts in circulating tumor cells (CTC) as platinum resistance test
    11th Annual British Thoracic Oncology Group Conference, 23-25 January 2013, Dublin, Ireland,
    In: Lung Cancer. Amsterdam: Elsevier, Jg. 79, 2013, Nr. Suppl. 1, S. S2
    DOI
  • Ölschläger, Katrin; Grabellus, Florian; Schnell, Rainer; Geffken, Mareike; Hoiczyk, Mathias; Ahrens, Marit; Podleska, Lars; Täger, Georg; Treckmann, Jürgen-Walter; Pöttgen, Christoph; Schuler, Martin; Bauer, Sebastian
    Chemotherapie bei resektablen Weichteilsarkomen mit komplexem Karyotyp : eine Single-Center Analyse
    The annual meeting of the German, Austrian and Swiss Society of Haematology and Oncology, 19.-23.10.2012, Stuttgart,
    Stuttgart, 2012
  • Ahrens, M.; Hoiczyk, M.; Grabellus, Florian; Täger, Georg; Pöttgen, Christoph; Schuler, Martin; Bauer, Sebastian
    Angiosarcomas of the adulthood - a large single center analysis
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 30.09.–04.10. 2011, Basel, Switzerland,
    In: Onkologie. Basel: Karger, Jg. 34, 2011, Nr. Suppl. 6, S. 254 – 254
    DOI
  • Gauler, Thomas; Theegarten, Dirk; Parr, A.; Schuhr, I.; Schmid, Kurt Werner; Eberhardt, Wilfried; Schuler, Martin; Hoffmann, Andreas-Claudius
    Decrease of circulating tumor cells associates with response to platinum-based chemotherapy in patients with non-small cell lung cancer, but not with small cell lung cancer
    14th World Conference on Lung Cancer (WCLC), July 03 - 07, 2011, Amsterdam, The Netherlands,
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 6, 2011, Nr. 6, Suppl. 2, S. S1114
  • Simon, S.; Grabellus, Florian; Täger, Georg; Treckmann, Jürgen-Walter; Schuler, Martin; Fletcher, J.; Bauer, Sebastian
    Development of xenograft-based in vivo models of gastrointestinal stromal tumors
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 30.09.–04.10. 2011, Basel, Switzerland,
    In: Onkologie. Basel: Karger, Jg. 34, 2011, Nr. Suppl. 6, S. 253 – 253
    DOI
  • Breitenbücher, Frank; Hoffarth, S.; Gauler, Thomas; Stergar, S. L.; Kasper, Stefan; Köhler, Jens; Worm, K.; Marten, A.; Schmid, Kurt Werner; Schuler, Martin
    Highly sensitive detection of somatic epidermal growth factor receptor (EGFR) gene mutations in circulating tumor cells (CTC) from patients with non-small cell lung cancer treated with cisplatin/pemetrexed or afatinib
    14th World Conference on Lung Cancer, July 3 – 7, 2011, Amsterdam, The Netherlands,
    In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 6, 2011, Nr. 6, Suppl. 2, S. S956 – S957
    DOI
  • Scheulen, Max Ernst; Nokay, B.; Richly, Heike; Hoffmann, Andreas-Claudius; Kalkmann, J.; Stattaus, Jörg; Bornfeld, Norbert; Schuler, Martin; Hense, Jörg
    Register trial of sorafenib (S) for patients (pts) with metastatic uveal melanoma (metUvMel)
    EORTC – NCI – ASCO Annual Meeting on ‘Molecular Markers in Cancer’, 27-29 October 2011, Brussels, Belgium,
    In: European Journal of Cancer (EJC). Amsterdam: Elsevier, Jg. 47, 2011, Nr. Suppl. 4, S. S30
    DOI
  • Mühlenberg, Thomas; Simon, S.; Fletcher, J. A.; Grabellus, Florian; Täger, Georg; Treckmann, Jürgen-Walter; Schuler, Martin; Bauer, Sebastian
    The BH3-mimetic ABT-263 enhances the apoptotic response of GIST cells to KIT-inhibitory treatments
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 30.09.–04.10. 2011, Basel, Switzerland,
    In: Onkologie. Basel: Karger, Jg. 34, 2011, Nr. Suppl. 6, S. 254
    DOI
  • Hilger, Ralf A.; Köhler, Jens; Kalkavan, H.; Richly, Heike; Hoffmann, Andreas-Claudius; Heinrichs, D.; Azaouagh, A.; Schuler, Martin; Trarbach, Tanja
    Interpatient pharmacokinetic variability of 5-FU within metastatic and adjuvant colon cancer patients : First results from the West German Cancer Center
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,
    In: Onkologie. Basel: Karger, Jg. 33, 2010, Nr. Suppl. 6, S. 173
    DOI